inspired patient driven science terry living parkinson disease 2012 annual report nele living lupus carola living parkinson disease letter stakeholder 8 ii management report board director 17 1 corporate governance statement 18 2 business performance review 41 3 operating financial review 44 iii consolidated financial statement 52 iv note consolidated financial statement 58 v responsibility statement 120 vi report statutory auditor 122 vii abbreviated statutory financial statement ucb sa 124 viii corporate societal responsiblity performance report 128 neil scientist ucb slough carrie living crohn disease u c b n n u l r e p rt 2 0 1 2 2 inspired patient driven science sten living deonna restless leg syndrome living ra rafaelle living epilepsy christer living mercedes mother parkinson disease son living epilepsy lakeisha bernadette living epilepsy living lupus vivian living osteoporosis victor living epilepsy tom living crohn disease u c b n n u l r e p rt 2 0 1 2 3 advancing pipeline central nervous system cns phase 1 phase 2 phase 3 filing neupro rotigotine advanced parkinson disease japan1 neupro rotigotine restless leg syndrome japan1 brivaracetam epilepsy pos2 adjunctive therapy vimpat lacosamide epilepsy pos2 monotherapy u vimpat lacosamide epilepsy pos2 monotherapy eu vimpat lacosamide epilepsy pos2 adjunctive therapy asia vimpat lacosamide epilepsy pos2 paediatric adjunctive therapy vimpat lacosamide epilepsy pgtcs3 adjunctive therapy 1 cns partner japan otsuka 2 partialonset seizure 3 primary generalised tonic clonic seizure immunology phase 1 phase 2 phase 3 filing cimzia certolizumab pegol rheumatoid arthritis japan cimzia certolizumab pegol axial spondyloarthritis cimzia certolizumab pegol psoriatic arthritis epratuzumab systemic lupus erythematosus cimzia certolizumab pegol juvenile idiopathic arthritis romosozumab sclerostin antibody postmenopausal osteoporosis cdp7657 anticd40l systemic lupus erythematosus ucb4940 immunological disease u c b n n u l r e p rt 2 0 1 2 4 key figure revenue rebitda core eps million million e 2013 3 400 680710 190205 2012 3 462 655 214 2011 3 246 687 191 2010 3 218 731 199 2009 3 116 698 174 2008 3 601 733 187 0 1 000 2 000 3 000 4 000 0 200 400 600 800 0 05 1 15 2 2008 2009 2010 2011 2012 revenue 3 601 3 116 3 218 3 246 3 462 net sale 3 027 2 683 2 786 2 876 3 070 rd expense 767 674 705 778 890 ratio rd expense revenue 21 22 22 24 26 recurring ebit rebit 531 453 467 439 415 recurring ebitda 733 698 731 687 655 ratio rebitda revenue 20 22 23 21 19 net profit 42 513 103 238 252 core eps per nondiluted share 186 174 199 191 214 net debt 2 443 1 752 1 525 1 548 1 766 ratio net debt rebitda 333 251 209 225 270 equity ratio 42 48 51 51 49 cash flow operating activity 366 295 506 292 355 capital expenditure including intangible asset 179 87 78 137 221 employee function yearend 2012 employee region yearend 2012 administration 872 belgium north america 1 950 marketing 2 036 sale france total 4 491 total 144 9 048 rest world 9 048 germany manufacturing 2 433 1 056 732 italy 131 asia pacific australia uk 1 670 spain 586 rd eu others 133 1 252 610 eu others ustria bulgaria czech republic denmark finland greece hungary ireland luxembourg netherlands poland portugal romania slovakia sweden asia pacific australia australia china hongkong india japan south korea rest world brazil kazakhstan mexico norway russia switzerland turkey ukraine north america canada u u c b n n u l r e p rt 2 0 1 2 5 2012 milestone rd milestone cimzia rheumatoid arthritis japan filing jan 2012 psoriatic arthritis phase 3 result feb 2012 rheumatoid arthritis start phase 3 cearly study feb 2012 juvenile idiopathic arthritis start phase 3 mar 2012 axial spondyloarthritis phase 3 result apr 2012 rheumatoid arthritis japan approval dec 2012 vimpat epilepsy pgtcs adjunctive therapy phase 2 result jan 2012 epilepsy po adjunctive therapy asia start phase 3 nov 2012 neupro parkinson disease restless leg syndrome u approval apr 2012 parkinson disease restless leg syndrome eu approval room temperature stable patch aug 2012 parkinson disease restless leg syndrome japan approval dec 2012 romosozumab postmenopausal osteoporosis start phase 3 apr 2012 olokizumab rheumatoid arthritis phase 2 topline result sept 2012 financial performance 34 655 214 billion revenue million rebitda core eps partnership ucb strengthens strategic alliance wilex jan aug 2012 ucb astellas announce agreement jointly develop commercialize cimzia japan jan 2012 ucb nodality enter multiyear strategic collaboration feb 2012 ucb oxford university announce new rd partnership mar 2012 ucb expands brazil may 2012 ucbharvard research alliance expands move forward june oct 2012 ucb newbridge pharmaceutical partner middle east african market nov 2012 biotie therapeutic reported positive phase 2b topline result tozadenant parkinson disease dec 2012 u c b n n u l r e p rt 2 0 1 2 6 corporate governance gerhard mayr became chairman board may 2012 anna richo appointed executive vice president general counsel nov 2012 bob trainor executive vice president general counsel retired dec 2012 greg duncan executive vice president president north american operation left feb 2013 new organizational structure deliver superior sustainable value patient feb 2013 gerhard mayr chairman board anna richo executive vice president general counsel cimzia vimpat reaching 41 000 patient living crohn reaching 234 000 patient disease rheumatoid arthritis across 34 country living epilepsy across 36 country 467 million net sale 334 million net sale approval japan dec 2012 3 indication development 2 filing feb 2013 1 indication development neupro keppra reaching 148 000 patient living reaching thousand patient living parkinson disease restless leg syndrome epilepsy across 53 country across 33 country 838 million net sale 133 million net sale 40 sale increase rest world launch u july 2012 approval japan dec 2012 u c b n n u l r e p rt 2 0 1 2 7 letter stakeholder gerhard mayr roch doliveux chairman chief executive officer inspired patient driven science rosanne carer child epilepsy u c b n n u l r e p rt 2 0 1 2 8 l e tt e r h e sta k e h l e r frauke living type 2 diabetes friend jerome living epilepsy dear shareholder partner colleague living severe disease 2012 completed ucbs transformation patientcentric biopharmaceutical company thanks remarkable achievement colleague ucb expect company growth many year driven core medicine emerging market new breakthrough achieving target year ucb reached crossover point ucbs performance emerging market another key net sale new core medicine exceeded driver growth sale 628 million 22 versus keppra ucbs leading medicine many year previous year 16 constant exchange rate core medicine cimzia vimpat neupro cvn acquisition majority stake meizler brazil mean achieved combined sale 934 million touching presence major emerging market life nearly 420 000 people living selected targeted ucb immunological neurological disorder overall achieved financial target revenue moreover keppra performed better expected reaching 34 billion 7 intense rd investment resisting generic competition europe u advance pipeline well expense launch enjoying intense growth asia driven japan neupro u resulting underlying profitability e keppra copromoted otsuka leading cns reassured recurring ebitda 655 million net company japan medicine market profit tax 252 million translating core exclusivity least 2018 earnings per share 214 line stable dividend policy considers longterm potential company board director proposed gross dividend 102 per share 2 u c b n n u l r e p rt 2 0 1 2 9 l e tt e r h e sta k e h l e r anne scientist ucb brainelalleud investing 26 revenue promising pipeline new medicine strengthening pipeline ucbs financial achievement complemented phase 3 development ucbs rich pipeline three new significant progress pipeline example potential medicine continues strengthen romozosumab neupro approved launched u sclerostin antibody potential breakthrough bone treatment parkinson disease pd restless leg loss disorder entered phase 3 postmenopausal syndrome rls neupro also approved japan osteoporosis codeveloped partner 25 december 2012 well cimzia first half amgen addition epratuzumab potential novel 2013 launch cimzia japan partner treatment lupus brivaracetam epilepsy astellas leading immunology company japan continued progress phase 3 neupro marketed otsuka also differentiated cimzia label u europe early stage pipeline focus potential competitor completed phase 3 program breakthrough offer true differentiation major new indication cimzia axial systematically discontinue project wealth spondyloarthritis well psoriatic arthritis combined quality pipeline internal external allows prevalence two disease half u make choice consequently one hand current indication decided pursue olokizumab phase 3 hand one external program tozadenant novel oral therapy parkinson disease developed partner biotie achieved positive phase 2b result december 2012 u c b n n u l r e p rt 2 0 1 2 10 l e tt e r h e sta k e h l e r christer living parkinson disease ensuring quality compliance across ucb continued operate highest broad responsibility commitment society standard quality safety compliance example embracing environmental social dimension passed inspection regulatory agency effort recognized ucb reached top 100 critical finding identified wci world sustainable company according industry leader drug safety approach benefit corporate knight torontobased specialized medium risk governance also successfully implemented financial information product company corporate integrity agreement u second last least engagement colleague year running ucb measure annual company strengthened reputation leading wide survey continued strengthen 2012 surpassing biopharmaceutical company new corporate industry standard according survey provider societal responsibility csr strategy societal reflects u c b n n u l r e p rt 2 0 1 2 11 l e tt e r h e sta k e h l e r neil scientist ucb slough patientcentricity valued medicine health solution make difference people living severe disease ucb entering 2013 position strength u cbs advance impressive given finally information throughout health care system force impacting global biopharmaceutical becoming transparent extent never experienced industry industry major inflection point build basis comparison insight combined technological scientific advance one hand face substantial challenge create foundation even better including expiry important patent stiffer economical healthcare people generic competition declining rd investment rising rd cost per project additionally economic new environment innovative biopharmaceutical crisis forced government europe beyond company capable rapidly harnessing tighten healthcare expenditure power contemporary technology affect industry commercial prospect could advantage complex environment company also impede patient access new medicine able provide sustainable value people developing developed country living severe disease internal capability alone partner build strategic alliance hand force demographic combine strength building unique advantage aging spendable power baby boomer power energizing technology advance inflection point new leader emerge ucb science provide unique opportunity innovative aspires one leader new biopharmaceutical biopharmaceutical company time leader focus bringing solution people consumer patient getting information suffer severe disease able share power greater accountability expected value bring patient payer u c b n n u l r e p rt 2 0 1 2 12 l e tt e r h e sta k e h l e r implementing clear strategy carrie living crohn disease inspired patient driven science ince 2004 ucbs strategy focused research strategy focus first secondin delivering superior sustainable solution class innovative approach prioritizing project people live severe disease targeting clear proof concept clear end point two set severe disease neurological disease focus manufacturing network rd scaleup disease immune system special focus launch appropriate augment internal rheumatologic gastroenterologic disease capability using strategic partnership large area constantly strive better understand small molecule commercial phase product patient serve using contemporary science securing costeffective supply completed create unique solution efficient way deliver biotech pilot plant belgium progressing buildout commercialscale manufacturing five key enablers lie behind strategy biotech plant switzerland initially intended manufacture cimzia 1 f ostering connectivity example connecting best university biotech company commercial strategy presence patient caregiver covering specialist physician payer patient group well payer north america europe major emerging market 2 developing diverse connected talent focusing china india russia brazil mexico turkey 3 ensuring compliance rule regulation collectively account 75 pharmaceutical 4 ruthlessly eliminating noncore activity emerging market 5 r eaching competitive profitability second half area continue learn bestinclass decade company outside biopharma industry area innovation customer insight cost management activitybased management u c b n n u l r e p rt 2 0 1 2 13 l e tt e r h e sta k e h l e r net sale geographical area 2012 3 070 million france 6 germany 10 italy north america 6 38 spain 4 uk ireland 4 eu 12 rest world 5 asia japan 8 6 helping thousand patient across 66 country 2013 priority aspiring superior growth result strategy ucb aim exceed result 2013 ucb expects revenue grow biopharma industry compounded growth also expect lowsingledigit percent excluding exchange rate impact invest peer rd proportionally approximately 34 billion recurring ebitda sale gradually reaching peer profitability 680 710 million core eps range 190 lower marketing selling expense well general 205 based 179 million share administrative expense peer major patent expiry many year 2013 ucb focus 7 priority three new core medicine fueling growth plus 1 growing cimzia vimpat neupro reach rich pipeline cutting edge science ucb patient poised build strong global presence neurology 2 building emerging market business immunology deliver significant return shareholder thanks current performance 3 advancing latestage pipeline growth core medicine confirm ambition 4 bringing innovative breakthrough potential medicine reach 15 million patient cimzia human clinical trial vimpat neupro representing peak sale least 5 ensuring quality compliance law 31 billion second half decade regulation 6 improving profitability versus peer strict focus value creation activity 7 developing passionately engaged colleague business partner u c b n n u l r e p rt 2 0 1 2 14 l e tt e r h e sta k e h l e r people living severe disease meeting ucb employee orchestrate forum achievement past present future energy every day make difference would possible without insight life people living severe disease work patient physician payer regulator impact life know committed follow commitment colleague partner strict regulatory standard research development support shareholder leadership manufacturing distribution product board would like thank ensure meet safety quality regulatory legal environmental requirement without effort would especially like thank people live would making happen severe disease family physician payer insight feedback knowledge last least thanks go ucb board inspiration director governance experience expertise well support challenging contribution also sincerely grateful talented committed diverse team ucb employee around ucb inspired patient driven science globe human talent greatest asset committed bring superior sustainable value organization wish recognize every patient stakeholder one engaged colleague invest much sincerely roch doliveux gerhard mayr chief executive officer chairman u c b n n u l r e p rt 2 0 1 2 15 l e tt e r h e sta k e h l e r upcoming milestone rd milestone 2013 cimzia axial spondyloarthritis filing u eu feb 2013 cimzia psoriatic arthritis filing u eu feb 2013 vimpat epilepsy po monotherapy u phase 3 result q2 2013 vimpat epilepsy po paediatric adjunctive therapy start phase 3 h1 2013 2014 epratuzumab systemic lupus erythematosus phase 3 result h1 2014 vimpat epilepsy po monotherapy eu phase 3 result q4 2014 cimzia juvenile idiopathic arthritis phase 3 result h2 2014 brivaracetam epilepsy po adjunctive therapy phase 3 result h2 2014 2015 vimpat epilepsy po adjunctive therapy asia phase 3 result h1 2015 romosozumab postmenopausal osteoporosis phase 3 result end 2015 2016 cimzia cearly rheumatoid arthritis phase 3 result cimzia exxelerate rheumatoid arthritis phase 3 result cvn peak sale 20152020 cimzia vimpat neupro 15 12 400 billion billion million 2013 financial guidance 34 680710 190205 billion revenue million rebitda core eps u c b n n u l r e p rt 2 0 1 2 16 ii ii management report board director 1 corporate governance statement 2 business performance review 3 operating financial review 17 1 corporate governance statement director auditor board director gerhard mayr chair evelyn du monceau vice chair roch doliveux executive director albrecht de graeve director arnoud de pret director harriet edelman director peter fellner director charlesantoine janssen director jeanpierre kinet director tom mckillop director norman j ornstein director bridget van rijckevorsel director inge basteleurs secretary board 31 december 2012 statutory auditor p ricewaterhousecoopers represented permanent representative jean fossion honorary director andré jaumotte honorary chair mark eyskens honorary chair george jacob de hagen honorary chair karel boone honorary chair daniel janssen honorary deputy chair prince lorenz belgium alan blinken michel didisheim eric janssen guy keutgen paul etienne maes gaëtan van de werve jeanlouis vanherweghem honorary chairman executive committee daniel janssen p aul etienne maes george jacob de hagen u c b n n u l r e p rt 2 0 1 2 18 ii n g e e n r e p rt f h e b ar f r e ct r belgianheadquartered company commitment committee executive committee charter highest standard corporate governance board corporate governance annually updated december director hereafter board ucb sa nv reviewed board line code hereafter ucb adopted charter corporate interpretation governance october 2005 required belgian accordance belgian company code code corporate governance first edition 2004 code following page provide factual information required article 96 belgian company code ucb ucbs corporate governance includes change adopted belgian code corporate governance ucbs corporate governance together relevant second edition march 2009 hereafter code event took place 2012 change reference code corporate governance taking account ucbs capital shareholder structure modification specific international aspect ucb 1 ucbs governance board committee charter corporate governance available composition main feature ucbs internal control ucb website wwwucbcominvestorsgovernance risk management system remuneration report charter describes main aspect ucbs corporate also includes explanation applicable governance including governance structure deviation code term reference board well 11 capital share 111 capital 113 warrant capital ucb modified 2012 1999 2000 respectively ucb issued 145 200 31 december 2012 amounted 550 095 156 236 700 warrant represented 183 365 052 share 145 200 issued 1999 warrant expired 236 700 warrant issued 2000 confer 112 share right subscribe one ordinary share following cancellation expiration exercise part since 29 february 2008 share capital ucb warrant 32 600 warrant still exercised represented 183 365 052 share hereafter ucb share 31 may 2013 ucb share may registered dematerialized share request shareholder may bearer share defensive warrant also issued following decision accordance law general meeting shareholder ucb hereafter general meeting 2008 excluding preferential right loan since 1 january 2008 shareholder longer request 600 000 represented 30 000 loan stock unit ucb share converted bearer ucb nominal value 20 1 000 warrant attached share pursuant belgian law 14 december 2005 confers right joint subscription 30million bearer ucb share registered custody account ordinary ucb share subscribed financière de investment account automatically converted tubize sa ucbs reference shareholder 24 april 2008 dematerialized ucb share 1 january 2008 1 january 2008 bearer ucb share deposited adhoc committee set meeting registration custody investment account meeting also appointed member committee automatically converted dematerialized ucb share committee decides predefined circumstance implementation warrant approval fully paid ucb share registered transfer warrant holder warrant may transferred prior approval board entered agreement ucb ensuring compliance registered ucb share recorded special register condition issuance exercise warrant ucb share admitted listing trading nyse euronext brussels proposed annual shareholder meeting 25 april 2013 cancel possibility bearer share within ucb 1 belgian code corporate governance second edition published march 2009 available website belgian corporate governance committee httpwwwcorporategovernancecommitteebe u c b n n u l r e p rt 2 0 1 2 19 ii n g e e n r e p rt f h e b ar f r e ct r 115 treasury share warrant may exercised adhoc committee ucb acquired 1 426 541 sold 4 620 025 ucb decides one predefined circumstance associated share 2012 31 december 2012 ucb held hostile takeover bid occurs total 3 301 706 ucb share 801 706 share 2 500 000 assimilated security representing 180 launch takeover bid third party judged total number ucb share hostile board ucb fipar sa affiliate indirectly controlled ucb change control ucb due transaction relating acquired 746 800 ucb share 2002 372 904 ucb share ucb stock one third party carried either 2003 1 064 200 ucb share 2004 370 000 ucb share stock market isolation concerted 2005 950 000 ucb share 2006 1 ucb share manner 2012 31 december 2012 ucb fipar sa held total threat takeover bid operation involving 2 691 534 ucb share 891 534 share 1 800 000 change control ucb assimilated security representing 147 total number ucb share defensive warrant agreement holder defensive warrant ucb expire ucb sca affiliate indirectly controlled ucb 23 april 2013 ucb share arising exercise acquired 61 200 ucb share 2007 50 384 ucb share warrant issued reference market price 2008 128 116 ucb share 2009 239 639 ucb share period prior issuance 2010 31 december 2012 ucb sca longer hold ucb share 114 convertible bond ucb share acquired ucb ucb fipar sa ucb sca order cover part ucbs obligation ucb issued senior unsecured 45 bond due 2015 resulting employee stock option plan stock award aggregate principal amount 500 million placed plan performance share plan ucb cover part institutional investor following accelerated bookbuilding ucbs obligation resulting convertible bond procedure 30 september 2009 hereafter convertible bond extraordinary general meeting decided additional detail please refer note 253 treasury share 6 november 2009 attach conversion right bond according decision general meeting held convertible bond denomination 50 000 6 november 2009 board authorized unlimited may converted 2 december 2009 duration time accordance article 622 2 section 15 october 2015 conversion price 38746 per 2 1 belgian company code dispose ucb ucb share upon receipt conversion request share outside stock exchange way sale bondholder board option sole discretion exchange contribution kind disposal ucbs best interest issue new ucb share ii authorization also cover disposal ucb share held deliver existing ucb share iii make combination direct subsidiary ucb within meaning article 627 two option belgian company code convertible bond converted according decision meeting board new ucb share current conversion price ucb would board director ucbs direct subsidiary issue 12 904 558 new share conversion price may authorized period five year starting revised accordance antidilution provision 7 november 2009 acquire ucb share maximum accordance term condition bond 20 total number ucb share exchange value case change control equivalent closing price ucb share euronext brussels day immediately preceding acquisition ucb lux sa purchased 26 april 2012 amount plus maximum 15 minus maximum 15 taking 70 million nominal convertible bond thereafter also account applicable legal requirement sold option equivalent one embedded bond ucb proposed general meeting 25 april 2013 bond listed euro mtf market institute authorized capital luxembourg stock exchange odify modality authorization proposed general meeting 25 april 2013 replacing 15 limit upper limit highest allow dematerialized register bond stock exchange course day lower floor 1 one euro renewing authorization ahead term period 5 year starting 26 april 2013 u c b n n u l r e p rt 2 0 1 2 20 ii n g e e n r e p rt f h e b ar f r e ct r hareholders shareholder structure 12 ucbs main shareholder financière de tubize sa financière de tubize act concert schwarz company listed euronext brussels hereafter financière de vermögensverwaltung gmbh co kg tubize reference shareholder holding listed no 14 table financière de tubize made transparency notification hereunder share covered agreement holding ucb 1 september 2008 subsequent including share held financière de tubize represent notification compliance law 2 may 2007 4081 share capital ucb publication significant shareholding listed company 5306 financière de tubize held janssen family according article 3 1 13 law 2 may 2007 remainder ucb share held public accordance latest subsequent notification made compliance law 2 may 2007 present ucb major shareholder 121 ucb controlling major shareholder 31 december 2012 date according notification compliance current voting law 2 may 2007 capital 550 095 156 share 183 365 052 1 financière de tubize sa tubize 66 370 000 3620 5 october 2012 2 ucb sa 801 706 31 december 2012 assimilated securities1 2 500 000 180 26 june 2012 option 2 6 606 638 27 april 2012 3 ucb fipar sa 891 534 31 december 2012 assimilated security 1 800 000 147 27 april 2012 4 schwarz vermögensverwaltung gmbh co kg 2 471 404 135 5 october 2011 tubize linked company concert 4 excluding option 74 834 644 4081 31 december 2012 5 capital group company 20 828 907 1136 5 september 2012 6 vanguard health care fund 5 821 811 317 30 march 2012 1 please see press release 28 june 2012 2 option exercised would represent additional voting right 360 information regarding assimilated security option required law tubize declared acting concert schwarz vermögensverwaltung gmbh co kg communication virtue article 74 7 law 1 april 2007 relating public takeover bid made jointly stable shareholder ucb ucb received communication made respectively 22 november 2007 17 december 2007 28 december 2007 following shareholder acting concert virtue article 74 7 law 1 april 2007 summary since september 2007 date voting right shareholder allocated follows september 2007 december 2012 financière de tubize 66 370 000 3620 66 370 000 3620 schwarz vermögensverwaltung gmbh co kg 9 885 618 539 2 471 404 135 ucb sa1 3 301 706 180 ucb fipar sa1 3 176 578 173 2 691 534 147 total voting right 79 432 196 4332 74 834 644 4081 1 voting right share ucb sa held ucb sa affiliate suspended compliance article 622 1 631 1 belgian company code u c b n n u l r e p rt 2 0 1 2 21 ii n g e e n r e p rt f h e b ar f r e ct r oard director board committee 13 b 131 board director composition board mandate roch doliveux albrecht de graeve independent director peter fellner expire next general meeting held 25 april 2013 assessed potential 1 january 2012 26 april 2012 composition candidate gncc proposed board board follows mandate renewed proposal submitted karel boone chair next shareholder general meeting evelyn du monceau vice chair tom mckillop reached age limit board roch doliveux executive director meeting 13 december 2012 decided make exception albrecht de graeve director age limit article 324 corporate governance arnoud de pret director charter tom mckillop given exceptional experience peter fellner director expertise retired ceo major pharmaceutical jeanpierre kinet director company light scientific background thomas leysen director gerhard mayr director peter fellner reelected start fourth term tom mckillop director director solely reason longer qualify norman j ornstein director independent director per applicable law gaëtan van de werve director pursuant article 96 2 6 belgian company code bridget van rijckevorsel director ucb declares currently three female director board 25 board member replacement alexandre van damme resigned director appointment board considered ucb via 15 march 2012 board governance nomination compensation committee gncc systematically taking account general meeting held 26 april 2012 enhancing diversity board includes searching thomas leysen gaëtan van de werve resigned senior female profile could add complementary value director tom mckillop reelected term board four 4 year independent director harriet edelman charlesantoine janssen functioning board elected director term four 4 year 2012 board met seven time attendance rate harriet edelman independent director april 2012 member follows roch doliveux executive director ucb qualify independent director gerhard mayr chair 100 evelyn du monceau vice chair 100 evelyn du monceau arnoud de pret bridget van rijckevorsel roch doliveux executive director 100 charlesantoine janssen representative reference shareholder eligible albrecht de graeve 100 qualify independent director arnoud de pret 100 harriet edelman 100 gerhard mayr albrecht de graeve harriet edelman peter fellner 100 peter fellner jeanpierre kinet tom mckillop charlesantoine janssen 100 norman ornstein meet independence criterion stipulated jeanpierre kinet 100 belgian company code board code tom mckillop 100 present composition board director norman j ornstein 100 follows bridget van rijckevorsel 100 since april 2012 first appointed end term independent 2012 board main area discussion review director office director decision ucbs strategy report gerhard mayr chair 2005 2015 x audit committee gncc ucbs corporate evelyn du monceau 1984 2015 governance organization risk risk management vice chair succession planning structuring ucb group roch doliveux 2004 2013 tax strategy appointment reserved board executive director remuneration policy management financial albrecht de graeve 2010 2013 x reporting rd debt refinancing investment program arnoud de pret 2005 2015 business development proposal financial commercial harriet edelman 2012 2016 x partnership license agreement divestments noncore peter fellner 2005 2013 x activity asset report resolution proposal charlesantoine janssen 2012 2016 shareholder published invitation general jeanpierre kinet 2008 2015 x meeting compliance belgian company code tom mckillop 2009 2016 x transaction contractual relationship norman j ornstein 2008 2015 x 2012 ucb including affiliated company bridget van rijckevorsel 1992 2015 member board giving rise conflict interest u c b n n u l r e p rt 2 0 1 2 22 ii n g e e n r e p rt f h e b ar f r e ct r tom mckillop participate secretary four meeting partly attended discussion regarding granting exception age andré van der toorn vice president treasure risk limit stipulated article 324 corporate management two meeting partly attended governance charter bo iversen vice president tax douglas minder director financial collaboration ifrs competence center 2012 board started induction program spread rené broekhuis vice president corporate compensation four induction session new director cover benefit one meeting entirely attended various area expertise required biopharmaceutical anna richo executive vice president deputy general company counsel partly attended robert trainor executive session 1 legal intellectual property internal audit vice president general counsel caroline vancoillie senior quality assurance drug safety corporate health safety director reporting consolidation raf remijsen director environment hse risk management treasury corporate finance aaron bartlone senior vice president corporate sa h session 2 finance investor information 2012 according term reference see charter session 3 people ucb corporate governance available ucb website session 4 global technical operation audit committee monitored financial reporting process company internal control risk management system assessment board effectiveness internal audit effectiveness 2011 board conducted internal assessment statutory audit annual consolidated account functioning well contribution success ucb independence external auditor including set strategic mission aim optimize provision additional service ucb audit composition operation board committee committee reviewed authorized fee addition well interaction ceo executive audit committee reviewed impairment corporate committee conducted chair board restructuring project equity value subsidiary chair gncc risk management including litigation tax ifrs external auditor satisfaction survey 132 board committee governance nomination compensation committee gncc audit committee board set governance nomination board set audit committee compensation committee gncc composition composition functioning term reference 26 april 2012 31 december 2012 follows accordance belgian company code composition audit committee end term independent office director 26 april 2012 follows evelyn du monceau chair 2015 end term independent office director gerhard mayr 2015 x tom mckillop 2016 x arnoud de pret chair 2015 albrecht de graeve 2013 x majority member gncc meet gerhard mayr 2015 x independence criterion set article 526ter belgian company code member competency albrecht de graeve gerhard mayr fulfill expertise required matter remuneration independence criterion set article 526ter belgian policy required article 526quater 2 belgian company code member competency company code accounting audit matter required article gncc met four time 2012 attendance rate 526bis 2 belgian company code audit member 100 committee attended committee composition complies belgian roch doliveux chair executive committee company code requiring least one member except discussing issue relating independent director code recommends majority fabrice enderlin executive vice president human resource member audit committee independent communication act secretary except case discussing issue relating ceo compensation audit committee met four time 2012 2012 according term reference see charter attendance rate member 100 except corporate governance available ucb website albrecht de graeve whose attendance rate 75 gncc reviewed appointment proposal submitted external auditor attended part meeting board approval performance executive audit committee part without management presence committee member remuneration reviewed internal external auditor presence succession planning ceo member audit committee meeting attended executive committee reviewed submitted detlef thielgen executive vice president chief financial board approval remuneration policy longterm officer doug gingerella senior vice president global incentive granted company management internal audit olaf elbracht vice president reporting performance criterion grant linked consolidation three time inge basteleurs vice president legal affair secretary general acted u c b n n u l r e p rt 2 0 1 2 23 ii n g e e n r e p rt f h e b ar f r e ct r 133 executive committee gncc 26 april 2012 tasked board composition executive committee supervise report governance ucb since 1 january 2012 31 october 2012 composition responsible corporate governance charter executive committee follows corporate governance statement roch doliveux ceo chair executive committee scientific committee greg duncan executive vice president president 10 june 2010 board set amongst north american operation member scientific committee assist board review quality ucb rd science competitive fabrice enderlin executive vice president corporate standing human resource communication committee member outstanding scientific ismail kola executive vice president president medical expertise following ucb newmedicines iris löwfriedrich executive vice president global project end term independent office director development chief medical officer peter fellner 2013 x mark mcdade executive vice president global operation jeanpierre kinet 2015 x jeanchristophe tellier executive vice president president european operation scientific committee met three time 2012 detlef thielgen executive vice president attendance rate member 100 chief financial officer member scientific committee meet robert trainor executive vice president regularly executive vicepresident president general counsel 31 december 2012 ucb newmedicines member scientific 31 december 2012 robert trainor retired executive committee also closely involved activity ucbs vice president general counsel 1 november 2012 scientific advisory board sab composed external anna richo joined executive committee executive leading scientific medical expert sab created vice president deputy general counsel 1 january 2013 september 2005 executive committee critically anna richo replaced robert trainor executive review rd activity ucb provide scientific appraisal vice president general counsel strategic input best way ucb become thriving biopharmaceutical leader advise greg duncan left ucbs executive committee end executive committee strategic choice related january 2013 early stage rd scientific committee report since 1 february 2013 composition executive board sabs appraisal ucbs research activity committee hence follows strategic orientation roch doliveux ceo chair executive committee fabrice enderlin executive vice president corporate human resource communication corporate societal responsibility ismail kola executive vice president president ucb newmedicines iris löwfriedrich executive vice president biopharma development solution chief medical officer mark mcdade executive vice president established brand solution supply anna richo executive vice president general counsel jeanchristophe tellier executive vice president biopharma brand solution detlef thielgen executive vice president chief financial officer functioning executive committee 2012 executive committee met two three day month transaction contractual relationship 2012 ucb including related company member executive committee u c b n n u l r e p rt 2 0 1 2 24 ii n g e e n r e p rt f h e b ar f r e ct r 14 remuneration report remuneration report describes ucbs executive remuneration nonexecutive director remuneration policy executive compensation level ucbs board member compensated service set remuneration policy form part broader cashbased compensation program level set human resource policy including performance pay set based benchmark include management talent development governance remuneration board member comparable european nomination compensation committee gncc biopharmaceutical company pay consists fixed oversees executive compensation policy plan annual retainer varying size based director committee role responsibility set forth mandate fee per meeting attended longterm corporate charter adopted board director equity incentive granted also form variable pay level pay approved 141 ucbs global reward principle general meeting shareholder 24 april 2008 new market assessment presented gncc accomplish company goal within highly competitive february 2013 leading new proposal global biopharma environment need qualified submitted board endorsement annual talented executive working high performance culture general assembly approval 2012 remuneration foster type culture fully engaged employee level ucb director follows critical competitive global reward program objective ucb global reward program annual fee fair equitable according market practice c hairman board 120 000 recognize reward high performance v ice chair 90 000 irectors 60 000 link executive pay individual contribution overall success ucb board attendance fee provide strong motivation reinforcing business c hairman board 2 000 per meeting strategy achievement corporate goal v ice chair 1 500 per meeting enable u attract retain industry best talent irectors 1 000 per meeting global level audit committee governance nomination global reward program support drive vision compensation committee annual compensation senior executive variable pay make c hairman board committee 15 000 significant component total remuneration offering ember board committee 7 500 variable pay program closely linked short term longterm individual company performance scientific advisory committee annual compensation 142 development ucb ember committee 7 500 remuneration policy application rule total remuneration policy remuneration member director board committee member 2012 ucb executive committee set board basis follows recommendation gncc gncc meet least twice per year time gerhard mayr chairman 127 000 k arel boone ended april 2012 49 000 considers market factor affecting company current future pay practice e velyn du monceau vice chair 115 500 r och doliveux executive director 67 000 evaluates effectiveness remuneration policy albrecht de graeve 74 500 term recognising performance determines appropriate evolution plan rnoud de pret 82 000 peter fellner 74 500 r eviews financial target different performance jeanpierre kinet 74 500 based compensation program homas leysen ended april 2012 23 500 etermines compensation level ucbs tom mckillop 74 500 management team norman j ornstein 67 000 remuneration policy ensures compensation b ridget van rijckevorsel 67 000 program member executive committee gaëtan van de werve ended april 2012 22 000 including equity incentive pension scheme termination arrangement fair appropriate attract retain lexandre van damme ended march 2012 16 000 motivate management team c harlesantoine janssen since april 2012 45 000 h arriet edelman since april 2012 45 000 u c b n n u l r e p rt 2 0 1 2 25 ii n g e e n r e p rt f h e b ar f r e ct r 143 statement remuneration policy applied reported year remuneration executive director section discusses competitive positioning strategy throughout performance period ongoing ucb adopts market operates achievement monitored moment vesting also provides overview executive compensation payout final result validated corporate structure purpose different element pay finance department final approval audit link pay performance committee addition base salary performance related incentive pay executive eligible range benchmark total reward program benefit perquisite line market compensation practice per global reward principle remuneration package intend fair appropriate attract retain 2012 ucb implemented significant change motivate management also must reasonable executive reward program introduction new view company economics relevant practice upper management compensation policy change comparable global biopharmaceutical company result ongoing drive strengthen link reward program executive contribution gncc regularly considers appropriate mix level overall success ucb change mainly impact cash equity award offer executive based variable pay scheme explained variable recommendation corporate human resource pay section department recommendation reviewed independent compensation consultant tower watson change fully aligned spirit belgian ensure market competitiveness total remuneration governance legislation therefore also european take consideration market trend affecting regulation executive compensation enable better sector market survey normally conducted every alignment executive compensation ucbs strategy year assess competitiveness compensation commitment deliver short longterm component base salary bonus longterm incentive goal performance executive data aged year describe element pay determined survey conducted based global market movement performance embedded incentivebased within executive compensation significant change element pay occur job content instance due company organization market pricing role may conducted time capture impact change executive committee compensation package composed base salary two main element b ase salary fixed element pay variable pay consisting cash bonus longterm incentive long term bonus incentive ucb benchmark executive total reward program defined comparator group international company within biopharmaceutical sector company pharmaceutical biotechnology activity benchmark take focussed approach peer company europe well benefit perquisite recognition u ucbs competitive positioning policy target median pay level comparator group element total direct compensation base salary variable pay actual compensation level individual determined according benchmark taking account performance base salary level experience relation benchmark target base salary determined based specific job comparator group monitored closely ensure dimension criterion relation level base year year robust data available view pay market typically pay role challenge industry consolidation impact stability market level base pay defined specific compensation underlying data level individual depends extent heshe impact business hisher level skill experience compensation element pay performance evolution base pay depends individual level executive compensation program based sustained performance level pay compared balance individual corporate performance market benchmark market factor inflation gncc competitiveness senior executive shortterm proposes salary increase ceo board longterm incentive take account performance ceo proposes gncc executive financial target set board committee member endorsement u c b n n u l r e p rt 2 0 1 2 26 ii n g e e n r e p rt f h e b ar f r e ct r variable pay bonus performance year 2012 new compensation policy cash bonus designed reward performance ucbs upper management entered effect company individual time horizon one year several implication variable pay policy new part new upper management compensation policy policy ensures appropriate level reward shortterm ceo 2012 shortterm incentive bonus performance rebalancing proportion pay target reduced 100 base pay 90 address longterm sustainable performance executive committee member 75 65 target variable pay level bonus longterm incentive align market practice lti brought closer median comparator group providing opportunity longterm incentive lti executive exceed median market level remuneration practice link significant portion company individual performance outstanding equitybased compensation midterm longterm variable pay target subject double performance company financial strategic goal performance multiplier consists corporate individual lti program benchmarked european performance multiplier mechanism guarantee strong biopharmaceutical company practice threetiered link individual contribution company performance incentive program includes stock option plan free interdependent calculation mechanism share plan stock award performance share plan delivers significant value company individual performance excellent conversely mechanism ensures new upper management compensation policy design company individual performance level result greater proportion variable pay linked lower expectation adequately reflected longterm rather shortterm performance significantly diminished value achieved relative size lti target represents value shortterm bonus performance assessment 2013 grant per new upper management corporate performance multiplier compensation policy longterm incentive target expressed percentage base pay longer fixed number corporate objective ceo set beginning share option award change made response year gncc approved board challenge maintaining appropriate competitive lti since 2012 performance year ucb adopted recurring grant size target level longterm incentive represent earnings income tax depreciation amortization 120 base pay ceo 80 executive rebitda preferred corporate performance metric committee member target incentive subject executive senior management corporate application double corporate individual performance multiplier defined percentage actual performance multiplier see table 2 rebitda versus budget translated payout curve following application corporate individual ensures acceptable range performance performance multiplier resulting value translated rewarded payout curve translated payout range number longterm incentive using binomial value 0 150 minimum payout threshold set award spread across existing longterm incentive 30 performance falling threshold result program based following allocation corporate performance multiplier 0 double multiplier mechanism design result stock option 30 variable pay opportunity stock award 35 individual performance multiplier performance share 35 qualitative objective ceo proposed stock option gncc approval board director gncc proposes individual performance multiplier ceo eligibility participation stock option plan board based performance assessment end board discretion vesting period typically three year year ceo proposes gncc date grant longer depending local executive committee member endorsement legislative requirement vested stock option exercisable share price exceeds original grant discussing individual performance gncc deliberates price thus executive incentivized increase achievement financial quantitative objective share price vesting period order benefit ceo nonfinancial aspect ceo stock option u stock appreciation right executive committee evaluation includes extent granted instead stock option follow individual carried duty line vesting rule stock option plan result employee company value expected leadership behaviour receiving cash amount equal appreciation ucb criterion evaluated executive stock instead actual share stock option stock committee member appreciation right expire tenth anniversary specific business achievement date grant grant price fixed grant date strategic input vision without discount underlying ucb share price team leadership executive committee team membership impact u c b n n u l r e p rt 2 0 1 2 27 ii n g e e n r e p rt f h e b ar f r e ct r stock award pension stock award plan provides conditional right ucb executive committee international nature common stock fulfilled upon remaining employment member participate pension plan available ucb three year grant date vesting period country contract plan varies line local three year date grant executive committee competitive legal environment member eligible participation board defined benefit plan ucb either frozen discretion executive incentivized outperform closed new entrant new executive committee biopharmaceutical market increase company share member would therefore automatically join either defined price vesting period optimize value contribution cash balance plan stock award moment vesting country delivery award may also made belgium phantom share award value based executive committee member participate cash evolution share price settled cash balance retirement benefit plan fully funded predetermined vesting date depending local ucb benefit retirement age capitalization legislative environment guaranteed rate return employer annual contribution affiliation plan ucb performance share plan contributes amount equal 915 annual base performance share plan ensures strong link salary target bonus ucb also provides annual pay performance performance share grant guaranteed return 25 increased belgian health ucb common stock senior executive group index minimum 325 defined belgian certain corporate target must met time legislation maximum 6 vesting performance criterion target defined executive committee member also participate board upon proposal gncc time ucb senior executive supplementary defined contribution grant metric used plan must address plan contribution plan twofold following requirement company contribution based actual corporate valid strategically relevant company result defined board stakeholder within influence control executive line sight company contribution equal 10 annual basic salary measurable predictable definable robust realistic accurately measurable time horizon chief executive officer benefit individual pension promise lump sum age 60 vesting period three year number share pension promise established roch doliveux awarded adjusted end vesting period based joined organization 2003 company performance goal actual company performance specified threshold beneficiary benefit retirement based average annual leaf prior vesting share awarded basic salary last five year would actuarially maximum award capped 150 original grant reduced ceo leave retirement country delivery award may also u made phantom share depending local member participate ucb retirement saving legislative environment plan plan composed qualified nonqualified component ucbs total contribution plan range 359 annual pay based age contribution irs limit made qualified part plan contribution irs limit made nonqualified component pensionable compensation level contribution limited executive committee member also participate deferred compensation plan fully funded employee participant contribute individual basis defer salary bonus germany executive committee member covered closed defined benefit pension plan plan promise pension case retirement disability death benefit case retirement disability amount 50 last annual base salary retirement disability u c b n n u l r e p rt 2 0 1 2 28 ii n g e e n r e p rt f h e b ar f r e ct r remuneration element 144 remuneration policy 2013 member executive committee also typically gncc carefully monitor impact new entitled participate international healthcare plan upper management compensation scheme would executive life insurance available senior make necessary adjustment based overall executive executive committee member also provided effectiveness policy certain executive perquisite company car benefit kind element disclosed 145 compensation section compensation executive committee executive committee remuneration policy member executive committee extensively described ucb charter chairman executive committee corporate governance 54 available chief executive officer ucb website remuneration chairman executive committee ceo roch doliveux composed termination arrangement abovementioned element base salary shortterm given international character executive incentive longterm incentive committee well dispersal various activity addition director fee board member across different geography member agreement ucb sa remuneration benefit granted governed different legal jurisdiction directly indirectly chairman executive executive committee termination agreement committee ceo ucb affiliate exception jeanchristophe tellier anna richo 2012 amount signed entry force belgian b ase salary earned 2012 1 320 412 corporate governance law 6 april 2010 limit level termination indemnity hortterm incentive bonus paid 2013 relating financial year 2012 457 963 service contract established 2003 roch doliveux provides case termination eligible longterm incentive number ucb share option lump sum equal 24 month actual base compensation see section plus actual average variable compensation relating ther component remuneration cost three previous year case termination due change pension insurance coverage monetary value control lump sum equal 36 month fringe benefit 2 071 971 amount includes ismail kola hold belgian employment contract retirement benefit based service cost 1 217 083 termination clause would entitle based performance external benchmark severance payment 18 month base salary bonus inflation board approved salary increase 3 case contract terminated company case 2013 ceo new annual base salary march 2013 change control ucb payment would equivalent 1 366 659 24 month base salary bonus ceo total compensation base salary bonus lti fabrice enderlin detlef thielgen specific 2012 amount 3 103 500excluding pension contribution termination provision belgian contract benefit represents 4 decrease value case termination local employment law compared 2011 line deployment new practice would apply compensation policy notably reduced target cash bonus iris löwfriedrich german employment agreement provides minimum six month notice caring entrepreneurship fund termination indemnity equal one year base salary roch doliveux continued contribute portion bonus overall would represent 18 month compensation fund set 2008 part termination package king baudouin foundation caring entrepreneurship robert trainor mark mcdade hold fund focus supporting entrepreneurship field u employment agreement clause included health wellness agreement specifying termination payment 18 month base salary bonus involuntary termination agreement company case change control jeanchristophe tellier greg duncan anna richo covered u employment agreement clause allowing severance payment equal 18 month base salary bonus involuntary termination employment agreement case change control ucb u c b n n u l r e p rt 2 0 1 2 29 ii n g e e n r e p rt f h e b ar f r e ct r member executive committee amount compensation stated reflects longterm incentive number ucb share option amount executive committee member earned see section 2012 based effective period service executive ther component remuneration cost committee member see section composition pension insurance coverage monetary value executive committee fringe benefit 3 096 022 amount includes remuneration benefit granted directly retirement benefit based service cost 1 143 166 indirectly global basis member aggregated executive committee compensation base executive committee company affiliate salary bonus lti 2012 amount 11 047 408 belonging group 2012 amount excluding pension contribution benefit b ase salary earned 2012 4 572 493 noted one new member joined executive committee 2012 hortterm incentive bonus paid 2013 relating financial year 2012 1 867 576 longterm incentive lti granted 2012 binomial binomial value binomial value value stock performance performance total binomial stock option 1 stock option 2 stock award 3 award 4 share 5 share 6 value lti 8 roch doliveux 45 000 333 900 24 000 619 200 28 750 372 025 1 325 125 ismail kola 15 000 111 300 7 500 193 500 8 750 113 225 418 025 robert trainor 7 15 000 111 300 10 000 280 663 8 750 113 225 505 188 iris löwfriedrich 15 000 111 300 7 200 185 760 8 050 104 167 401 227 fabrice enderlin 15 000 111 300 7 200 185 760 8 050 104 167 401 227 detlef thielgen 15 000 111 300 7 200 185 760 8 050 104 167 401 227 greg duncan 12 000 89 040 6 000 154 800 7 000 90 580 334 420 jeanchristophe tellier 12 000 89 040 6 000 154 800 7 000 90 580 334 420 mark mcdade 12 000 89 040 6 000 154 800 7 000 90 580 334 420 anna richo9 40 000 1 477 186 1 477 186 1 number right acquire one ucb share price 3236 1 april 2015 31 march 2022 1 january 2016 31 march 2022 roch doliveux fabrice enderlin detlef thielgen ismail kola 2 2012 value stock option calculated based binomial methodology 742 defined tower watson 3 number ucb share phantom share delivered free vesting period three year still employed ucb 4 2012 value stock award calculated based binomial methodology 2580 per share award defined tower watson 5 number ucb share phantom share delivered free vesting period three year still employed ucb upon fulfilment predefined performance condition 6 2012 value performance share calculated based binomial methodology 1294 per performance share defined tower watson 7 robert trainor granted phantom stock award 2 500 ucb share 1 december 2012 addition grant 1 april 2012 8 binomial valuation objective technique pricing longterm incentive determines fair value stock price life longterm incentive 9 1 november 2012 anna richo granted signon stock award 40 000 ucb share 20 000 share delivered 1 november 2013 1 november 2014 u c b n n u l r e p rt 2 0 1 2 30 ii n g e e n r e p rt f h e b ar f r e ct r longterm incentive vesting 2012 schedule showing longterm incentive granted executive committee member previous year reported previous annual report vested calendar year 2012 accumulated information table detail longterm incentive granted 2012 stock option stock awards1 performance shares1 number vested number total value total value exercised 12 exercised 3 number vested upon vesting 4 number vested upon vesting roch doliveux 36 000 24 000 769 200 21 750 697 088 greg duncan 10 100 10 100 4 625 148 231 4 219 135 219 detlef thielgen 5 000 15 000 6 600 211 530 5 250 168 263 mark mcdade 12 000 12 200 391 010 5 250 168 263 fabrice enderlin 12 000 12 000 7 200 230 760 5 250 168 263 iris löwfriedrich 15 000 7 500 240 375 6 563 210 344 robert trainor 5 15 000 32 500 1 325 625 32 813 1 349 857 ismail kola6 15 000 655 388 based decision taken gncc 20 february 2012 upon vesting stock award performance share ucb deliver number share cash order cover tax social security liability due beneficiary award 1 jeanchristophe tellier ismail kola joined ucb 2008 lti grant addition greg duncan became member executive committee 2012 lti vesting 2 stock option granted iris löwfriedrich 1 april 2009 vested 1 april 2012 exercise price eur 2138 stock appreciation right granted robert trainor greg duncan mark mcdade 1 april 2009 vested 1 april 2012 exercise price 2219 stock option granted roch doliveux detlef thielgen fabrice enderlin 1 april 2008 vested 1 january 2012 exercise price 2201 3 fabrice enderlin detlef thielgen exercised stock option granted 1 april 2008 exercise price eur 2201 greg duncan exercised stock appreciation right granted 1 april 2009 exercise price eur 2219 4 upon vesting ucb share value 3205 represents market value share delivered vesting date determined average high low price ucb share date 5 addition vesting 2009 grant robert trainor stock award including phantom award granted 2012 performance share outstanding subject accelerated vesting date retirement per plan rule section 409a internal revenue code award subject deferral delivered 2013 6 1 december 2009 ismail kola granted signon phantom stock award delivery share payment cash amount 1 december 2012 ucb share value 43 695 1 december 2012 2013 longterm incentive grant ucbs policy grant number longterm incentive defined policy actual grant value known based corporate individual performance april 1 based share price day multiplier attributed performance year grant found number option award granted made april 1 following close performance april 1 2013 resulting grant value reported year grant size based valuation share price 2013 annual report stock option 2013 stock award 2013 performance share 2013 roch doliveux 55 991 13 769 27 828 fabrice enderlin 12 170 2 993 6 049 ismail kola 18 560 14 564 9 224 iris löwfriedrich 13 397 3 295 6 658 mark mcdade 15 214 3 741 7 561 detlef thielgen 14 904 3 665 7 407 anna richo 19 476 4 790 9 680 jeanchristophe tellier 11 272 2 772 5 602 u c b n n u l r e p rt 2 0 1 2 31 ii n g e e n r e p rt f h e b ar f r e ct r feature ucbs internal control 15 risk management system 151 internal control board ucbs governing body one role reliable data result properly stated provide entrepreneurial leadership ucb within accordance requirement framework prudent effective control enables procedure coordinated global internal risk assessed managed ucb management audit function advance issuance halfyear responsible establishing maintaining adequate internal annual account result procedure reviewed control provide reasonable assurance regarding reporting consolidation team well finance achievement objective reliable nature financial legal department external auditor appropriate information compliance relevant law regulation followup potential issue identified performed performing internal control process within ucb consideration adjustment reported financial information efficient manner disclosure evaluated audit committee assist board responsibility result procedure reviewed ceo monitoring management ucb ucb group cfo subsequently audit committee whole effectiveness ucbs overall internal prior publication account control process overall financial reporting process external auditor global internal audit function ucb update business plan annual basis effectiveness prepares detailed annual budget financial year considered approved board management global internal audit function provides independent reporting system place providing management objective assurance activity designed evaluate add financial operational performance measurement value improve ucbs internal control operation indicator management account prepared monthly bringing systematic disciplined approach evaluation cover major area business variance recommending enhancement ucbs governance plan previous forecast analyzed explained compliance risk management internal control process acted timely manner addition regular board global internal audit group undertakes audit plan discussion meeting held least monthly financial compliance operational audit review executive committee discus performance specific reviewed approved audit committee project discussed required information covering relevant company activity program includes system developed support ucbs long term objective independent review system internal control managed professionally staffed information risk management finding status corrective management team action taken address regularly reported writing executive committee status completion audit plan well summary 152 risk management finding status corrective action reported global risk management policy applicable whole writing audit committee four time per year ucb group affiliate worldwide describes ucbs ucb adopted formal procedure focused internal commitment provide effective risk management system control financial reporting referred across ucb order minimize exposure risk transparency directive process process intended could threaten corporate objective help minimize risk selective disclosure help ensure board responsible approving ucb group material information disclosure made ucb strategy goal objective overseeing investor creditor regulator accurate complete establishment implementation review ucb timely fairly present ucbs condition help ensure group risk management system adequate disclosure material financial nonfinancial information significant event transaction risk board assisted audit committee responsibility appreciation risk risk process consists number activity identified key management audit committee examines regular contributor internal control process includes basis area risk could significantly affect ucb executive committee member required certify group financial situation reputation monitor writing understand complied overall risk management process ucb ucbs requirement related financial reporting process including providing reasonable assurance effective corporate risk management committee consisting efficient operation reliable financial information executive committee member senior management compliance law regulation promote representative business function reporting understanding broad range potential issue executive committee provides strategic leadership detailed checklist provided complete endorses corporate risk assessment prioritization assist certification addition detailed process drive establishment risk mitigation plan worldwide review sale credit account receivables within business function operation supported inventory trade inventory accrual provision global risk management system effectively efficiently reserve performed finance director assess report mitigate manage actual potential risk individual business unit required acknowledge exposure chair corporate risk management writing financial reporting area based committee report directly ceo provides periodic u c b n n u l r e p rt 2 0 1 2 32 ii n g e e n r e p rt f h e b ar f r e ct r status update directly executive committee risk management strategy objective global annual basis audit committee well internal audit function responsible independently board regularly reviewing well validating risk management process ucb jointly agreeing business executive committee responsible implementing function action mitigate control assessed risk rivate investment transaction trading ucb share 16 p board approved dealing code prevent insider board designated robert trainor executive trading offence market abuse particularly vice president general counsel 1 june 2011 period preceding publication result information anna richo executive vice president general counsel would likely significant effect price 1 january 2013 insider trading compliance officer whose ucb share price share issued duty responsibility defined dealing code company targeted planned operation document dealing code establishes list key employee reviewed updated board 15 december 2011 director inform compliance officer dealing code establishes rule director executive transaction ucb share intend make management key employee prohibit account code fully compliance directive dealing ucb share financial instrument issued 20036ec insider dealing market manipulation company designated period preceding belgian law 2 august 2002 supervision announcement financial result socalled closed financial sector financial service period prohibits trading ucb share dealing code available ucb website socalled special closed period person wwwucbcominvestorsgovernanceinsidertrading soon possession privileged information 17 external audit general meeting held 26 april 2012 reappointed pwc appointed external auditor affiliate pricewaterhousecoopers hereafter pwc external ucb group worldwide auditor ucb legal term three 3 year 2012 fee paid ucb auditor amounted permanent representative designated pwc ucb belgium jean fossion audit audit related nonaudit related total pwc belgium 491 000 112 743 2 400 606 143 pwc outside belgium 1 713 613 118 954 153 108 1 985 675 total 2 204 613 231 697 155 508 2 591 818 u c b n n u l r e p rt 2 0 1 2 33 ii n g e e n r e p rt f h e b ar f r e ct r nformation requested article 34 18 royal decree 14 november 2007 following element may impact event set abovementioned notification benefit takeover bid see section 11 candidate presented approval 181 ucbs capital structure date capital ucb fully paid indication different class share class share right obligation attached 183 holder security percentage total special control right share capital represents description right 31 december 2012 security 29 february 2008 capital company amounted 550 095 156 represented 184 system control employee 183 365 052 share par value fully paid share scheme control share entitled right right exercised directly different class share see section 112 employee system 182 restriction either legal prescribed article 185 restriction either legal association transfer prescribed article security association voting right restriction transfer security apply existing ucb share entitle holder thereof vote fully paid share according article 11 ucbs article general meeting association hereafter article association follows article 38 article association ucb share give right one vote fully paid share registered may transferred prior agreement board director person entity acquires subscribes beneficial ownership share whether registered capital b shareholder holding share fully paid wish company conferring right vote obliged transfer part shareholding notify intention declare within period required law number share registered letter board director indicating name purchased subscribed together total number candidate approved number share offered share held number total exceeds proportion sale price proposed term sale 3 total voting right exercisable possible board director may registered letter oppose reduction general meeting shareholder sale within month notification presenting another procedure followed time person candidate purchaser selling shareholder candidate obliged make initial declaration mentioned increase proposed board right preemption voting strength 5 75 10 subsequently share offered sale unless proposed seller withdraws additional 5 total voting right acquired defined sale within 15 day following sale share voting right fall one limit specified notification right preemption exercisable unit price occur according modality described legislation corresponding lower two following amount applicable disclosure large shareholding issuer average closing price ucb ordinary share whose security admitted trading regulated market continuous trading market euronext brussels failure respect statutory requirement penalized 30 stock exchange working day preceding notification manner laid article 516 company code preceding paragraph reduced amount still noone may general meeting shareholder cast greater paid number vote relating share unit price offered third party proposed approval accordance paragraph declared holding least twenty day date meeting abovementioned notification board director shall taken notification exercise right preemption treasury share ucb share held ucb direct name account purchasing candidate indirect affiliate law voting right presented board price payable within proposed general meeting 25 april 2013 month notification without prejudice favorable financial instrument whatever nature granting condition offered third party presented approval owner thereof right acquire initiative c board reply within period month ucb share exceeding threshold would notification set first paragraph subsection b trigger notification requirement sale may take place condition less favorable u c b n n u l r e p rt 2 0 1 2 34 ii n g e e n r e p rt f h e b ar f r e ct r 186 agreement shareholder large majority director nonexecutive known ucb may board member result restriction transfer least three nonexecutive director independent security exercise accordance legal criterion adopted voting right board agreement ucb aware expired n single director group director may dominate terminated decisionmaking ucb knowledge content written composition board guarantee diversity agreement might result restriction transfer contribution experience knowledge ability required security exercise voting right ucbs specialist international activity c andidates fully available carry function 187 rule governing appointment take five directorship listed company replacement board member gncc gather information allowing board ensure article association company criterion set met time company shall managed board director appointment renewal term office least three member whether shareholder appointed new directorship appointment gncc performs four year general meeting shareholder assessment existing required ability knowledge time subject dismissal general meeting shareholder experience board profile ideal candidate retiring director eligible reelection period office drawn basis assessment proposed retiring director reappointed cease immediately board discussion definition closing ordinary general meeting shareholder profile established gncc selects candidate general meeting shareholder shall determine fixed fit profile consultation board member variable remuneration director value including chair executive committee possibly attendance voucher charged operating expense using recruitment firm recommendation final candidate made gncc board board decides general meeting decides simple majority vote proposal submitted shareholder approval matter candidate proposed board selection process ruled company charter appointment reference shareholder representative corporate governance follows board vicechair present candidate chosen reference shareholder board consultation gncc dialogue board member composition board director duration mandate age limit composition director appointed general meeting shareholder fouryear term term may renewed board opinion number ten fifteen member appropriate efficient decisionmaking moreover age limit seventy stipulated director one hand contribution experience knowledge shall give hisher current term day annual general different field hand number also allows meeting shareholder following hisher seventieth birthday change board composition managed without board may propose exception rule undue disruption way within provision law article association ucb board shall procedure appointment renewal term composed least three member general meeting process appointment reelection director run shareholder decides number director upon proposal board strives maintain optimum level ability board experience within ucb board large majority board member proposal appointment renewal resignation possible nonexecutive director retirement director examined board based curriculum vitae director directorship candidate recommendation gncc available consultation ucbs website curriculum gncc assesses director candidate vitae mention director directorship reelection next general meeting shareholder listed company commitment effectiveness make recommendation board regarding reelection appointment director special attention given evaluation chair director appointed general meeting board chairman board committee shareholder following proposal board upon recommendation gncc assessment conducted chair board chair gncc meeting director proposing candidate general meeting shareholder capacity director case may chair board take particular account following criterion member board committee chair board assessment conducted chair gncc senior independent director chair gncc assessment conducted chair board senior u c b n n u l r e p rt 2 0 1 2 35 ii n g e e n r e p rt f h e b ar f r e ct r independent director session based questionnaire cover director role governance company board ucbs governing body effectiveness board amongst others evaluate commitment contribution constructive power take decision matter involvement discussion decisionmaking law expressly attribute general meeting shareholder board act collegially feedback given gncc report board make recommendation proposed reelection role responsibility functioning board determined ucbs article association term board submits general meeting shareholder reference board board committee proposal concerning appointment renewal resignation described charter possible retirement director proposal communicated general meeting shareholder part among matter may law take decision agenda relevant shareholder meeting board reserved key area delegated wide power administration executive committee see point 5 general meeting shareholder resolve proposal board area majority vote opt create management committee sense article 524 belgian company code since preferred event vacancy term board empowered permanently delegate power granted law fill post allow decision ratified next general representation ucb general meeting shareholder board role provide entrepreneurial leadership ucb proposal appointment state whether candidate within framework prudent effective control proposed executive director define term proposed enables risk assessed managed board set ucbs mandate ie four year accordance strategic aim ensures necessary financial human article association indicate place useful resource place ucb meet objective review information relation professional qualification management performance board set ucbs value candidate addition main function directorship standard ensures obligation shareholder candidate may obtained consulted others understood met take collegiate responsibility board also indicates whether candidate meet sound exercise authority power independence criterion particular stipulated power board reserved concern mainly article 526ter company code fact director following end also receives information order qualify independent may hold mandate required relation three consecutive term maximum twelve year case director meet independence 1 definition ucbs mission value strategy risk tolerance criterion proposal submitted general meeting key policy shareholder acknowledge independent character 2 monitoring proposal appointment available ucbs website management performance implementation wwwucbcom company strategy effectiveness board committee performance external auditor 187 b rule governing amendment ucbs article association 3 appointment removal rule governing amendment article among member chair board association set belgian law decision amend consultation board member conducted chair article association made general governance nomination compensation committee meeting majority 75 vote cast provided gncc least 50 share capital ucb present among member chair member represented meeting audit committee gncc member attendance quorum met first extraordinary scientific committee general meeting second general meeting convened chair executive committee following proposal decide without attendance quorum gncc member executive committee following proposal 188 power board member gncc recommendation chair particular power issue buy executive committee back share person major external body person power board defined belgian law outside ucb requested represent ucb certain article association subsidiary recommendation chair term reference board responsibility executive committee board reserved described r eviews succession planning chair executive charter corporate governance company follows committee executive committee member proposed gncc 4 endorsement appointment removal senior u c b n n u l r e p rt 2 0 1 2 36 ii n g e e n r e p rt f h e b ar f r e ct r executive recommendation chair 189 significant agreement executive committee ucb party take effect alter terminate upon change 5 e nsure integrity timely disclosure financial control ucb following takeover statement ucb group ucb material bid effect thereof except financial nonfinancial information shareholder nature financial market disclosure would seriously 6 approve framework internal control risk prejudicial ucbthis exception management set executive management shall apply ucb controlled internal audit direct access specifically obliged disclose audit committee information basis legal requirement 7 preparation general meeting shareholder decision proposed considered meeting c onvertible bond ucb sa amount 500 million 450 fixed rate senior unsecured 8 e xecutive management structure general organization convertible security issued 22 september 2009 ucb ucb group state case change control 9 approval annual budget including rd program concept defined term condition capital plan increase overall annual budget approved general meeting held including rd program capital plan 6 november 2009 bondholder right require issuer redeem bondholder bond 10 longterm major finance operation r etail bond ucb sa amount 750 million 11 c reating establishing closing settling transferring 575 fixed rate senior unsecured security issued subsidiary branch production location major division 27 november 2009 state case change exceeding value 50 million control concept defined term 12 allotment merger division purchase sale pledging condition approved general instrument share value exceeding 20 million meeting held 6 november 2009 bondholder involving third party right require issuer redeem bondholder bond 13 purchase sale pledging property asset value exceeding 50 million lease period exceeding institutional bond ucb sa amount nine 9 year aggregate amount expenditure 500 million 575 fixed rate senior unsecured security exceeding 20 million issued 10 december 2009 state case change control concept defined 14 term condition plan grant stock term condition approved stock option employee general meeting held 29 april 2010 bondholder 15 informed end every semester right require issuer redeem charitable donation excess 10 000 ytd bondholder bond single beneficiary facility agreement amount 1 000 million 16 request chair executive committee amongst others ucb sa commerzbank board may also asked pronounce event ag fortis bank sanv mizuho corporate diverging opinion among majority member bank nederland nv joint coordinator mandated executive committee chair lead arranger book runner royal bank scotland nv belgium branch ing belgium sanv kbc bank nv bank tokyomitsubishi ufj ltd authorization shareholder exists date barclays capital dnb bank asa sumitomo allowing board issue new ucb share mitsui banking corporation mandated lead arranger dated 14 november 2009 amended restated according decision general meeting held 30 november 2010 7 october 2011 change 6 november 2009 board board director control clause approved general meeting direct subsidiary authorized period held 26 april 2012 five year starting 7 november 2009 acquire share ucb maximum 20 issued share exchange hybrid bond ucb amount 300 million fixed value equivalent closing price ucb share tofloating rate perpetual subordinated security issued euronext brussels day immediately preceding 18 march 2011 include 4 h stepup change acquisition plus minus maximum 15 taking also control term condition state account applicable legal requirement case change control concept defined term condition applicable interest rate warrant see section 113 increased 500 base point unless ucb elect reimburse predefined condition event hostile bond point change control clause takeover exercised abovementioned adhoc approved general meeting 28 april 2011 committee decides facility agreement amount 150 million ucb lux sa borrower ucb sa promoter guarantor european investment bank dated 9 may 2012 change control clause approved general meeting 26 april 2012 u c b n n u l r e p rt 2 0 1 2 37 ii n g e e n r e p rt f h e b ar f r e ct r ucb stock award performance share plan 1810 agreement ucb ucb share granted annually ucb certain board member employee employee according grade performance criterion providing compensation vest according rule plan three year board member resign made upon condition beneficiary remains continuous redundant without valid reason employment ucb group employment employee cease takeover bid also vest upon change control merger f detail see section 143 main contractual 31 december 2012 following number stock award term hiring termination arrangement performance share outstanding ceo member executive committee 4 45 700 stock award 132 085 vest 2013 agreement provide specific compensation board member case termination takeover bid 395 025 performance share 124 325 vest 2013 addition executive committee member identified section 143 seven employee u benefit change control clause executive committee change control clause guarantee termination member contract described compensation employment employee cease remuneration report section143 takeover bid 19 application article 523 belgian company code excerpt minute meeting board held board director established article 523 1 march 2012 company code applicable operation board discussed recommendation present governance nomination compensation committee relating executive committee member ceo b aron karel boone chair bonus 2011 performance base salary c ountess evelyn du monceau vice chair march 2012 2012 lti grant resolved r roch doliveux executive director bonus lti grant approved proposed b aron albrecht de graeve director r peter fellner director financial consequence company cost p rofessor jeanpierre kinet director company ir thomas mckillop director c eo bonus 1 550 557 130 target individual r gerhard mayr director performance r norman j ornstein director c ount arnoud de pret director c eo base salary increase 3 r alexandre van damme director c eo lti 2012 stock option 45 000 3 year 8 month r bridget van rijckevorsel director vesting stock award 24 000 3 year vesting psp mr gaëtan van de werve director 28 750 3 year vesting cost ucb vesting r thomas leysen director difference might exist purchase price share company exercise price attendance determined accordance condition stipulated plan rule mr inge basteleurs secretary general board discussed recommendation governance nomination compensation committee prior discussion decision board director lti program 2012 resolved following concerning following item resulting governance nomination compensation committee 191 approval ucb stock option pproval executive committee ceo bonus plan 2012 2011 performance base salary 1 march 2012 present operation designed past 2012 lti grant promote shareholding approximately 1 250 employee pproval stock option plan 2012 ucb group within company including executive director member executive pproval stock award plan 2012 committee financially encourage pproval performance share plan 2012 continuing involve success company make aware value roch doliveux executive director stated direct ucb share market whilst adhering rule financial interest implementation said decision governing insider information accordance article 523 company code director withdrew meeting order attend discussion board director concerning issue participate vote u c b n n u l r e p rt 2 0 1 2 38 ii n g e e n r e p rt f h e b ar f r e ct r financial consequence operation ucb performance share plan reserved senior company basically consist difference executive exceeded expectation might exist purchase price share considered top performer including executive company price resale share director member executive committee concerned beneficiary exercising option proposed governance nomination compensation accordance condition stipulated plan rule committee reason grant line remuneration policy beneficiary distribution board director approved intended provide long term incentive vesting linked recommendation governance nomination condition beneficiary remains employed within compensation committee concerning rule group least three year grant date pre stock option allocation basis job category defined target achieved ucb group payout level responsibility thus number 3 600 000 vary 0 150 granted amount depending option shall allocated 1 250 employee level achievement performance condition ucb group estimate take account employee hired promoted eligible level financial consequence operation company 1 january 2012 1 april 2012 basically consist value ucb share time vesting b stock appreciation right sar u ucb ucb performance share plan two metric grant sars rather stock option u approved recommendation governance sar plan follows rule ucb stock option nomination compensation committee board plan difference instead granting real april 2012 vesting 2012 plan 1 adjusted net profit share participant provides ability tax 50 2 beating consensus revenue 50 benefit appreciation value ucb stock distribution board director approved appreciation paid cash moment exercise recommendation governance nomination c etting exercise price exercise price compensation committee concerning rule option lowest two following amount free share grant basis job category level average closing price 30 calendar day responsibility thus number 300 000 share shall preceding offer 231 march 2012 allocated 38 senior executive within group final closing price day preceding amount known 1 april 2012 case new offer 31 march 2012 recruit psps share shall allocated payout ranging 0 150 depending meeting performance u cb determine different exercise price condition set board director final amount eligible employee subject legislation requires known april 1 2012 case new recruit different exercise price order benefit reduced taxation 193 allocation stock award e vesting stock option vesting period performance share exceptional 3 year date grant except country circumstance allowed less favorable accordance measure concurrent creation 192 approval ucb stock award incentive stock pool board approved allocate year 2012 100 000 share allocation stock plan 2012 ucb performance exceptional circumstance beneficiary identified share plan 2012 executive committee senior executive ucb stock award plan reserved senior grant approved executive committee executive including executive director member governance nomination compensation committee executive committee proposed gncc informed yearend designed promote shareholding among category personnel ucb group within company 194 delegating power financially encourage continuing involve success company make aware board decided delegate power chairman value ucb share market whilst adhering executive committee company currently rule governing insider information line roch doliveux senior executive vice president remuneration policy beneficiary intended fabrice enderlin acting individually right sub provide long term incentive free share grant linked delegate order ensure execution decision condition beneficiary remains employed within taken specifically finalize rule regulation group end vesting period ie normally issue documentation beneficiary three year grant date financial consequence exercise procedure operation company basically consist value ucb share time vesting u c b n n u l r e p rt 2 0 1 2 39 ii n g e e n r e p rt f h e b ar f r e ct r pplication article 96 2 section 2 belgian 110 company code deviation code principle 29 guideline secretary board principle 718 anna richo joined executive committee report general counsel instead chairman 1 november 2012 advice governance board jointly constant basis monitor nomination compensation committee based corporate governance compliance ucb alignment previously existing departure payment executive committee member board principle 36 tom mckillop join discussion director granted anna richo departure payment board director 13 december 2012 decided eighteen month grant exception age limit article 324 corporate governance charter u c b n n u l r e p rt 2 0 1 2 40 ii n g e e n r e p rt f h e b ar f r e ct r 2 business performance review1 business performance review operating financial review based consolidated financial statement ucb group company prepared accordance ifrs separate statutory financial statement ucb sa prepared accordance belgian generally accepted accounting principle together report board director general assembly shareholder well auditor report filed national bank belgium within statutory period available request website 21 key highlight revenue 2012 increased 7 3 462 million net sale went 7 due solid performance three core product cimzia vimpat neupro strong keppra sale japan resistance generic erosion europe partially offset generic competition mature product portfolio royalty income fee 10 result lower biotechnology ip revenue increased 23 due new milestone partially offset lower contract manufacturing sale recurring ebitda reached 655 million 2012 compared 687 million 2011 reflecting revenue increase offset launch expense cimzia vimpat neupro rd investment n et profit increased 238 million 2011 252 million 2012 reflecting strong revenue lower nonrecurring higher financing expense core eps increased 191 2011 214 per share 2012 terry living parkinson disease 1 due rounding financial data may add table included management report u c b n n u l r e p rt 2 0 1 2 41 ii n g e e n r e p rt f h e b ar f r e ct r actual variance million 2012 2011 actual rate cst rate revenue 3 462 3 246 7 2 net sale 3 070 2 876 7 2 royalty income fee 168 187 10 14 revenue 224 183 23 18 gross profit 2 378 2 233 6 1 marketing selling expense 875 837 5 0 research development expense 890 778 14 10 general administrative expense 198 191 4 2 operating income expense 0 12 96 92 recurring ebit rebit 415 439 5 16 non recurring income expense 26 91 71 72 ebit operating profit 389 348 12 1 net financial expense 147 115 29 28 profit income tax 242 233 3 16 income tax expense credit 7 9 30 2 profit continuing operation 235 224 5 16 profit loss discontinuing operation 17 14 21 20 net profit 252 238 8 14 attributable ucb shareholder 256 238 8 15 attributable noncontrolling interest 4 0 na na recurring ebitda 655 687 5 12 capital expenditure including intangible asset 221 137 61 na net financial debt 1 766 1 548 14 na cash flow operating activity 355 292 21 na weighted average number share non diluted 1793 1785 0 na eps per weighted average number share non diluted 143 134 7 15 core eps per weighted average number share non diluted 214 191 12 4 22 2012 key event number key event affected eptember 2012 new pilot biotechnology plant affect ucb financially ucbs brainelalleud site belgium plant focus developing ucbs molecule research clinical trial manufacturing process designed optimised important agreement initiative move development full scale industrial production facility include multiple fermentation reactor ecember 2012 biotie therapy reported positive well integrated laboratory topline result phase 2b study evaluating adenosine a2a antagonist tozadenant syn115 june october 2012 ucbharvard research parkinson disease pd ucb hold 92 biotie alliance expands move forward ucb licence exclusive worldwide right tozadenant launched second third collaborative research project phase 3 development commercialization ucb harvard build upon innovative research currently analyzing data full detail decision alliance signed 2011 second research project development expected first quarter aim driving translation developing small molecule 2013 compound induction autophagy potential application treatment neurodegenerative disease n ovember 2012 exemed pharmaceutical acquires third focused human microbiome develop new ucbs indian production facility vapi ucbs vapi therapeutic application immunology plant currently focus production packaging distribution ucb mature drug mainly ay 2012 ucb expands brazil ucb meizler indian market exemed pharmaceutical continue biopharma privatelyowned brazilian pharmaceutical activity also planning bring new business company announced signed agreement site ucb acquires 51 meizler biopharma part partnership ucb bring part mature n ovember 2012 exclusive partnership agreement new medicine meizler biopharmas portfolio newbridge pharmaceutical several middle commercialization brazil east african market make ucbs core product cimzia vimpat neupro available patient u c b n n u l r e p rt 2 0 1 2 42 ii n g e e n r e p rt f h e b ar f r e ct r pril 2012 convertible bond ucb purchased seizure fully controlled despite current treatment 70 million par value outstanding 2015 convertible 1 2 concomitant antiepileptic drug enrolment trial bond 500 million 450 convertible bond issued plan due external competition market ucb sa 30 september 2009 clinical trial patient design reason patient currently levetiracetam excluded first result expected arch 2012 collaboration university h2 2014 brivaracetam present opportunity oxford see investment gbp 36 million extend ucbs leadership within epilepsy providing new project field translational medicine better treatment challenging disease f ebruary 2012 ucb nodality enter ucb0942 new drug candidate innovative multiyear strategic collaboration utilize mechanism action preandpost synaptic inhibitor nodalitys proprietary single cell network profiling ppsi developed treatment drug scnp technology assist development several refractory epilepsy singledose multipledose phase 1 ucb compound field immunology study completed satisfactorily however january 2012 ucb astellas announce development molecule continue agreement jointly develop commercialize cimzia japan following decision otsuka immunology pharmaceutical discontinue collaboration december 2012 cimzia certolizumab pegol immunology ucb astellas agreed codevelop approved japan treatment adult patient copromote cimzia certolizumab pegol japan rheumatoid arthritis ra following submission january august 2012 strategic alliance marketing authorisation japanese ministry wilex strengthened ucb exercised health labour welfare mhlw january 2012 subscription oversubscription right issuance ucb astellas pharma inc agreed codevelop new share wilex ag munich germany company copromote cimzia japan specializing development drug diagnostic february april 2012 phase 3 trial cimzia agent cancer ucb acquired additional share psoriatic arthritis psa axial spondyloarthritis wilex total holding 1447 axspa including ankylosing spondylitis reported first positive result submission u eu regulatory authority followed november december regulatory update pipeline progress accepted filing u eu regulatory authority february 2013 central nervous system cns march 2012 cimzia phase 3 program juvenile november 2012 ucb started new phase 3 clinical idiopathic arthritis jia started scheduled u trial vimpat lacosamide asia designed first result expected second half 2014 investigate efficacy safety lacosamide adjunctive september 2012 ucb announced topline phase 2 therapy adult patient partialonset seizure initial result olokizumab rheumatoid arthritis study result phase 3 study expected first met primary endpoint demonstrating significant half 2015 reduction disease activity score week 12 however u european monotherapy phase 3 program current data suggest sufficient differentiation vimpat partialonset seizure track potential versus tocilizumab ucb progress first result expected second quarter 2013 program internally phase 3 exploring fourth quarter 2014 respectively option olokizumab including partnering vimpat openlabel pilot phase 2 study adjunctive therapy primary generalised tonicclonic seizure april 2012 romosozumab sclerostin antibody also known pgtcs reported positive result january discussion cdp7851 amg 785 phase 3 clinical trial started regulatory agency move phase 3 development treatment postmenopausal osteoporosis pmo pgtcs ongoing initial result phase 3 program expected paediatric phase 3 program due start first end 2015 half 2013 e xpanding pipeline ucb initiated phase 1 study n eupro rotigotine received u regulatory approval assess ucb4940 new mechanism action april since july 2012 room temperature stable patch treatment immunological disease available u early advanced parkinson clinical development project immunology disease pd well restless leg syndrome rls namely phase 3 program cimzia exxelerate august room temperature stable patch approved cearly epratuzumab systemic lupus eu early advanced pd well rls erythematosus sle also cdp7657 sle december 2012 neupro approved japan phase 1 advancing parkinson disease restless leg syndrome ucbs cns partner otsuka pharmaceutical exclusive right february 2013 ucb partner amgen inc developing marketing neupro japan announced pursue phase 3 clinical trial program cdp7851 amg785 acceleration fracture healing phase 3 study evaluating brivaracetam adjunctive based evaluation currently available phase 2 therapy treatment partial onsetseizures result accelerated fracture healing study general adult epilepsy ongoing study evaluates regulatory guidance fracture healing program efficacy safety brivaracetam dos 100 200 mgday compared placebo adjunctive treatment 700 adult epilepsy patient partial onset u c b n n u l r e p rt 2 0 1 2 43 ii n g e e n r e p rt f h e b ar f r e ct r 3 operating financial review1 scope change result divestment remaining nonpharma activity ie film september 2004 surface specialty february 2005 ucb report result activity part profit discontinued operation recurring nonrecurring transaction decision onetime nature affect ucbs result shown separately nonrecurring item besides ebit earnings interest tax operating profit line recurring ebit rebit recurring operating profit reflecting ongoing profitability company biopharmaceutical activity included recurring ebit equal line operating profit impairment restructuring income expense reported consolidated financial statement core eps core net profit net profit attributable ucb shareholder adjusted aftertax impact nonrecurring item financial oneoffs tax contribution discontinued operation net amortization linked sale per nondilutive weighted average number share core product core product ucbs newly launched medicine cimzia vimpat neupro one ucbs priority growth three product including continued launch new indication carola living parkinson disease 1 due rounding financial data may add table included management report 2012 consolidated financial statement first financial statement group early adopted ia 19r 2011 financials restated ia 19r always applied u c b n n u l r e p rt 2 0 1 2 44 ii n g e e n r e p rt f h e b ar f r e ct r et sale product total net sale amount 31 n 3 070 million 7 higher period actual variance million 2012 2011 actual rate cst rate core product cimzia 467 312 50 41 vimpat 334 218 53 44 neupro 133 95 40 38 product keppra including keppra xr 838 966 13 16 zyrtec including zyrtecd cirrus 249 260 4 8 xyzal 128 108 19 17 omeprazole 79 76 4 3 metadate cd 65 62 5 3 nootropil 63 69 9 8 714 710 0 3 total net sale 3 070 2 876 7 2 core product cimzia certolizumab pegol moderately severely xyzal levocetirizine allergy reported net sale active rheumatoid arthritis ra crohn disease cd 128 million 19 mainly due growing market share available u switzerland brazil russia argentina japan offset generic competition european market chile mexico reached net sale 467 million omeprazole generic product hyperacidity disease increase 155 million 50 reached net sale 79 million compared 76 million vimpat lacosamide epilepsy addon therapy last year treatment partialonset seizure showed 334 million net metadate cd methylphenidate hci attention deficit sale 53 hyperactivity disorder reported net sale 65 million neupro rotigotine parkinson disease pd restless u increase 5 despite generic launch leg syndrome rls net sale increased 95 million september 2012 133 million plus 40 nootropil piracetam cognitive disorder saw decrease net sale 9 69 million 63 million product product net sale mature product remained stable keppra levetiracetam epilepsy reported net sale 838 million 55 million keppra xr u 13 lower last year net sale decreased due postpatent erosion europe 28 partially compensated increase 40 rest world mainly due e keppra japan zyrtec cetirizine including zyrtecdcirrus allergy decreased net sale 4 249 million due generic competition u c b n n u l r e p rt 2 0 1 2 45 ii n g e e n r e p rt f h e b ar f r e ct r net sale product 2012 3 070 million 2011 2 876 million cns cns 28 45 29 47 immunology allergy immunology allergy 27 24 et sale geographical area 32 n north america net sale repor ted ucb reached europe net sale reached 1 275 million 2012 1 171 million increase 24 year 9 cimzia net sale increased 63 81 million 15 constant currency cimzia patient suffering 2011 133 million 2012 antiepileptic drug vimpat crohn disease cd rheumatoid ar thritis ra increased 33 76 million neupro treatment net sale increased 42 321 million anti parkinson disease restless leg syndrome reached epileptic drug vimpat available addon therapy net sale 114 million increase 22 yearover treatment par tialonset seizure achieved net sale year keppra net sale decreased 28 represented 251 million 58 bringing neupro 451 million due generic competition allergy drug u market second half 2012 net sale reached xyzal 25 zyrtec 7 decreased total level 15 million keppra franchise amounted 236 million 105 million due generic competition nootropil 4 yearoveryear including decrease 16 decreased 33 million net sale product related keppra xr venlafaxine xr reached net sale contributed 363 million reduction 4 versus 39 million 17 tussionex hydorcodone plistirex previous year chlorpheniramine polistirex net sale amounted 34 million rest world net sale 2012 amounted 23 due fur ther generic competition net sale 628 million increase 22 mainly related growth product reached 275 million 15 7 asia including e keppra japan zyrtec xyzal constant rate contributed 264 million 201 million japan market leading e keppra grew 40 yearoveryear three new core product cimzia vimpat neupro available patient region contributed 24 million net sale geographical area 2012 3 070 million 2011 2 876 million france france 6 7 germany germany 10 11 italy 6 italy north america north america 6 37 spain 33 4 spain ukireland 6 5 ukireland rest world 5 europe 5 rest world 6 12 japan europe asia japan 7 asia 14 6 8 6 u c b n n u l r e p rt 2 0 1 2 46 ii n g e e n r e p rt f h e b ar f r e ct r actual actual rate constant rate million 2012 2011 million million net sale north america 1 171 943 228 24 140 15 core product cimzia 321 226 95 42 71 31 vimpat 251 158 92 58 74 46 neupro 15 0 15 14 product keppra including keppra xr 236 228 8 4 10 4 venlafaxine xr 39 47 8 17 11 23 tussionex 34 44 10 23 13 29 275 240 35 15 16 7 net sale europe 1 275 1 403 129 9 136 10 core product cimzia 133 81 51 63 49 61 vimpat 76 57 19 33 18 32 neupro 114 94 20 22 19 21 product keppra 451 630 180 28 182 29 xyzal 48 64 16 25 16 25 zyrtec including cirrus 57 61 4 7 4 7 nootropil 33 38 5 14 5 13 363 378 14 4 16 4 net sale rest world 628 515 113 22 85 16 core product cimzia 13 5 8 177 8 158 vimpat 7 3 4 162 4 151 neupro 4 2 3 193 3 189 product zyrtec including cirrus 184 191 7 4 19 10 keppra 152 108 43 40 35 32 xyzal 80 43 36 84 35 80 nootropil 30 31 2 1 2 158 132 25 19 20 15 unallocated 4 15 total net sale 3 070 2 876 194 7 71 2 33 royalty income fee actual variance million 2012 2011 actual rate cst rate biotechnology ip 88 104 15 20 toviaz 38 39 2 2 zyrtec u 19 18 5 3 23 26 12 17 royalty income fee 168 187 10 14 royalty income fee 2012 amounted 168 million u royalty income received overthecounter sale 19 million 10 compared period remained stable amounted 19 million last year biotechnology intellectual property ip decreased royalty income decreased 3 million 88 million due expiration patent royalty 23 million paid pfizer overactive bladder treatment toviaz fesoterodine went 2 38 million zyrtec u c b n n u l r e p rt 2 0 1 2 47 ii n g e e n r e p rt f h e b ar f r e ct r 34 revenue actual variance million 2012 2011 actual rate cst rate contract manufacturing sale 85 93 8 12 astellas otsuka 75 22 238 223 provas profit sharing 29 39 26 26 xyzal milestone profit sharing 13 7 78 74 22 22 1 5 revenue 224 183 23 18 revenue 2012 amounted 224 million neupro new partner jointly develop 23 41 million commercialize cimzia japan astellas contract manufacturing sale decreased 85 million profit sharing agreement novartis provas 8 lower compared period last year contract jalra icandra germany represents 29 million manufacturing sale major part related 26 agreement gsk announced 2009 xyzal milestone profit sharing 78 2011 otsukarelated revenue pertains 13 million mainly related received sale reimbursement rd expense milestone recognised milestone japanese market part agreement entered otsuka ucb 2008 codevelop e keppra cimzia japan since early 2012 collaboration otsuka focus e keppra 35 gross profit actual variance million 2012 2011 actual rate cst rate revenue 3 462 3 246 7 2 net sale 3 070 2 876 7 2 royalty income fee 168 187 10 14 revenue 224 183 23 18 cost sale 1084 1 013 7 5 cost sale product service 791 730 9 8 royalty expense 141 128 10 6 amortization intangible asset linked sale 152 155 2 6 gross profit 2 378 2 233 6 1 product service 2 503 2 328 7 2 net royalty income 27 60 54 59 amortization intangible asset linked sale 152 155 2 6 gross profit 2 378 million 6 higher 2011 following royalty expense royalty increased 128 million increase revenue 2011 141 million 2012 due higher royalty relating launched product cimzia vimpat neupro cost sale three component cost sale partially offset decrease biotechnology ip product service royalty expense amortization venlafaxine xr royalty expense intangible asset linked sale cost sale product service cost sale product service increased 61 million 730 million 2011 254 net sale 791 million 2012 258 net sale due product mix u c b n n u l r e p rt 2 0 1 2 48 ii n g e e n r e p rt f h e b ar f r e ct r actual variance million 2012 2011 actual rate cst rate biotechnology ip 35 42 16 22 106 86 23 20 royalty expense 141 128 10 6 amortization intangible asset linked sale stream trade name etc amortization expense ifrs 3 business combination ucb reflected intangible asset product already balance sheet significant amount intangible asset relating launched amounted 152 million 2012 3 million celltech schwarz pharma acquisition inprocess lower compared 2011 mainly due expiration research development manufacturing knowhow royalty writedown period certain intangible asset ecurring ebit recurring ebitda 36 r actual variance million 2012 2011 actual rate cst rate revenue 3 462 3 246 7 2 net sale 3 070 2 876 7 2 royalty income fee 168 187 10 14 revenue 224 183 23 18 gross profit 2 378 2 233 6 1 marketing selling expense 875 837 5 0 research development expense 890 778 14 10 general administrative expense 198 191 4 2 operating income expense 0 12 96 92 total operating expense 1 963 1 794 9 5 recurring ebit rebit 415 439 5 16 add amortization intangible asset 176 180 3 6 add depreciation charge 64 68 6 8 recurring ebitda rebitda 655 687 5 12 operating expense encompassing marketing selling recurring ebit 24 million 5 due higher expense research development expense general operating expense administrative expense operating income total amortization intangible asset product related expense reached 1 963 million 2012 9 higher last went 180 million 176 million year reflecting mainly due end usefull life certain 38 million higher marketing selling expense driven intangible asset launch neupro u july 2012 epreciation charge amounted 64 million continued launch e keppra japan regional expansion cimzia vimpat neupro recurring ebitda 5 655 million compared 2011 reflecting higher revenue contrasted higher 112 million higher research development expense operating expense due ongoing launch activity reflecting well advanced latestage clinical development ucbs core product major region well e keppra including project last development phase high rd expense due late stage pipeline progressing phase 3 phase 3 well cvn lifecycle management 8 million higher general administrative expense 12 million decrease operating incomeexpenses mainly related due reimbursement expense 2011 reoccur 2012 u c b n n u l r e p rt 2 0 1 2 49 ii n g e e n r e p rt f h e b ar f r e ct r et profit core eps 37 n actual variance million 2012 2011 actual rate cst rate recurring ebit 415 439 5 16 impairment charge 10 39 74 74 restructuring expense 40 27 47 45 gain disposal 31 1 100 100 non recurring income expense 7 25 72 76 total non recurring income expense 26 91 71 72 ebit operating profit 389 348 12 1 net financial expense 147 115 29 28 profit income tax 242 233 3 16 income tax expense credit 7 9 30 2 profit continuing operation 235 224 5 16 profit discontinued operation 17 14 21 20 net profit 252 238 6 14 net profit attributable ucb shareholder 256 238 8 15 aftertax nonrecurring item financial oneoffs 35 70 50 50 profit discontinued operation 17 14 21 21 tax oneoffs 3 66 96 98 amortization intangible linked sale 152 155 2 6 tax amortization intangible 41 43 6 9 core net profit attributable ucb shareholder 383 340 13 4 weighted average number share 1793 1785 0 na core eps attributable ucb shareholder 214 191 12 4 total nonrecurring incomeexpenses amounted net financial expense increased 115 million 2011 26 million pretax expense compared 91 million pre 147 million 2012 32 million including 9 million tax expense 2011 2012 nonrecurring item include oneoff loss debt extinguishment related convertible impairment nonfinancial asset result bond 13 million writeoff wilex investment yearly impairment testing restructuring expense related average tax rate recurring activity 7 shape reorganization support function severance 2012 compared 30 period last year cost gain divestment primary care market low income tax rate arising year 2012 due u australia expense related litigation recognition previously unrecognized tax loss optimization civil investigate demand october 2011 significant proportion loss arising higher tax united state department justice united jurisdiction nonrecurring item lead tax credit state attorney office eastern district pennsylvania 15 million compared tax credit 86 million issued civil investigative demand ucb inc relating 2011 includes oneoff tax income due release price reporting cimzia u federal government liability longer required sale marketing cimzia u company cooperated fully investigation september 2012 net profit amount 252 million 14 million government concluded investigation without 2011 256 million attributable ucb imposing fine penalty taking action shareholder 4 million noncontrolling interest company net profit attributable ucb shareholder adjusted 2011 nonrecurring item included impairment charge aftertax impact nonrecurring item financial 39 million mainly related syn118 oneoffs aftertax contribution discontinued optimization manufacturing facility 27 million operation net amortization linked sale give rise restructuring expense include primarily new organization core net profit 383 million 13 higher 2011 european operation nonrecurring core eps attributable ucb shareholder expense composed u 30 million restructuring amounted 214 compared 191 2011 per nondilutive epratuzumab licence agreement immunomedics weighted average number share ucb additional amortizationdepreciation u c b n n u l r e p rt 2 0 1 2 50 ii n g e e n r e p rt f h e b ar f r e ct r 38 capital expenditure tangible capital expenditure resulting ucb noncurrent liability increase noncurrent liability biopharmaceutical activity amounted 160 million 2 863 million 2 959 million mainly related 2012 compared 82 million 2011 2012 capital increase long term debt employee benefit expenditure related mainly new biotech pilot decrease deferred tax liability plant brainelalleud belgium biotech plant current liability increase current liability bulle switzerland 1 612 million 1 808 million result share swap acquisition intangible asset reached 61 million 2012 transaction 43 million ucb share total amount versus 55 million 2011 software development cost 176 million increase short term bank loan milestone incurred collaboration agreement net debt net debt increased 218 million inlicencing deal 1 548 million end december 2011 1 766 million addition foreseen agreement ucb end december 2012 underlying profitability offset lonza manufacturing lonza pegylated antibody dividend payment 2011 result fragmentbased bulk active ucb participated shareholder perpetual bond prefinancing related capital expenditure depreciation charge investment recognized cost good sold added back recurring ebitda 310 cash flow statement calculation purpose evolution cash flow generated biopharmaceuticals 39 balance sheet activity affected following cash flow operating activity amounted 355 million compared 292 million 2011 stem intense intangible asset intangible asset decreased focus improving working capital 42 million 1 525 million 31 december 2011 1 483 million 31 december 2012 includes ongoing cash flow investing activity show outflow amortization intangible asset 175 million mainly 266 million 2012 compared 131 million 2011 related acquisition celltech schwarz pharma result higher spending tangible intangible impact yearly impairment testing 7 million asset acquisition 51 meizler biopharma decreasing u dollar increasing british pound brazil acquisition 25 schwarz pharma zuhai company ltd pr china goodwill goodwill amount 4 823 million 24 million increase 31 december 2011 31 december 2012 cash flow financing activity outflow reflecting acquisition meizler biopharma brazil partially 27 million includes repurchase convertible offset impact decreasing u dollar bond dividend paid ucb shareholder increasing british pound shareholder perpetual subordinated bond compensated higher borrowing noncurrent asset noncurrent asset increased 86 million mainly driven investment biotech plant deferred tax related recognition 311 outlook 2013 employee benefit decrease interest rate derivative ucb expects financial result 2013 driven current asset increase 1 706 million continued growth cimzia vimpat neupro 31 december 2011 1 822 million 31 december 2012 emerging market partially offset postexclusivity expiry stem increase cimzia neupro inventory erosion keppra higher cash due focus working capital monetization unrealized gain derivative revenue 2013 anticipated grow lowsingledigit percent excluding exchange rate impact approximately shareholder equity ucbs shareholder equity 34 billion 4 593 million decreased 108 million 31 december 2011 31 december 2012 important recurring ebitda expected approximately change stem net profit noncontrolling interest 680 710 million 252 million comprehensive income 135 million core earnings per share expected corresponding including change related ia 19 revised range 190 205 based 1793 million cumulative translation adjustment dividend share outstanding payment 201 million u c b n n u l r e p rt 2 0 1 2 51 ii n g e e n r e p rt f h e b ar f r e ct r iii iii consolidat ed f inancial tatem ents 1 consolidated income statement 2 consolidated statement comprehensive income 3 consolidated statement financial position 4 consolidated statement cash flow 5 consolidated statement change equity 1 consolidated income statement year ended 31 december note 2012 2011 restated million continuing operation net sale 5 3 070 2 876 royalty 168 187 revenue 8 224 183 revenue 3 462 3 246 cost sale 1 084 1 013 gross profit 2 378 2 233 marketing selling expense 875 837 research development expense 890 778 general administrative expense 198 191 operating income expense 11 0 12 operating profit impairment restructuring income expense 415 439 impairment nonfinancial asset 12 10 39 restructuring expense 13 40 27 income expense 14 24 25 operating profit 389 348 financial income 15 86 90 financing cost 15 233 205 profit loss income tax 242 233 income tax expense credit 16 7 9 profit loss continuing operation 235 224 discontinued operation profit loss discontinued operation 7 17 14 profit 252 238 attributable equity holder ucb sa 256 238 noncontrolling interest 4 0 basic earnings per share continuing operation 37 134 126 discontinued operation 37 009 008 total basic earnings per share 143 134 diluted earnings per share continuing operation 37 133 126 discontinued operation 37 008 007 total diluted earnings per share 141 132 53 2 consolidated statement comprehensive income year ended 31 december note 2012 2011 restated million profit period 252 238 comprehensive income net gain loss available sale financial asset 17 2 2 exchange difference translation foreign operation 75 39 effective portion gain loss cash flow hedge 17 5 12 net gain loss hedge net investment foreign operation 17 0 0 remeasurment defined benefit obligation 17 68 42 income tax relating component comprehensive income 17 5 6 comprehensive income loss period 135 11 total comprehensive income period 117 227 attributable equity holder ucb sa 121 227 noncontrolling interest 4 0 total comprehensive income period 117 227 u c b n n u l r e p rt 2 0 1 2 54 iii c n l e f n n c l tat e e n t 3 consolidated statement financial position 2011 1st jan 2011 year ended 31 december note 2012 restated restated million asset noncurrent asset intangible asset 18 1 483 1 525 1 641 goodwill 19 4 823 4 799 4 718 property plant equipment 20 602 500 505 deferred income tax asset 30 505 466 235 investment associate 0 0 16 financial asset including derivative financial instrument 21 125 180 123 total noncurrent asset 7 538 7 470 7 238 current asset inventory 22 616 537 434 trade receivables 23 835 851 705 income tax receivables 13 13 9 financial asset including derivative financial instrument 21 40 38 61 cash cash equivalent 24 318 267 494 1 822 1 706 1 703 asset disposal group classified held sale 0 0 28 total current asset 1 822 1 706 1 731 total asset 9360 9 176 8 969 equity liability equity capital reserve attributable ucb shareholder 25 4 594 4 699 4 503 noncontrolling interest 1 2 2 total equity 4 593 4 701 4 505 noncurrent liability borrowing 27 193 42 32 bond 28 1 697 1 730 1 683 financial liability including derivative financial instrument 29 68 60 43 deferred income tax liability 30 123 217 314 employee benefit 31 290 234 194 provision 32 438 472 218 trade liability 33 150 108 127 total noncurrent liability 2 959 2 863 2 611 current liability borrowing 27 197 45 308 financial liability including derivative financial instrument 29 200 116 79 provision 32 51 71 92 trade liability 33 1 295 1 294 1 172 income tax payable 65 86 198 1 808 1 612 1 849 liability disposal group classified held sale 0 0 4 total current liability 1 808 1 612 1 853 total liability 4 767 4 475 4 464 total equity liability 9 360 9 176 8 969 u c b n n u l r e p rt 2 0 1 2 55 iii c n l e f n n c l tat e e n t 4 consolidated statement cash flow year ended 31 december note 2012 2011 restated million profit year attributable ucb shareholder 256 238 noncontrolling interest 4 0 adjustment profit loss discontinued operation 7 17 14 adjustment noncash transaction 34 175 204 adjustment item disclose separately operating cash flow 34 7 9 adjustment item disclose investing financing cash flow 34 103 129 change working capital 34 15 110 cash flow generated operation 535 456 tax paid period 180 164 net cash flow generated operating activity 355 292 acquisition intangible asset 18 61 55 acquisition property plant equipment 20 160 82 acquisition subsidiary net cash acquired 6 68 3 acquisition investment 1 5 subtotal acquisition 290 145 proceeds sale intangible asset 6 1 proceeds sale property plant equipment 1 1 proceeds sale business unit net cash disposed 17 8 proceeds sale investment 0 4 dividend received 0 0 subtotal disposal 24 14 net cash flow used investing activity 266 131 proceeds issuance perpetual subordinated bond 25 0 295 repayment bond 28 20 0 proceeds borrowing 27 862 345 repayment borrowing 27 556 594 payment finance lease liability 2 2 acquisition issuance treasury share 25 4 137 dividend paid ucb shareholder net dividend paid share 25 201 177 interest received 71 67 interest paid 185 184 net cash flow used financing activity 27 387 cash discontinued operation 6 2 net increase decrease cash cash equivalent 56 224 net cash cash equivalent beginning period 24 253 477 effect exchange rate fluctuation 1 0 net cash cash equivalent end period 24 308 253 cash cash equivalent 318 267 bank overdraft 10 14 u c b n n u l r e p rt 2 0 1 2 56 iii c n l e f n n c l tat e e n t 5 consolidated statement change equity 2012 million attributed equity holder ucb sa cumulative translation total stockholder retained earnings cash flow hedge share capital available sale noncontrolling treasury share net investment reserve share premium financial asset hybrid capital adjustment interest equity hedge total balance 1 january 2012 2 151 295 262 2 615 159 303 1 10 55 4 699 2 4 701 profit period 256 256 4 252 comprehensive 63 75 2 5 135 135 income loss total comprehensive income 256 63 75 2 5 121 4 117 dividend 178 178 178 sharebased payment 16 16 16 transfer reserve 17 17 0 0 treasury share 6 6 6 equity component linked 7 7 7 convertible bond put call option 29 29 29 noncontrolling interest dividend shareholder 23 23 23 perpetual subordinated bond business combination 11 11 1 10 balance 31 december 2012 2 151 295 239 2 669 49 378 3 5 55 4 594 1 4 593 2011 restated million attributed equity holder ucb sa cumulative translation total stockholder retained earnings cash flow hedge share capital available sale noncontrolling treasury share net investment reserve share premium financial asset hybrid capital adjustment interest equity hedge total balance 1 january 2011 2 151 0 125 2 568 280 342 1 2 55 4 590 2 4 592 effect early adoption 2 85 87 87 ia 19r note 22 restated 2 151 0 125 2 566 195 342 1 2 55 4 503 2 4 505 profit period 238 238 0 238 comprehensive 36 39 2 12 11 0 11 income loss total comprehensive income 238 36 39 2 12 227 0 227 dividend 177 177 177 sharebased payment 11 11 11 transfer reserve 5 5 0 0 treasury share 142 142 142 issuance perpetual 295 295 295 subordinated bond dividend shareholder 18 18 18 perpetual subordinated bond balance 31 december 2011 2 151 295 262 2 615 159 303 1 10 55 4 699 2 4 701 restated u c b n n u l r e p rt 2 0 1 2 57 iii c n l e f n n c l tat e e n t iv iv note consolidated financial statement 1 general information 60 2 summary significant accounting policy 60 3 critical judgement accounting estimate 71 4 financial risk management 73 5 segment reporting 79 6 business combination 80 7 discontinued operation 81 8 revenue 81 9 operating expense nature 81 10 employee benefit expense 82 11 operating income expense 82 12 impairment nonfinancial asset 83 13 restructuring expense 83 14 income expense 83 15 financial income financing cost 84 16 income tax expense credit 85 17 component comprehensive income 86 18 intangible asset 87 19 goodwill 88 20 property plant equipment 89 21 financial asset 90 22 inventory 91 23 trade receivables 92 24 cash cash equivalent 93 25 capital reserve 93 26 sharebased payment 94 27 borrowing 98 28 bond 99 29 financial liability 100 30 deferred tax asset liabilities101 31 employee benefit 102 32 provision 105 33 trade liability 106 34 note consolidated statement cash flow 107 35 financial instrument category 108 36 derivative financial instrument 109 37 earnings per share 111 38 dividend per share112 39 commitment contingency 113 40 related party transaction 114 41 event balance sheet date 116 42 ucb company 116 59 1 general information ucb sa ucb company subsidiary ucb sa parent company limited liability company together group global biopharmaceutical company incorporated domiciled belgium focused severe disease two therapeutic area namely registered office 60 allée de la recherche b1070 central nervous system disorder immunology brussels belgium ucb sa listed euronext brussels consolidated financial statement company stock exchange year ended 31 december 2012 comprise board director approved consolidated financial company subsidiary within group ucb statement statutory financial statement ucb pharma sa wholly owned subsidiary branch sa issue 26 february 2013 shareholder uk integrated account requested approve statutory financial statement ucb sa annual meeting 25 april 2013 2 summary significant accounting policy principal accounting policy applied preparation hanges accounting 22 c consolidated financial statement set policy consistently applied year policy disclosure presented unless otherwise stated 221 new amended standard adopted 21 basis preparation group current year group early adopted amendment ia 19 revised june 2011 consolidated financial statement company endorsed european union june 2012 hereafter prepared accordance international financial ia 19r group applied ia 19r retrospectively reporting standard ifrs ifric interpretation accordance transitional provision set adopted use european union ifrss issued ia 19173 transitional provision international accounting standard board iasb impact future period opening statement financial effective time preparing consolidated financial position earliest comparative period presented statement adopted use european union 1 january 2011 restated endorsement procedure established european commission amendment ia 19 change accounting defined benefit plan termination benefit significant consolidated financial statement prepared change relates accounting change defined benefit using historical cost convention except certain item obligation plan asset amendment require including available sale financial asset derivative financial recognition change defined benefit obligation fair instrument liability cashsettled share based value plan asset occur hence eliminate payment arrangement measured fair value corridor approach permitted previous version preparation consolidated financial statement ia 19 accelerate recognition past service cost conformity ifrs requires use certain critical actuarial gain loss recognized immediately accounting estimate also requires management exercise comprehensive income order net pension judgement process applying group accounting asset liability recognized consolidated statement policy area involving higher degree judgement financial position reflect full value plan deficit complexity area assumption estimate surplus furthermore interest cost expected return significant consolidated financial statement plan asset used previous version ia 19 disclosed note 3 replaced netinterest amount ia 19r calculated applying discount rate net defined necessary comparative reclassified benefit liability asset ia 19r introduces certain change order enhance interperiod comparability information presentation defined benefit cost including presented current prior year extensive disclosure u c b n n u l r e p rt 2 0 1 2 60 iv n e h e c n l e f n n c l stat e e n t 222 impact early application ia 19r 2012 consolidated financial statement group adjusted opening equity 1 january 2011 first financial statement group early figure 2011 restated ia 19r adopted ia 19r revised standard adopted always applied retrospectively accordance ia 8 consequently million net employee benefit obligation net deferred tax liability equity balance reported 1 january 2011 87 99 4 592 effect early application ia 19r recorded comprehensive income 105 20 85 retained earnings 2 0 2 restated balance 1 january 2011 194 79 4 505 balance reported 31 december 2011 86 223 4 823 effect early application ia 19r opening balance 107 20 87 movement year recorded comprehensive income 42 6 36 currency translation adjustment 3 1 2 income statement 4 1 3 restated balance 31 december 2011 234 249 4 701 effect consolidated income statement follows million 2011 decrease employee benefit expense social tax 4 increase income tax expense 1 increase profit year 3 effect consolidated statement comprehensive income follows million 2011 remeasurement defined benefit obligation 42 income tax 6 decrease comprehensive income 36 decrease total comprehensive income year 33 ifrss ifric interpretation effective first time financial year beginning 1 january 2012 material impact group ew standard interpretation yet adopted 23 n following new standard amendment existing liability part fair value change due entity standard interpretation issued credit risk recorded comprehensive income effective financial year beginning 1 january 2012 rather income statement unless creates early adopted accounting mismatch group yet assess ifrs 9 full impact intends adopt ifrs 9 later r 9 financial instrument address classification accounting period beginning 1 january 2015 measurement recognition financial asset group also consider impact remaining phase financial liability ifrs 9 issued november 2009 ifrs 9 completed board october 2010 replaces part ia 39 relate classification measurement financial instrument r 10 consolidated financial statement effective ifrs 9 requires financial asset classified two 1 january 2014 latest build existing principle measurement category measured fair value identifying concept control determining measured amortized cost determination factor whether entity included within made initial recognition classification depends consolidated financial statement parent company entity business model managing financial standard provides additional guidance assist instrument contractual cash flow characteristic determination control difficult assess instrument financial liability standard retains group currently assessing ifrs 10 full impact ia 39 requirement main change r 11 joint arrangement effective 1 january 2014 case fair value option taken financial latest ifrs 11 seek provide user financial u c b n n u l r e p rt 2 0 1 2 61 iv n e h e c n l e f n n c l stat e e n t statement greater clarity entity involvement goodwill initially measured excess aggregate joint arrangement requiring entity recognize consideration transferred fair value non contractual right obligation arising joint controlling interest net identifiable asset acquired arrangement participates independently liability assumed consideration lower arrangement legal structure two fair value net asset subsidiary acquired form joint arrangement ifrs 11 joint operation difference recognized profit loss joint venture group currently evaluating intercompany transaction balance unrealized gain impact standard transaction group company eliminated r 12 disclosure interest entity effective unrealized loss also eliminated unless transaction 1 january 2014 latest ifrs 12 includes provides evidence impairment asset transferred disclosure requirement form interest accounting policy subsidiary changed entity including joint arrangement associate special necessary ensure consistency policy adopted purpose vehicle balance sheet vehicle group group currently evaluating impact standard r 13 fair value measurement aim improve 242 change ownership interest consistency reduce complexity providing precise subsidiary without change definition fair value single source fair value control measurement disclosure requirement use across group treat transaction noncontrolling interest ifrss requirement largely aligned result loss control transaction ifrs u gaap extend use fair value equity owner group purchase non accounting provide guidance controlling interest difference consideration applied use already required permitted paid relevant share acquired carrying value standard within ifrss u gaap group net asset subsidiary recorded equity gain currently evaluating impact standard loss disposal noncontrolling interest also ifrss ifric interpretation recorded equity yet effective would expected material impact group 243 disposal subsidiary group cease control retained interest 24 consolidation entity remeasured fair value change carrying amount recognized profit loss fair value 241 subsidiary initial carrying amount purpose subsequently accounting retained interest associate joint subsidiary entity including special purpose entity venture financial asset addition amount previously group power govern financial recognized comprehensive income respect operating policy generally accompanying shareholding entity accounted group directly disposed one half voting right existence related asset liability may mean amount effect potential voting right currently exercisable previously recognized comprehensive income convertible considered assessing whether group reclassified profit loss control another entity subsidiary fully consolidated date control transferred group 244 associate deconsolidated date control cease associate entity group group us acquisition method accounting significant influence control generally accompanying account business combination consideration shareholding 20 50 voting right transferred acquisition subsidiary fair value investment associate accounted using equity asset transferred liability incurred equity method accounting initially recognized cost interest issued group consideration transferred carrying amount increased decreased recognize includes fair value asset liability resulting investor share profit loss investee contingent consideration agreement acquisitionrelated date acquisition group investment associate cost expensed incurred identifiable asset acquired includes goodwill identified acquisition liability contingent liability assumed business combination measured initially fair value ownership interest associate reduced acquisition date acquisitionbyacquisition basis significant influence retained proportionate share group recognises noncontrolling interest amount previously recognized comprehensive acquiree either fair value noncontrolling interest income classified profit loss appropriate proportionate share acquirees net asset group share associate postacquisition profit contingent consideration transferred group loss recognized income statement share recognized fair value acquisition date subsequent postacquisition movement comprehensive income change fair value contigent consideration recognized comprehensive income corresponding deemed asset liability recognized accordance adjustment carrying amount investment ia 39 either profit loss change cumulative postacquisition movement adjusted comprehensive income contingent consideration carrying amount investment group classified equity remeasured subsequent share loss associate equal exceeds interest settlement accounted within equity associate including unsecured receivables u c b n n u l r e p rt 2 0 1 2 62 iv n e h e c n l e f n n c l stat e e n t group recognize loss unless incurred change fair value monetary security denominated obligation made payment behalf associate foreign currency classified available sale analysed translation difference resulting change unrealized gain transaction group amortized cost security change associate eliminated extent group interest carrying amount security translation difference related associate unrealized loss also eliminated unless change amortized cost recognized profit transaction provides evidence impairment loss change carrying amount recognized asset transferred accounting policy associate comprehensive income changed necessary ensure consistency policy adopted group translation difference nonmonetary financial asset liability reported part fair value gain loss dilution gain loss arising investment associate recognized income statement translation difference nonmonetary financial asset equity classified available sale included available sale reserve comprehensive income 25 segment reporting 263 group company group activity one segment biopharmaceuticals result financial position group entity significant class business either none currency hyperinflationary singularly aggregate chief operating decision economy functional currency different maker executive committee review presentation currency translated presentation operating result operating plan make resource currency follows allocation decision companywide basis therefore ucb operates one segment ssets liability balance sheet presented translated closing rate date balance sheet oreign currency 26 f income expense income statement translated average exchange rate unless average translation reasonable approximation cumulative effect rate prevailing transaction date case following important exchange rate used income expense translated rate date preparing consolidated financial statement transaction resulting exchange difference recognized comprehensive income referred cumulative closing rate average rate translation adjustment 2012 2011 2012 2011 consolidation exchange difference arising usd 1320 1296 1285 1390 translation net investment foreign operation borrowing currency instrument designated jpy 114320 99770 102485 110661 hedge investment taken gbp 0813 0836 0811 0867 comprehensive income foreign operation partially chf 1207 1217 1205 1231 wholly disposed sold exchange difference recorded equity recognized income statement part gain loss sale closing rate represent spot rate goodwill fair value adjustment arising acquisition 31 december 2012 31 december 2011 foreign entity treated asset liability foreign entity translated closing rate 261 functional presentation currency item included individual financial statement 27 revenue group entity measured using currency primary economic environment entity operates functional currency consolidated financial statement revenue recognized probable future economic presented euro functional currency benefit associated transaction flow entity company presentation currency group benefit measured reliably amount revenue considered reliably measured 262 transaction balance contingency relating sale resolved revenue represents fair value consideration foreign currency transaction translated received receivable sale good ordinary functional currency using exchange rate prevailing course group activity revenue shown net date transaction foreign exchange gain value added tax return rebate trade discount cash loss resulting settlement transaction discount related medicaid medicare u translation yearend exchange rate monetary similar programme country asset liability denominated foreign currency recognized income statement except deferred comprehensive income qualifying cash flow hedge qualifying net investment hedge u c b n n u l r e p rt 2 0 1 2 63 iv n e h e c n l e f n n c l stat e e n t 271 net sale 29 research development revenue sale good recognized 291 internallygenerated intangible significant risk reward ownership good asset research development transferred buyer expenditure group retains neither continuing managerial internal research development cost expensed involvement degree usually associated incurred due long development period significant ownership effective control good sold uncertainty related development new product amount revenue measured reliably risk related outcome clinical trial well likelihood regulatory approval probable economic benefit associated concluded group internal development cost transaction flow entity general qualify capitalization intangible asset cost incurred incurred respect transaction measured reliably 292 acquired intangible asset estimate expected sale return chargebacks granted inprocess research development project acquired via government agency wholesaler managed care business combination right acquired via either customer deducted revenue time related licensing arrangement separate purchase capitalized revenue recorded incentive offered intangible asset estimate calculated basis intangible asset amortized straightline basis historical experience specific term estimated useful life moment individual agreement available use 272 royalty income mpairment 210 royalty recognized accrual basis accordance substance relevant agreement nonfinancial asset 273 revenue reporting date group review carrying amount intangible asset goodwill property plant revenue comprises revenue generated equipment determine whether indication licensing profitsharing agreement well contract impairment indication exists recoverable manufacturing agreement revenue recognized amount asset estimated order determine earned related service performed extent impairment loss irrespective whether indication impairment impairment assessment group receives third party upfront milestone intangible yet available use goodwill carried similar payment related sale outlicensing annually asset amortized impairment product revenue associated performance milestone loss recognized amount asset carrying recognized based upon achievement milestone amount exceeds recoverable amount event event substantive objectively determinable represents important point development life possible estimate recoverable amount cycle pharmaceutical product upfront payment individual asset group estimate recoverable license fee subsequent deliverable amount cashgenerating unit cgu asset initially reported deferred income recognized belongs recoverable amount higher asset fair revenue earned period development value less cost sell value use determine value collaboration manufacturing obligation use group us estimate future cash flow generated asset cgu using method 274 interest income used initial measurement asset cgu basis mediumterm plan business activity interest recognized time proportion basis take estimated cash flow discounted using appropriate rate account effective yield asset reflects current market assessment time value money risk specific asset cgu 275 dividend income impairment loss recognized directly income statement impairment nonfinancial asset dividend recognized shareholder right caption nonfinancial asset goodwill receive payment established suffered impairment reviewed possible reversal impairment reporting date reversal 28 cost sale impairment recognized income statement impairment loss reversed extent asset carrying amount exceed carrying amount cost sale includes primarily direct production cost would determined net depreciation related production overhead amortization amortization impairment loss recognized related intangible asset well service rendered startup impairment loss goodwill never reversed cost expensed incurred royalty expense directly intangible asset assessed impairment compound linked good sold included cost good sold compound basis u c b n n u l r e p rt 2 0 1 2 64 iv n e h e c n l e f n n c l stat e e n t estructuring expense 211 r 213 intangible asset income expense 2131 patent license trademark expense made group order better intangible asset positioned face economic environment patent license trademark intangible asset operates presented income statement collectively referred intangible asset shown restructuring expense historical cost intangible asset acquired business gain loss arising upon sale intangible asset combination recognized fair value acquisition date property plant equipment well increase intangible asset except goodwill amortized reversal provision litigation tax litigation useful life straightline basis moment litigation related discontinued operation presented available use ie regulatory approval income statement income expense obtained estimated useful life based lower contract life economic useful life 212 income tax 5 20 year intangible asset except goodwill considered finite economic useful life therefore intangible asset indefinite life identified tax expense period comprises current deferred income tax tax recognized income 2132 computer software statement except extent relates item recognized comprehensive income directly acquired computer software license capitalized equity case tax also recognized basis cost incurred acquire bring use comprehensive income directly equity respectively specific software cost amortized estimated useful life 3 5 year straightline basis current income tax charge calculated basis tax law enacted substantively enacted balance sheet date country company subsidiary 214 goodwill operate generate taxable income deferred income tax recognized using liability method goodwill arises acquisition subsidiary associate temporary difference arising carrying joint venture represents excess amount asset liability consolidated financial consideration transferred group interest statement corresponding tax base used net fair value net identifiable asset liability computation taxable profit contingent liability acquiree fair value deferred income tax liability generally recognized noncontrolling interest acquiree goodwill initially taxable temporary difference deferred income recognized asset cost subsequently carried tax asset recognized extent probable cost less accumulated impairment loss goodwill related future taxable profit available acquisition subsidiary presented separately deductible temporary difference carried forward tax credit face balance sheet whereas goodwill arising carried forward loss utilized deferred income tax upon acquisition associated company included accounted arises initial recognition investment associated company goodwill initial recognition asset liability ucb operates one segment one cash generating transaction business combination unit purpose impairment testing time transaction affect neither accounting taxable profit goodwill considered indefinite life tested impairment annually whenever indication carrying amount deferred income tax asset may impaired comparing carrying amount reviewed balance sheet date reduced recoverable amount recoverable amount extent longer probable sufficient taxable cashgenerating unit less carrying amount profit available allow part asset unit impairment loss allocated first reduce recovered carrying amount goodwill allocated unit deferred income tax calculated tax rate asset unit pro rata basis expected apply period liability settled carrying amount asset unit impairment loss asset realized deferred tax asset liability goodwill reversed discounted disposal subsidiary joint venture attributable deferred tax asset liability offset amount goodwill included determination legally enforceable right offset current tax liability profit loss disposal entity asset deferred income tax relate event fair value identifiable asset taxable entity taxation authority liability contingent liability exceeds cost management periodically evaluates position taken tax business combination excess remaining reassessment return respect situation applicable tax recognized directly profit loss regulation subject interpretation establishes provision appropriate basis amount expected paid tax authority u c b n n u l r e p rt 2 0 1 2 65 iv n e h e c n l e f n n c l stat e e n t roperty plant 215 p 216 lease equipment property plant equipment carried cost less lease classified finance lease term accumulated depreciation impairment loss except lease transfer substantially risk reward property plant equipment construction ownership lessee lease classified carried cost less accumulated impairment loss operating lease cost includes directly attributable cost bringing asset working condition intended use 2161 finance lease purchased software integral functionality asset held finance lease recognized asset related equipment capitalized part equipment group lower fair value present value minimum lease payment less cumulative borrowing cost directly attributable acquisition depreciation impairment loss corresponding construction production qualifying asset capitalized liability lessor included balance sheet part cost asset obligation finance lease subsequent cost included asset carrying amount lease payment apportioned finance charge recognized separate asset appropriate reduction lease obligation achieve constant probable future economic benefit associated rate interest remaining balance liability item flow group cost item finance charge recognized income statement measured reliably repair maintenance expensed incurred depreciable amount leased asset allocated accounting period period expected use land depreciated systematic basis consistent depreciation policy depreciation calculated using straightline method group adopts depreciable asset owned allocate cost asset land property reasonable cer tainty group obtain construction residual value ownership end lease term period estimated useful life depreciation commences expected use useful life asset otherwise asset ready used asset depreciated shor ter lease term residual value useful life asset useful life reviewed least financial yearend expectation differ previous estimate change 2162 operating lease isare accounted change accounting estimate accordance ia 8 accounting policy change lease payment operating lease recognized accounting estimate error income statement straightline basis term relevant lease benefit received receivable following useful life applicable main property incentive enter operating lease also spread plant equipment category straightline basis lease term b uildings 20 33 year achinery 7 15 year 217 financial asset laboratory equipment 7 year p rototype equipment 3 year 2171 classification furniture fixture 7 year group classifies financial asset following category fair value profit loss loan vehicle 5 7 year receivables available sale classification depends c omputer equipment 3 year purpose financial asset acquired sset held finance lease shorter asset useful management determines classification financial asset life leasing term initial recognition gain loss disposal determined comparing proceeds disposal carrying amount 2172 financial asset fair value recognized income expense income profit loss statement instrument classified fair value profit loss investment property indicative land building held held trading designated upon initial earn rental asset initially carried cost recognition financial asset designated fair value depreciated straightline basis estimated profit loss group manages investment useful life underlying useful life correspond make purchase sale decision based selfused tangible asset given insignificant amount fair value accordance group financial market investment property separately presented risk management policy derivative financial instrument balance sheet also categorized held trading unless designated hedge u c b n n u l r e p rt 2 0 1 2 66 iv n e h e c n l e f n n c l stat e e n t 2173 loan receivables loan receivables nonderivative financial asset criterion group us determine fixed determinable payment quoted objective evidence impairment loss include active market included current asset except ignificant financial difficulty issuer obligor maturity greater 12 month balance sheet date classified noncurrent asset group breach contract default delinquency loan receivables comprise trade receivables interest principal payment cash cash equivalent balance sheet group economic legal reason relating borrower financial difficulty granting borrower 2174 available sale financial asset concession lender would otherwise consider available sale financial asset nonderivative financial becomes probable borrower enter asset either designated category bankruptcy financial reorganization classified category included disappearance active market financial noncurrent asset unless management intends dispose asset financial difficulty investment within 12 month balance sheet date bservable data indicating measurable 2175 recognition measurement decrease estimated future cash flow group first assesses whether objective evidence regular purchase sale financial asset recognized impairment exists trade date date group commits purchase sell asset investment initially recognized loan receivables category amount loss fair value plus transaction cost financial asset measured difference asset carrying carried fair value profit loss financial asset amount present value estimated future cash fair value profit loss initially recognized fair flow excluding future credit loss value transaction cost expensed income incurred discounted financial asset original effective statement financial asset derecognized right interest rate carrying amount asset reduced receive cash flow investment expired amount loss recognized consolidated transferred group transferred income statement loan heldtomaturity investment substantially risk reward ownership available variable interest rate discount rate measuring sale financial asset financial asset fair value impairment loss current effective interest rate profit loss subsequently carried fair value loan determined contract practical expedient receivables carried amortized cost using effective group may measure impairment basis interest method less impairment loss instrument fair value using observable market price fair value listed investment based current bid subsequent period amount impairment loss price market financial asset active decrease decrease related objectively unlisted security group establishes fair value using event occurring impairment recognized valuation technique improvement debtor credit rating reversal previously recognized impairment loss recognized gain loss arising change fair value consolidated income statement financial asset fair value profit loss category recognized income statement period arise gain loss arising change 2182 asset classified available sale fair value available sale financial asset group assesses end reporting period recognized directly comprehensive income whether objective evidence financial asset disposal impairment availableforsale financial asset group financial asset impaired debt security cumulative gain loss deferred equity group us criterion referred case recycled income statement equity investment classified available sale significant prolonged decline fair value security mpairment 218 cost also evidence asset impaired evidence exists available sale financial asset financial asset cumulative loss measured difference acquisition cost current fair value less impairment 2181 asset carried amortized cost loss financial asset previously recognized profit loss removed equity recognized profit group assesses end reporting period loss impairment loss recognized consolidated income whether objective evidence financial asset statement equity instrument reversed group financial asset impaired financial asset consolidated income statement subsequent period group financial asset impaired impairment loss fair value debt instrument classified available incurred objective evidence impairment sale increase increase objectively related result one event occurred initial event occurring impairment loss recognized recognition asset loss event loss event profit loss impairment loss reversed event impact estimated future cash flow consolidated income statement financial asset group financial asset reliably estimated u c b n n u l r e p rt 2 0 1 2 67 iv n e h e c n l e f n n c l stat e e n t erivative financial 219 cash flow hedge forecast transaction subsequently instrument result recognition financial asset financial liability associated gain loss recognized hedging activity directly equity reclassified income statement period period asset acquired group us derivative financial instrument hedge liability assumed affect income statement exposure foreign exchange interest rate risk arising cash flow hedge relationship discontinued prospectively operational financing investment activity hedge fails effectiveness test hedging instrument group engage speculative transaction sold terminated exercised management revoke derivative financial instrument initially recorded fair designation forecasted transaction longer highly value attributable transaction cost recognized probable forecasted transaction longer highly income statement incurred derivative financial probable still expected occur hedging gain instrument subsequently remeasured fair value loss previously deferred equity remain equity transaction affect profit loss method recognising resulting gain loss depends whether derivative financial instrument forecasted transaction longer expected designated hedging instrument nature occur gain loss released immediately item hedged group designates derivative financial income statement instrument either cash flow hedge fair value hedge net investment hedge 2192 fair value hedge group document inception transaction change fair value derivative financial instrument relationship hedging instrument hedged designated qualify fair value hedge item well risk management objective strategy recorded income statement together change undertaking various hedging transaction group fair value hedged asset liability also document assessment hedge inception attributable hedged risk ongoing basis whether derivative financial instrument used hedging transaction highly effective offsetting change fair value cash flow 2193 net investment hedge hedged item hedge net investment foreign operation full fair value hedging derivative financial instrument accounted similarly cash flow hedge gain loss classified noncurrent asset liability remaining hedging instrument relating effective portion hedged item 12 month current asset hedge recognized comprehensive income liability remaining maturity hedged item less gain loss relating ineffective portion recognized 12 month immediately income statement within financial income gain loss accumulated equity recycled embedded derivative financial instrument separated income statement foreign operation partially host contract accounted separately disposed sold economic characteristic risk host contract embedded derivative financial instrument closely related separate instrument term 2194 derivative financial instrument embedded derivative financial instrument would meet qualify hedge accounting definition derivative financial instrument certain derivative financial instrument qualify combined instrument measured fair value hedge accounting change fair value derivative profit loss financial instrument qualify hedge accounting recognized immediately income statement within 2191 cash flow hedge financial income effective portion change fair value derivative financial instrument designated qualify 220 inventory cash flow hedge recognized comprehensive income gain loss relating ineffective portion recognized immediately income statement within raw material consumables good purchased resale financial income valued lower cost net realisable value cash flow hedge firm commitment forecasted cost determined using weighted average cost method transaction result recognition nonfinancial cost work progress finished good comprises asset nonfinancial liability time asset cost conversion cost incurred bringing liability recognized associated gain loss inventory present location condition derivative financial instrument previously conversion cost include cost production recognized equity included initial measurement related fixed variable production overhead cost asset liability including depreciation charge net realisable value represents estimated selling price less estimated cost completion cost incurred marketing selling distribution u c b n n u l r e p rt 2 0 1 2 68 iv n e h e c n l e f n n c l stat e e n t 221 trade receivables 2243 hybrid capital bond condition hybrid capital issued satisfy trade receivables recognized initially fair value criterion stipulated ia 32 financial instrument subsequently measured amortized cost using effective presentation instrument accounted equity interest rate method less provision impairment instrument group hybrid capital classified equity interest 222 cash cash equivalent reflected dividend shareholder statement change equity cash cash equivalent comprise cash hand demand deposit shortterm highly liquid 225 bond borrowing investment original maturity three month less bank overdraft bank overdraft shown within bond borrowing overdraft initially measured fair borrowing current liability balance sheet value net transaction cost incurred subsequently measured amortized cost using effective interest oncurrent asset 223 n rate method difference proceeds net transaction cost settlement redemption disposal group held borrowing recognized term borrowing sale discontinued accordance group accounting policy operation borrowing classified current liability unless group unconditional right defer settlement liability least 12 month balance sheet date discontinued operation component company either disposed classified held sale represents major separate line business ompound financial 226 c geographical area operation part single coordinated plan dispose subsidiary acquired instrument exclusively view resale compound financial instrument issued group noncurrent asset disposal group classified comprise convertible bond converted held sale carrying amount recovered ordinary share option issuer number principally sale transaction sale considered share issued vary change fair highly probable noncurrent asset disposal group value past due existence option measured lower carrying amount fair value issuer redeem cash convertible bond less cost sell carrying amount recovered separated debt derivative component principally sale transaction rather continuing use impairment loss upon initial classification upon initial recognition bond fair value debt held sale recognized income statement component determined based present value noncurrent asset classified held sale neither contractually determined stream cash flow discounted depreciated amortized rate interest applied time market instrument comparable credit status providing substantially cash flow term 224 share capital without conversion option subsequent initial recognition debt component 2241 ordinary share measured based amortized cost using effective interest method ordinary share classified equity incremental cost directly attributable issue new share option remainder proceeds allocated shown equity deduction net tax proceeds conversion option recognized within derivative company issue preference mandatory subsequent initial recognition derivative component redeemable preference share measured fair value gain loss upon measurement recognized income statement 2242 treasury share result board decision 2010 revoke ucbs right related cash settlement option derivative group company purchase company component reclassified equity based fair value equity share capital treasury share consideration date revocation equity component paid including attributable direct cost net income remeasured subsequent initial recognition except tax deducted equity attributable conversion expiry company equity holder share cancelled reissued share subsequently reissued transaction cost directly attributable bond consideration received net directly attributable offering incremental included calculation incremental transaction cost related income tax amor tized cost using effective interest method effect included equity attributable company amor tized income statement life equity holder instrument u c b n n u l r e p rt 2 0 1 2 69 iv n e h e c n l e f n n c l stat e e n t 227 trade payable asset excluding interest recognized immediately statement financial position charge credit comprehensive income period occur trade payable initially measured fair value remeasurement recorded comprehensive income subsequently measured amortized cost using effective recycled however entity may transfer amount interest method recognized comprehensive income within equity past service cost recognized profit loss period plan amendment netinterest calculated applying 228 employee benefit discount rate net defined benefit liability asset defined benefit cost split three category 2281 pension obligation ervice cost pastservice cost gain loss curtailment settlement group operates various postemployment scheme including defined benefit defined contribution n etinterest expense income pension plan r emeasurement defined contribution plan pension plan group present first two component defined group pay fixed contribution separate entity benefit cost line item employee benefit expense legal constructive obligation pay consolidated income statement nature expense contribution event fund hold aggregation curtailment gain loss accounted sufficient asset pay employee benefit relating pastservice cost remeasurements recorded employee service current prior period comprehensive income obligation contribution defined contribution pension plan recognized employee benefit expense consolidated income statement due prepaid 2282 postretirement employee benefit contribution recognized asset extent group company provide postretirement healthcare cash refund reduction future payment available benefit retiree group net obligation typically defined benefit plan define amount pension amount future benefit employee earned benefit employee receive retirement usually return service current prior period dependent one factor age year expected cost benefit accrued period service compensation liability recognized employment using methodology used defined consolidated statement financial position respect benefit plan defined benefit pension plan present value defined benefit obligation less fair value plan asset 2283 termination benefit surplus resulting calculation limited present value economic benefit available form termination benefit payable employment refund plan reduction future contribution terminated normal retirement date plan employee accepts voluntary redundancy exchange benefit group recognises termination benefit defined benefit obligation calculated independent demonstrably committed either terminating actuary using projected unit credit method full employment current employee according detailed actuarial valuation based updated personnel information formal plan without possibility withdrawal providing performed least every three year additionally termination benefit result offer made encourage net fluctuation recognized balance sheet voluntary redundancy benefit falling due 12 10 one year next due plan circumstance month balance sheet date discounted present significant membership change modification plan etc value full actuarial valuation also required year full actuarial valuation required projection known rollforwards previous year updated 2284 profitsharing bonus plan assumption discount rate salary increase turnover used group recognises liability expense rollforward valuation individual employee bonus profitsharing based formula take data last full valuation date used taking consideration profit attributable company account assumption salary increase possibly shareholder certain adjustment group recognises turnover valuation measure liability provision contractually obliged applicable balance sheet date 31 december market past practice created constructive obligation value retirement plan asset also established reliable estimate obligation made reported date regardless whether full roll forward valuation performed 2285 sharebased payment present value defined benefit obligation determined discounting estimated future cash outflow group operates several equitysettled cashsettled using yield high quality corporate bond sharebased compensation plan maturity date approximating term related group fair value employee service received exchange obligation denominated currency grant stock option recognized expense benefit expected paid total amount expensed determined reference remeasurement comprising actuarial gain loss fair value stock option granted excluding effect asset ceiling applicable return plan impact nonmarket service performance vesting u c b n n u l r e p rt 2 0 1 2 70 iv n e h e c n l e f n n c l stat e e n t condition example profitability remaining employee 229 provision entity specified time period nonmarket vesting condition included provision recognized balance sheet assumption number option expected vest total amount expensed recognized present obligation legal constructive vesting period period specified result past event vesting condition satisfied probable outflow resource embodying fair value stock option plan measured economic benefit required settle obligation grant date using blackscholes valuation model take account expected life cancellation rate reliable estimate made amount option balance sheet date entity revise obligation estimate number option expected vest recognises impact revision original estimate amount recognized provision best estimate income statement corresponding expenditure required settle present obligation adjustment equity balance sheet date provision measured present value expenditure expected required proceeds received net directly attributable settle obligation using discount rate reflects current transaction cost credited share capital nominal value market assessment time value money risk share premium option exercised specific obligation increase provision due fair value amount payable employee respect passage time recognized interest expense share appreciation right settled cash restructuring provision recognized group recognized expense corresponding increase detailed formal plan raised valid expectation liability period employee become affected carry restructuring unconditionally entitled payment liability remeasured starting implement plan announcing main balance sheet date settlement date feature affected change fair value liability recognized personnel expense income statement 3 critical judgement accounting estimate estimate judgement continuously evaluated ritical accounting 32 c based historical experience factor including expectation future event believed estimate assumption reasonable circumstance preparation financial statement conformity ifrs adopted use european union requires ritical judgement 31 c management make estimate assumption affect applying group reported amount asset liability disclosure contingent asset liability date financial accounting policy statement reported amount revenue expense reporting period 311 revenue recognition management base estimate historical experience nature group business many sale various assumption reasonable transaction simple structure circumstance result form basis making reported amount revenue expense may sale agreement may consist multiple arrangement readily apparent source actual result occurring different time group definition equal estimate estimate also party outlicensing agreement involve assumption reviewed periodically effect upfront milestone payment may occur several revision reflected financial statement period year involve certain future obligation revenue determined necessary recognized significant risk reward ownership transferred group retain continuing managerial involvement effective 321 sale allowance control good sold obligation group accrual expected sale return charge fulfilled might result cash receipt initially back rebate including u medicaid drug recognized deferred income released income rebate program u federal medicare program subsequent accounting period based different similar rebate country estimate based condition specified agreement analysis existing contractual obligation legislation historical trend group experience assessment u c b n n u l r e p rt 2 0 1 2 71 iv n e h e c n l e f n n c l stat e e n t management total accrual item group applied following key assumption adequate based upon currently available information value use calculation required impairment testing interpretation relevant regulation deduction intangible asset goodwill yearend based management estimate actual deduction growth rate terminal value 30 might differ estimate difference could impact accrual recognized balance sheet future iscount rate respect goodwill period consequently level sale recognized intangible related marketed product 90 income statement future period often time iscount rate respect intangible related lag several month recording estimate pipeline product 13 final accounting sale allowance general discount rebate deduction shown invoice since cash flow also take account tax expense accounted immediate deduction gross posttax discount rate used impairment testing sale income statement sale return charge management estimate use posttax discount back rebate discount mentioned rate approximates result using pretax rate applied invoice estimated deducted sale presented pretax cash flow balance sheet appropriate accrual account deducted sale 323 environmental provision 322 intangible asset goodwill group provision environmental remediation cost disclosed note 32 significant group intangible asset carrying amount element environmental provision consist cost 1 483 million note 18 goodwill carrying amount fully clean refurbish contaminated site treat 4 823 million note 19 intangible asset amortized contamination certain site mainly related useful life straightline basis discontinued chemical film activity group moment available use ie regulatory approval obtained future remediation expense affected number uncertainty include amongst others detection management estimate useful life acquired previously unknown contaminated site method inprogress rd compound equates period extent remediation percentage waste attributable compound benefit patent protection data group financial capability exclusivity intangible asset acquired potentially responsible party given inherent difficulty business combination comprises compound estimating liability area cannot guaranteed marketed patent protection data additional cost incurred beyond amount exclusivity exists management estimate useful life currently accrued effect resolution environmental equates period compound realize matter result operation cannot predicted due substantially cash contribution uncertainty concerning amount timing intangible asset goodwill regularly reviewed future expenditure result future operation impairment whenever indication change arise could impact provision recognized impairment might exist intangible asset yet balance sheet future available use goodwill subject least annual impairment testing 324 employee benefit assess impairment estimate made group currently many defined benefit plan future cash flow expected result use disclosed note 31 calculation asset asset eventual disposal estimated cash flow liability related plan based upon statistical adjusted present value using appropriate actuarial assumption particular case discount rate reflects risk uncertainty present value defined benefit obligation associated forecasted cash flow impacted assumption discount rate used arrive actual outcome could vary significantly estimate present value future pension liability assumption discounted future cash flow factor entrance future increase salary benefit absence competition technical obsolescence lower furthermore group us statisticallybased assumption expected right could result shortened useful life covering area future withdrawal participant impairment plan estimate life expectancy actuarial assumption used might differ materially actual result due change market economic condition higher lower employee turnover longer shorter life span participant change factor assessed difference could impact asset liability recognized balance sheet future period u c b n n u l r e p rt 2 0 1 2 72 iv n e h e c n l e f n n c l stat e e n t 4 financial risk management group exposed various financial risk arising 41 market risk underlying operation corporate finance activity financial risk market risk including currency risk market risk risk change market price interest risk price risk credit risk liquidity risk foreign exchange rate interest rate equity price affect group income statement value note present information group exposure holding financial instrument objective market risk abovementioned risk group policy process management manage control market risk exposure managing risk group management capital group enters derivative financial instrument risk management carried group treasury also incurs financial liability order manage market risk department policy approved financial risk possible group seek apply hedge accounting management committee frmc order manage volatility income statement frmc established includes chief group policy practice enter derivative financial officer head accounting reporting transaction speculative purpose consolidation department financial control department internal audit department tax department treasury 411 foreign exchange risk risk department group operates across world exposed frmc responsible movement foreign currency affecting net income r eviewing result ucb risk assessment financial position expressed euro group actively monitor currency exposure appropriate pproval recommended risk management strategy enters transaction aim preserving value onitoring compliance financial market risk asset anticipated transaction group us management policy forward contract foreign exchange option cross currency swap hedge certain committed anticipated pproval policy change foreign exchange flow financing transaction r eporting audit committee instrument purchased hedge transaction exposure group financial risk management policy established primarily denominated u dollar gb pound japanese yen frmc need identify analyse risk faced swiss franc currency group group set appropriate risk limit control important exposure group financial risk management monitor risk adherence limit risk management policy hedge period minimum 6 maximum policy reviewed frmc semiannual basis 26 month anticipated cash flow primarily derived reflect change market condition group activity sale royalty outlicensing revenue provided natural hedge exist group certain investment foreign operation whose net asset exposed foreign currency translation risk currency exposure arising net asset group foreign operation u managed borrowing denominated u dollar provides economic hedge currency exposure arising net asset group foreign operation switzerland uk managed forward contract group investment subsidiary hedged mean borrowing forward contract currency considered material longterm neutral effect translation exposure arising consolidation foreign currency denominated financial statement group foreign subsidiary shown cumulative translation adjustment group consolidated statement change equity u c b n n u l r e p rt 2 0 1 2 73 iv n e h e c n l e f n n c l stat e e n t 412 effect currency fluctuation 31 december 2012 euro strengthened weakened 10 following currency variable held constant impact equity posttax profit forth year would follows change rate impact strenghtening impact equity income statement million weakening eur loss gain loss gain 31 december 2012 usd 10 140 1 10 174 2 gbp 10 72 0 10 88 0 chf 10 36 0 10 44 0 change rate impact strenghtening impact equity income statement million weakening eur loss gain loss gain 31 december 2011 usd 10 158 8 10 184 1 gbp 10 39 9 10 48 11 chf 10 38 1 10 47 1 group policy practice enter derivative transaction speculative purpose 413 interest rate risk 414 effect interest rate fluctuation change interest rate may cause variation interest 100 basis point increase interest rate balance income expense resulting interestbearing asset sheet date would increased equity 19 million liability addition affect market value 2011 0 million 100 basis point decrease interest rate certain financial asset liability instrument described would decreased equity 20 million 2011 0 million following section market risk financial asset 100 basis point increase interest rate balance sheet interest rate group major debt instrument date would increased profit loss 5 million fixed floating described note 27 group us 2011 5 million 100 basis point decrease interest interest rate derivative manage interest rate risk rate would decreased profit loss 5 million described note 36 2011 7 million change profit loss group designates derivative financial instrument would result change fair value cash flow interest rate swap hedging instrument fair value interest rate derivative designated foreign currency hedge fixed rate financial asset liability denominated floating rate liability group derivative financial instrument hedged item qualify hedge accounting well inefficient accounted fair value profit loss por tion fair value hedge designated por tion fixed rate borrowing group retail bond 2012 change fair value resulting interest rate institutional eurobond derivative designated euro denominated floating rate liability group highly probable future cash flow fixed rate debt instrument issued 2013 accounted equity ia 39 change fair value resulting interest rate derivative designated foreign currency denominated floating rate liability group accounted profit loss consequence underlying future cash flow result derivative instrument qualifying accounting change fair value equity ia 39 u c b n n u l r e p rt 2 0 1 2 74 iv n e h e c n l e f n n c l stat e e n t 415 market price risk change market value certain financial asset exposure financial asset credit risk derivative financial instrument affect income controlled setting policy limiting credit exposure financial position group financial longterm asset high quality counterparties regular review credit rating held contractual purpose marketable setting defined limit individual counterparty security held mainly regulatory purpose risk criterion set group treasury investment policy loss value managed review prior investing based generally considered high quality long term credit continuous monitoring performance investment rating 5 year credit default swap rate change risk profile appropriate reduce exposure netting agreement investment equity bond debenture fixed isda international swap derivative income instrument entered basis guideline association master agreement signed respective regard liquidity credit rating counterparties maximum exposure credit risk resulting financial activity without considering netting amount subject market price risk rather immaterial agreement equal carrying amount financial asset therefore impact equity income statement plus positive fair value derivative instrument reasonable change market price risk assumed negligible similar 2011 2012 group purchased treasury 43 liquidity risk share well american style call option providing right purchase share ucb sa liquidity risk risk group able accounted equity 2009 issued convertible meet financial obligation fall due group bond maturing 2015 group repurchased 70 million approach managing liquidity ensure far 2012 equity component linked possible always sufficient liquidity meet convertible bond amount 41 million 2011 48 million liability due normal circumstance without net tax result ucbs decision revoke cash incurring unacceptable loss risking damage settlement option linked convertible bond group reputation group maintains sufficient reserve cash 42 credit risk readily realisable marketable security meet liquidity requirement time addition group certain unutilized revolving committed facility disposal credit risk arises possibility counterparty transaction may unable unwilling meet balance sheet date group following obligation causing financial loss group trade source liquidity available receivables subject policy active risk management c ash cash equivalent note 24 focus assessment country risk credit 318 million 2011 267 million availability ongoing credit evaluation account monitoring procedure certain concentration within trade arketable nonequity security note 21 receivables counterparty credit risk particularly 1 million 2011 0 million u due sale via wholesaler note 23 u nutilized committed facility note 27 credit exposure critical country certain southern 1045 million 2011 1 085 million european country group obtained credit insurance existing 1 billion syndicated committed revolving credit u group entered trade receivable facility group maturing 2016 undrawn per end financing agreement qualifies derecognition according 2012 85 million bilateral committed credit facility term condition agreement ucb drawn 40 milion per end 2012 linearly degressive retain nonpayment late payment risk relating 2016 2025 transferred trade receivables u c b n n u l r e p rt 2 0 1 2 75 iv n e h e c n l e f n n c l stat e e n t table analysis contractual maturity group maturity date excluding impact netting amount financial liability relevant maturity grouping based mentioned respect financial derivative remaining period balance sheet date contractual indicative contractual undiscounted cash flow contrac tual cash less 1 2 million note total flow 1 year 2 year 5 year 5 year 31 december 2012 bank borrowing 27 252 252 73 0 29 150 debenture short term loan 27 111 111 111 0 0 0 finance lease liability 27 17 17 3 10 2 2 convertible bond 28 393 484 19 19 446 0 retail bond 28 780 833 43 790 0 0 institutional eurobond 28 524 614 29 29 556 0 trade liability 33 1445 1445 1295 46 89 15 bank overdraft 27 10 10 10 0 0 0 interest rate swap 17 17 7 2 5 2 put call option noncontrolling interest 36 29 46 0 0 46 0 forward exchange contract used hedging purpose outflow 579 579 560 19 0 0 inflow 576 576 557 19 0 0 forward exchange contract derivative financial instrument fair value profit loss outflow 2 104 2 104 1 877 227 0 0 inflow 2 092 2 092 1 889 203 0 0 31 december 2011 bank borrowing 27 47 47 22 1 24 0 debenture short term loan 27 7 7 7 0 0 0 finance lease liability 27 19 19 2 3 11 3 convertible bond 28 444 590 22 22 546 0 retail bond 28 773 879 43 43 793 0 institutional eurobond 28 513 644 29 29 586 0 trade liability 33 1 402 1 402 1 294 28 49 31 bank overdraft 27 14 14 14 0 0 0 interest rate swap 28 28 7 9 25 0 forward exchange contract used hedging purpose outflow 452 452 344 108 0 0 inflow 446 446 341 105 0 0 forward exchange contract derivative financial instrument fair value profit loss outflow 3 248 3 248 3 016 0 231 0 inflow 3 181 3 181 2 978 0 203 0 u c b n n u l r e p rt 2 0 1 2 76 iv n e h e c n l e f n n c l stat e e n t 44 capital risk management group policy respect managing capital safeguard group ability continue going concern order provide return shareholder benefit patient reduce group external debt order obtain capital structure consistent others industry million 2012 2011 restated total borrowing note 27 390 87 bond note 28 1 697 1 730 less cash cash equivalent note 24 available sale debt security 321 269 note 21 cash collateral related financial lease obligation net debt 1 766 1 548 total equity 4 593 4 701 total financial capital 6 359 6 249 gearing ratio 28 25 45 fair value estimation fair value financial instrument traded active market carrying amount less impairment provision trade available sale financial asset based quoted receivables trade payable assumed approximate market price balance sheet date fair value fair value financial liability disclosure purpose estimated discounting future fair value financial instrument traded contractual cash flow current market interest rate active market determined using established valuation available group similar financial instrument technique option pricing model estimated discounted value cash flow group us variety fair value hierarchy method make assumption based market condition existing balance sheet date effective 1 january 2009 group adopted amendment ifrs 7 financial instrument measured quoted market price used longterm debt balance sheet fair value amendment requires technique estimated discounted cash flow used disclosure fair value measurement level following determine fair value remaining financial instrument fair value measurement hierarchy fair value interest rate swap calculated present value estimated future cash flow fair level 1 quoted unadjusted price active market value forward exchange contract determined using identical asset liability discounted value exchanged amount currency level 2 technique input converted prevailing spot rate balance sheet date significant effect recorded fair value observable either directly indirectly level 3 technique use input significant effect recorded fair value based observable market data u c b n n u l r e p rt 2 0 1 2 77 iv n e h e c n l e f n n c l stat e e n t financial asset measured fair value million level 1 level 2 level 3 total 31 december 2012 financial asset available sale asset note 21 quoted equity security 23 0 0 23 quoted debt security 3 0 0 3 derivative financial asset note 36 forward foreign exchange contract cash flow hedge 0 6 0 6 forward exchange contract fair value profit loss 0 27 0 27 interest rate derivative cash flow hedge 0 0 0 0 interest rate derivative fair value profit loss 0 7 0 7 million level 1 level 2 level 3 total 31 december 2011 financial asset available sale asset note 21 quoted equity security 31 0 0 31 quoted debt security 2 0 0 2 derivative financial asset note 36 forward foreign exchange contract cash flow hedge 0 6 0 6 forward exchange contract fair value profit loss 0 32 0 32 interest rate derivative cash flow hedge 0 0 0 0 interest rate derivative fair value profit loss 0 63 0 63 financial liability measured fair value million level 1 level 2 level 3 total 31 december 2012 financial liability derivative financial liability note 36 forward foreign exchange contract cash flow hedge 0 7 0 7 forward exchange contract fair value profit loss 0 36 0 36 interest rate derivative cash flow hedge 0 1 0 1 interest rate derivative fair value profit loss 0 14 0 14 put call option noncontrolling interest 0 29 0 29 million level 1 level 2 level 3 total 31 december 2011 financial liability derivative financial liability note 36 forward foreign exchange contract cash flow hedge 0 19 0 19 forward exchange contract fair value profit loss 0 99 0 99 interest rate derivative cash flow hedge 0 0 0 0 interest rate derivative fair value profit loss 0 31 0 31 put call option noncontrolling interest 0 0 0 0 reporting period ending 31 december 2012 transfer level 1 level 2 fair value measurement transfer level 3 fair value measurement u c b n n u l r e p rt 2 0 1 2 78 iv n e h e c n l e f n n c l stat e e n t 5 segment reporting group activity one segment biopharmaceuticals operating result operating plan make resource allocation decision companywide basis therefore ucb significant class business either operates one segment enterprisewide disclosure singularly aggregate chief operating decision product sale geographic area revenue major maker executive committee review customer presented 51 product sale information net sale consist following million 2012 2011 cimzia 467 312 vimpat 334 218 neupro 133 95 keppra includ keppra xr 838 966 zyrtec includ zyrtecd cirrus 249 260 xyzal 128 108 omeprazole 79 76 metadate cd 65 62 nootropil 63 69 venlafaxine xr 40 48 tussionex 34 44 product 640 618 total net sale 3 070 2 876 52 geographic information table show sale geographic market customer located million 2012 2011 north america 1 171 943 germany 297 318 france 172 198 italy 172 176 spain 138 162 uk ireland 125 145 belgium 36 41 country 959 893 total net sale 3 070 2 876 table illustrates property plant equipment geographic market asset located million 2012 2011 north america 79 70 switzerland 154 78 germany 22 23 france 2 2 spain 2 2 uk ireland 91 89 belgium 233 220 country 19 16 total 602 500 u c b n n u l r e p rt 2 0 1 2 79 iv n e h e c n l e f n n c l stat e e n t nformation major customer 53 ucb 1 customer individually account u sale 3 wholesaler accounted 11 total net sale end 2012 approximately 85 u sale 2011 83 6 business combination meizler biopharma 30 may 2012 ucb acquired 51 issued immunology ucb bring part mature new outstanding share meizler biopharma meizler medicine meizlers portfolio commercialisation privatelyowned brazilian pharmaceutical company brazil based ucbs control board director purchase price equal u 80 million 64 million minus management ucb fully consolidated meizler 51 meizlers net debt adjustment net debt total purchase price allocated preliminary finalised time financial statement net tangible intangible asset based upon historic published term deal purchase book value 30 may 2012 set forth excess price may increased u 30 million certain cash purchase price preliminary net tangible contingent payment purchase agreement also grant asset intangible asset recorded goodwill selling shareholder put option exercisable 2014 company expects continue obtain information 2015 2016 remaining share meizler grant measurement period one year acquisition ucb call option providing right purchase selling date assist determining fair value net asset shareholder remaining share meizler 2016 note 254 acquired acquisition date noncontrolling interest exercise price based multiple ebitda amount contingent consideration put result preceding year call option remaining 49 share meizler meizler privatelyheld brazilian pharmaceutical company estimated value recorded 31 december 2012 founded 1990 based outside sao paulo yet finalised subject change could team 130 employee commercializes portfolio significant preliminary purchase price allocation inlicensed specialty product brazilian market covering meizler follows different therapeutic area including central nervous system million acquisition date cash consideration 64 recognised amount identifiable asset acquired liability assumed provisional fair value noncurrent asset 4 current asset 17 noncurrent liability 5 current liability 10 total identifiable net asset 6 goodwill 58 income statement year includes net sale loss 73 million 104 million respectively meizler business combination effected 1 january 2012 ucbs net sale loss would 126 million 196 million respectively u c b n n u l r e p rt 2 0 1 2 80 iv n e h e c n l e f n n c l stat e e n t 7 discontinued operation profit discontinued operation 17 million environmental claim site ucb retained 2011 profit 14 million arose mainly termination liability settled past 12 month well tax liability partial reversal provision related unwinding discount rate legacy film chemical activity including termination 8 revenue million 2012 2011 revenue generated mean profitsharing agreement 31 44 upfront payment milestone payment reimbursement 108 46 contract manufacturing revenue 85 93 total revenue 224 183 revenue generated profitsharing agreement stella jointly development commercialization relates primarily following item cimzia japan r evenue copromotion provas jalra ilestone payment due agreement actient icandra germany novartis pharmaceutical r evenue copromotion xyzal u gsk xyzal japan sale milestone sanofi revenue contract manufacturing activity mainly linked toll manufacturing agreement entered 2012 ucb received milestone payment gsk shire well contract manufacturing revenue reimbursement different party mainly earned product related actient pharmaceutical tsuka codevelopment e keppra neupro japan agreement delsym 9 operating expense nature table illustrates certain item expense recognized income statement using classification based nature within group million note 2012 2011 restated employee benefit expense 10 902 829 depreciation property plant equipment 20 55 60 amortization intangible asset 18 175 186 impairment nonfinancial asset 12 10 39 total 1 142 1 114 u c b n n u l r e p rt 2 0 1 2 81 iv n e h e c n l e f n n c l stat e e n t 10 employee benefit expense million note 2012 2011 restated wage salary 667 595 social security cost 84 83 postemployment benefit defined benefit plan 31 30 28 postemployment benefit defined contribution plan 24 16 sharebased payment employee director 26 34 20 insurance 36 38 employee benefit 27 49 total employee benefit expense 902 829 total employee benefit expense allocated discontinued operation employee benefit consist along functional line within income statement except mainly termination benefit severance payment case discontinued operation longterm shortterm disability benefit included relevant determination profit headcount 31 december 2012 2011 hourly paid 869 848 monthly paid 3 716 3 912 management 4 463 3 746 total 9 048 8 506 information regarding postemployment benefit sharebased payment found note 22 26 31 11 operating income expense operating income expense amounted 0 million 2011 12 million consists mainly amortization nonproduction related intangible asset 6 million 2011 6 million reversal provision 3 million 2011 6 million impairment reversal impairment respect trade receivables tangible fixed asset 1 million 2011 1 million reimbursement third party development expense incurred group 3 million 2011 5 million grant received 3 million expense related health care reform u u c b n n u l r e p rt 2 0 1 2 82 iv n e h e c n l e f n n c l stat e e n t 12 impairment nonfinancial asset review recoverable amount group asset impairment charge related group property resulted recognition impairment charge amounting plant equipment certain administrative building 10 million 2011 39 million manufacturing facility amounted 3 million 2011 22 million 2012 trademark patent licence impairment charge amount 0 million 2011 4 million impairment reasonably possible change key assumption respect intangible asset 2011 7 million management based determination asset recoverable amount would cause asset carrying amount result yearly impairment testing additional exceed recoverable amount impairment charge 7 million trademark patent licence recognized 2011 6 million 13 restructuring expense restructuring expense 31 december 2012 amount function severance cost 2011 restructuring 40 million 2011 27 million related expense mainly related new organization shape restructuring cost reorganization support european operation 14 income expense income amounted 24 million 2011 expense october 2011 united state department justice 25 million comprised following item united state attorney office eastern district pennsylvania issued civil investigative demand ther income 31 million 2012 compared ucb inc relating price reporting cimzia 0 million 2011 divestment primary care u federal government sale marketing market u australia cimzia u company cooperated fully ther expense amounted 7 million investigation september 2012 government 2011 25 million 2012 mainly relate concluded investigation without imposing fine penalty taking action company patent infringment suit aaipharma ucb optimization ucb company structure u sale omeprazole product hatchwaxman patent infringement suit ucb 25 million expense 2011 related mallinkckrodt u filed anda restructuring epratuzumab license agreement metadate cd paragraph iv certification immunomedics ucb immunomedics received patent infringement suit u apotex nonrefundable cash payment totalling u 30 million upon ucb sale univasc uniretic execution amendment additional amortization moexipril product depreciation government concluded investigation without imposing fine penalty taking action company u c b n n u l r e p rt 2 0 1 2 83 iv n e h e c n l e f n n c l stat e e n t 15 financial income financing cost net financing cost year amounted 147 million 2011 115 million breakdown financing cost financial income follows financing cost million 2012 2011 interest expense convertible bond 31 33 retail bond 43 43 institutional eurobond 29 29 borrowing 40 25 interest expense related interest rate derivative 0 4 financial charge finance lease 1 1 impairment equity security 13 0 net fair value loss foreign exchange derivative 0 62 net foreign exchange loss 62 0 net financial income expense 5 8 loss debt extinguishment 9 0 total financing cost 233 205 financial income million 2012 2011 interest income bank deposit 16 8 interest rate derivative 4 0 dividend income 0 0 net gain interest rate derivative 4 29 net fair value gain foreign exchange derivative 62 0 net foreign exchange gain 0 53 total financial income 86 90 impairment equity security related investment wilex note 213 april 2012 ucb purchased 70 million par value outstanding convertible bond loss debt extinguishment 9 million note 281 u c b n n u l r e p rt 2 0 1 2 84 iv n e h e c n l e f n n c l stat e e n t 16 income tax expense credit million 2012 2011 restated current income tax 136 327 deferred income tax 129 318 total income tax expense credit 7 9 group operates internationally implying subject weighted average tax rate applicable profit loss income tax many different tax jurisdiction consolidated company income tax expense group profit tax income tax recognized income statement differs theoretical amount would arise using detailed follows million 2012 2011 restated profit loss tax 242 233 income tax expense credit calculated domestic tax rate 5 68 applicable respective country theoretical income tax rate 2 30 reported current income tax 136 327 reported deferred income tax 129 318 total reported tax charge credit 7 9 effective income tax rate 27 4 difference theoretical reported tax 12 59 expense nondeductible tax purpose 118 85 nontaxable income 39 127 increase decrease tax provision 24 249 effect previously unrecognized tax loss used period 9 60 tax credit 115 100 variation tax rate 13 5 tax rate effect 0 10 current tax adjustment related prior year 11 16 deferred tax adjustment related prior year 66 185 effect unused tax credit tax loss recognized deferred tax 28 107 withholding tax 10 2 tax 1 1 total income tax expense credit 12 59 low theoretical income tax rate arising year due significant proportion loss arising higher tax jurisdiction effective tax rate remains low due continued recognition previously unrecognized tax loss u c b n n u l r e p rt 2 0 1 2 85 iv n e h e c n l e f n n c l stat e e n t 17 component comprehensive income million 2012 2011 restated available sale financial asset gain loss arising year 2 2 less reclassification adjustment gain loss included income statement 0 0 2 2 cashflow hedge gain loss arising year 5 8 less reclassification adjustment gain loss included income statement 0 4 5 12 net investment hedge gain loss arising year 0 0 less reclassification adjustment gain loss included income statement 0 0 0 0 remeasurement defined benefit obligation gain loss arising year 63 36 less reclassification adjustment gain loss included income statement 0 0 63 36 u c b n n u l r e p rt 2 0 1 2 86 iv n e h e c n l e f n n c l stat e e n t 18 intangible asset 2012 trademark patent million licence total gross carrying amount 1 january 2 505 170 2 675 addition 3 137 140 disposal 62 1 63 transfer one heading another 7 15 8 business combination 1 1 effect movement exchange rate 2 1 3 gross carrying amount 31 december 2 438 320 2 758 accumulated amortization impairment loss 1 january 1 072 78 1 150 amortization charge year 151 24 175 disposal 58 58 impairment loss recognized income statement 7 7 transfer one heading another 7 9 2 transfer asset held sale effect movement exchange rate 1 1 accumulated amortization impairment loss 31 december 1 164 111 1 275 net carrying amount 31 december 1 274 209 1 483 2011 trademark patent million licence total gross carrying amount 1 january 2 441 173 2 614 addition 1 54 55 disposal 39 6 45 transfer one heading another 60 52 8 transfer asset held sale 0 0 0 effect movement exchange rate 42 1 43 gross carrying amount 31 december 2 505 170 2 675 accumulated amortization impairment loss 1 january 917 56 973 amortization charge year 159 27 186 disposal 39 6 45 impairment loss recognized income statement 10 7 17 transfer one heading another 1 6 5 transfer asset held sale 0 0 0 effect movement exchange rate 24 0 24 accumulated amortization impairment loss 31 december 1 072 78 1 150 net carrying amount 31 december 1 433 92 1 525 group amortises intangible asset amortization year group recognized total impairment intangible asset allocated cost sale intangible charge 7 million 2011 17 million related yearly asset related compound amortization impairment testing impairment charge detailed charge related software allocated function note 12 presented income statement use software caption impairment nonfinancial asset majority group intangible asset arose intangible asset includes software process previous acquisition 2012 group acquired development project major part milestone intangible asset totalling 140 million 2011 55 million incurred collaboration agreement addition related mainly milestone incurred collaboration agreement inlicencing deal addition software capitalized eligible software development cost u c b n n u l r e p rt 2 0 1 2 87 iv n e h e c n l e f n n c l stat e e n t 19 goodwill million 2012 2011 cost 1 january 4 799 4 718 acquisition 58 0 effect movement exchange rate 34 81 net book value 31 december 4 823 4 799 group test goodwill impairment reporting significant change key assumption date frequently indication goodwill comparing 2011 might impaired purpose impairment testing cash flow beyond projected forecasted period terminal group operates one segment biopharma value extrapolated using estimated growth rate 3 one single cash generating unit cgu represents 2011 3 growth rate exceed longterm lowest level goodwill monitored average growth rate relevant territory recoverable amount cgu determined based cgu operates valueinuse calculation methodology applied group revenue expense eur performing impairment testing modified usd based country following important exchange rate compared 2011 used preparing future cash flow key assumption 2012 2011 calculation performed based cash flow usd 125 145 projection derived financials underlying gbp 0835 0870 strategic plan approved management covering period jpy 120 120 10 year given nature industry longterm chf 120 130 projection used fully model appropriate product lifecycles based patent expiry therapeutic area longterm projection based past starting risk free short term libor eur 6 month performance management expectation market long term eu generic government bond 10 year development adjusted specific risk include discount rate applied determined based revenue growth rate newly launched product weighted average cost capital dcf model including 10 year benchmark cost debt equity adjusted probability reaching commercial stage new reflect specific asset country risk associated product indication cgu given industry group used discount rate probability success future product launch marketed product 9 2011 10 pipeline expected date thereof product 13 2011 13 discount rate reviewed least annually postpatent expiry erosion since aftertax cash flow incorporated calculation valueinuse cgu posttax discount rate used order remain consistent use posttax discount rate approximates result using pretax rate applied pretax cash flow tax rate 28 used 2011 3127 sensitivity analysis based management assessed reasonable change key assumption determination recoverable amount would cause carrying value cgu materially exceed recoverable amount information purpose sensitivity analysis using 0 perpetual growth rate combined overall discount rate 1757 discount rate would result impairment goodwill u c b n n u l r e p rt 2 0 1 2 88 iv n e h e c n l e f n n c l stat e e n t 20 property plant equipment 2012 office computer equipment million land plant vehicle asset building machinery construction total gross carrying amount 1 january 569 541 128 69 1 307 addition 2 16 7 135 160 disposal 2 3 8 10 23 transfer one heading another 18 33 9 11 13 business combination 0 3 0 0 3 effect movement exchange rate 1 2 0 0 3 gross carrying amount 31 december 550 588 136 183 1 457 accumulated depreciation 1 january 271 424 112 0 807 depreciation charge year 20 27 8 0 55 impairment charge 1 1 0 1 3 disposal 2 2 8 0 12 transfer one heading another 3 18 12 0 3 business combination 0 0 0 0 0 effect movement exchange rate 1 1 0 1 1 accumulated depreciation 31 december 286 467 100 2 855 net carrying amount 31 december 264 121 36 181 602 2011 office computer equipment million land plant vehicle asset building machinery construction total gross carrying amount 1 january 544 512 121 61 1 238 addition 10 13 8 51 82 disposal 6 5 8 5 24 transfer one heading another 13 15 5 38 5 transfer asset held sale 1 0 0 0 1 effect movement exchange rate 7 6 2 0 15 gross carrying amount 31 december 569 541 128 69 1 307 accumulated depreciation 1 january 230 391 108 4 733 depreciation charge year 20 29 11 0 60 impairment charge 17 4 0 1 22 disposal 4 4 9 5 22 transfer one heading another 5 1 0 0 4 transfer asset held sale 0 0 0 0 0 effect movement exchange rate 3 5 2 0 10 accumulated depreciation 31 december 271 424 112 0 807 net carrying amount 31 december 298 117 16 69 500 none group property plant equipment subject plant equipment impairment charge detailed restriction title property plant note 12 presented income statement equipment pledged security liability caption impairment nonfinancial asset 2012 group acquired property plant capitalized borrowing cost equipment totalling 160 million 2011 82 million 12 month 2012 capitalized borrowing cost addition related mainly investment amounted 3 million 2011 0 million construction biological pilot plant brainelalleud belgium biological plant bulle switzerland leased asset supporting new product delivery device well improvement replacement capital expenditure ucb lease building office equipment number finance lease agreement carrying value leased year group recognized total impairment building 17 million 2011 19 million charge 3 million 2011 22 million property u c b n n u l r e p rt 2 0 1 2 89 iv n e h e c n l e f n n c l stat e e n t 21 financial asset 211 noncurrent financial asset million 2012 2011 available sale financial asset refer 25 33 cash deposit 6 9 derivative financial instrument note 36 8 63 loan granted third party 3 3 reimbursement right respect german defined benefit plan 23 23 financial asset 60 49 total financial asset year end 125 180 212 current financial asset million 2012 2011 clinical trial material 7 0 available sale financial asset refer 1 0 derivative financial instrument note 36 32 38 total financial asset year end 40 38 213 available sale financial asset current noncurrent available sale financial asset comprise following million 2012 2011 equity security 23 31 debt security 3 2 total available sale financial asset year end 26 33 movement carrying value available sale financial asset follows 2012 2011 million equity debt equity debt security security security security 1 january 31 2 15 3 addition 7 1 18 2 disposal 0 0 0 4 revaluation equity 2 0 2 0 gain loss reclassified equity income statement 0 0 0 1 impairment charge note 15 13 0 0 0 31 december 23 3 31 2 u c b n n u l r e p rt 2 0 1 2 90 iv n e h e c n l e f n n c l stat e e n t group investment listed debt security mainly january 2012 ucb participated capital increase issued european government well financial partially participated august 2012 capital increase institution bond classified available wilex consequently ucbs stake wilex decreased sale measured fair value fair value listed 1538 1447 2012 material decrease fair debt security determined reference published price value investment led impairment 13 million quotation active market thru profit loss 2011 0 million note 15 financial asset include investment wilex biotie september 2012 ucb participated biotie therapy therapy classified available sale ucb capital increase ucbs stake decreased 92 2011 significant influence measured fair value 95 decrease fair value related investment upon initial recognition amount 2 million 31 december 2012 recognized comprehensive income refer note 17 none financial asset either past due year end 22 inventory million 2012 2011 raw material consumables 79 112 work progress 388 278 finished good 141 130 good purchased resale 8 17 inventory 616 537 cost inventory recognized expense included cost sale amounted 659 million 2011 599 million inventory pledged security inventory stated net realisable value writedown inventory amounted 16 million 2012 2011 8 million included cost sale total inventory increased 79 million mainly related buildup cimzia neupro stock u c b n n u l r e p rt 2 0 1 2 91 iv n e h e c n l e f n n c l stat e e n t 23 trade receivables million 2012 2011 trade receivables 673 657 less provision impairment 4 5 trade receivables net 669 652 vat receivable 36 37 interest receivables 5 10 prepaid expense 35 32 accrued income 15 14 receivables 35 52 royalty receivables 40 54 trade receivables 835 851 carrying amount trade receivables concentration credit risk respect approximates fair value respect trade trade receivables credit exposure critical receivables fair value estimated carrying country southern european country amount less provision impairment group obtained credit insurance group cooperates receivables carrying value approximates fair value given dedicated wholesaler certain country largest shortterm maturity amount outstanding trade receivable 2012 single customer 22 2011 22 mckesson corp u aging analysis group trade receivables yearend follows 2012 2011 gross gross carrying carrying million amount impairment amount impairment past due 620 0 557 1 past due less one month 15 0 50 0 past due one month three month 5 0 13 0 past due three month six month 12 0 10 0 past due six month one year 7 1 11 1 past due one year 14 3 16 3 total 673 4 657 5 based historical default rate group belief concern 92 2011 92 outstanding provision impairment necessary respect trade balance balance sheet date receivables past due past due one month movement provision impairment respect trade receivables shown million 2012 2011 balance 1 january 5 13 impairment charge recognized income statement 1 0 utilization reversal provision impairment 2 8 effect movement exchange rate 0 0 balance 31 december 4 5 class within trade receivables contain impaired asset u c b n n u l r e p rt 2 0 1 2 92 iv n e h e c n l e f n n c l stat e e n t carrying amount group trade receivables denominated following currency million 2012 2011 eur 232 271 usd 359 363 jpy 43 38 gbp 54 21 currency 147 158 trade receivables 835 851 maximum exposure credit risk reporting date fair value class receivable mentioned group hold collateral security 24 cash cash equivalent million 2012 2011 shortterm bank deposit 201 192 cash bank hand 117 75 cash cash equivalent 318 267 bank overdraft note 27 10 14 cash cash equivalent less bank overdraft reported cash flow statement 308 253 25 capital reserve hare capital 251 share premium issued share capital company amounted first call date interest floating 3 month 550 million 2011 550 million represented euribor 9889 bps bond listed 183 365 052 share 2011 183 365 052 share company luxembourg stock exchange share without par value 31 december 2012 perpetual subordinated bond qualify equity 72 403 411 share registered 110 961 641 instrument group ia 32 financial instrument bearer dematerialized share holder ucb share presentation due entitled receive dividend declared also entitled one vote per share shareholder meeting bond perpetual maturity company authorized unissued capital subordinated cb may elect defer interest payment mandatory u 31 december 2012 share premium reserve amounted payment event occurred previous 12 month 1 601 million 2011 1 601 million junior security repurchase redemption parity junior security ybrid capital 252 h accordingly interest presented interest expense income statement accounted corresponding accounting dividend shareholder 8 march 2011 ucb sa completed placement within statement change equity transaction 300 million perpetual subordinated bond bond cost deducted hybrid capital taking tax issued 99499 offer investor coupon effect account 775 per annum first five year bond maturity date however ucb right hybrid capital amounted 295 million 31 december 2012 redeem bond 101 5th anniversary 23 million dividend shareholder perpetual issue 18 march 2016 quarter thereafter subordinated bond presented retained earnings u c b n n u l r e p rt 2 0 1 2 93 iv n e h e c n l e f n n c l stat e e n t reasury share 253 ifrs acquisition value surplus arose schwarz pharma business combination 232 million 2011 232 million group acquired thru ucb sa ucb fipar sa equity component linked convertible bond 1 426 541 treasury share total amount 49 million 41 million 2011 48 million net tax result issued 6 867 242 treasury share total amount ucbs decision revoke cash settlement option linked 235 million net disposal 5 440 701 treasury share convertible bond refer note 226 net amount 186 million remeasurement value defined benefit obligation group retained 5 993 240 treasury share 184 million 2011 121 million 43 million related share swap deal 31 december 2012 2011 7 133 941 treasury share acquired put call option related meizler biopharma order honour exercise share option share 29 million award granted board director certain purchase remaining 25 noncontrolling interest category employee ucb fipar ucb sa schwarz pharma zuhai company ltd 11 million right resell share later date group purchased 1 806 638 call option ucb share total premium 12 million umulative translation 255 c adjustment ther reserve 254 cumulative translation adjustment reserve represents cumulative currency translation difference relating reserve amounted 49 million 2011 159 million consolidation group company use functional consists following item currency euro 26 sharebased payment group operates several equitybased cash option become exercisable vesting period based compensation plan including share option plan three year except eligible employee subject share appreciation right plan share award plan legislation requires longer vesting period order performance share plan compensate employee benefit reduced taxation employee leaf service rendered group option usually lapse upon expiry period six month option lapse case death share option plan share award plan retirement case involuntary termination tax performance share plan equitysettled whereas share paid upon grant group obligation appreciation right plan cashsettled plan besides repurchase settle option cash plan group also operates employee share purchase plan uk u reload feature option transferable except case death share appreciation right sars plan similar hare option plan 261 characteristic share option plan except share appreciation reserved ucb employee u plan cash settled share option granted u option holder right plan 2005 2006 transformed sars except three employee since 2007 eligible u employee remuneration committee granted option ucb sa granted sars share executive committee member senior executive senior middle management ucb group exercise price granted option hare award plan 262 plan equal lowest following two value average closing price ucb share remuneration committee granted free ucb sa share euronext brussels 30 day preceding offer executive committee member senior executive free share service condition attached closing price ucb share euronext brussels whereby beneficiary required remain service day grant three year post grant date share award lapse upon leaving different exercise price determined eligible group except upon leaving retirement death employee subject legislation requires different case vest immediately beneficiary exercise price order benefit reduced taxation entitled dividend vesting period u c b n n u l r e p rt 2 0 1 2 94 iv n e h e c n l e f n n c l stat e e n t erformance share plan 263 p limit placed employee participation plan follows b etween 1 10 participant compensation remuneration committee granted performance share executive committee member senior executive u 25 000 per year per participant achieved outstanding performance performance aximum u 5 million total ownership u share conditional beneficiary completing three employee form share plan rolling period year service vesting period also subject 12 month fulfilment certain company performance condition 31 december 2012 plan 512 participant 2011 performance share lapse upon leaving group except 388 specific vesting condition share upon leaving retirement death case vest based payment expense incurred plan immaterial immediately beneficiary entitled dividend vesting period hare saving plan 266 264 p hantom share option uk share award purpose plan encourage holding ucb performance share plan share employee uk participant save certain portion salary payroll deduction ucb group also phantom share option phantom share match every 5 share bought participant 1 free award performance phantom share plan collectively share share held account employee name referred phantom plan phantom plan apply independent company act trustee certain employee employment contract employee contribution plan limited lower certain affiliate group governed similar rule group share option share award 10 participant compensation performance share plan except settlement gbp 1 500 per year per participant 31 december 2012 plan 86 participant 2011 mployee share purchase 265 e 66 sharebased payment expense incurred plan u plan immaterial plan intended provide employee ucb affiliate harebased 267 u opportunity purchase common share group share acquired discount 15 payment expense funded ucb employee save defined percentage salary payroll deduction share purchased total sharebased payment expense incurred aftertax employee contribution share held group amounted 34 million 2011 20 million independent third party banking institution account included relevant functional line within employee name income statement follows million 2012 2011 cost sale 4 3 marketing selling expense 8 6 research development expense 9 6 general administrative expense 11 5 operating expense 2 0 total operating expense 34 20 equitysettled share option plan 12 9 share award plan 3 2 performance share plan 2 1 cashsettled share appreciation right plan 15 7 phantom share option share award performance share plan 2 1 u c b n n u l r e p rt 2 0 1 2 95 iv n e h e c n l e f n n c l stat e e n t 268 share option plan movement number share option outstanding related weighted average exercise price 31 december 2012 2011 weighted weighted weighted average number weighted average number average exercise share average exercise share fair value price option fair value price option outstanding 1 january 660 2972 9 089 547 662 3055 7 660 505 new option granted 882 3286 2 153 700 650 2668 1 934 900 option forfeited 707 3010 253 600 708 3224 416 878 option exercised 525 2562 1 362 040 399 2405 88 980 option expired 0 0 outstanding 31 december 727 3088 9 627 607 660 2972 9 089 547 number option fully vested 1 january 3 362 747 2 259 505 31 december 3 625 207 3 362 747 share option outstanding 31 december 2012 following last exercise date exercise price last exercise date range exercise price number share option 21 april 2013 1994 1 753 31 may 2013 2658 2794 90 100 05 april 2014 3128 429 31 august 2014 4010 4020 268 300 31 march 2015 3733 3760 302 881 31 march 2016 4014 4057 509 748 31 march 2017 4357 4654 1 069 100 31 march 2018 2201 2573 934 650 31 march 2019 2138 2275 1 125 746 31 march 2020 3162 1 347 000 31 march 2021 2532 2687 1 834 200 31 march 2022 3236 2 143 700 total outstanding 9 627 607 weighted average fair value share option granted volatility determined primarily reference 2012 882 2011 650 historically observed share price ucb last five year probability early exercise reflected fair value determined based black expected life option expected forfeiture rate scholes valuation model based actual turnover employee category eligible stock option compensation significant assumption used measurement fair value share option 2012 2011 share price grant date 3383 2695 weighted average exercise price 3236 2668 expected volatility 3485 3341 expected option life year 5 5 expected dividend yield 302 371 risk free interest rate 212 345 expected annual forfeiture rate 700 700 u c b n n u l r e p rt 2 0 1 2 96 iv n e h e c n l e f n n c l stat e e n t hare appreciation right sars plan 269 movement sars model input blackscholes model fair value liability 31 december 2012 found table remeasured reporting date fair value sars grant date determined using 2012 2011 outstanding right 1 january 2 096 250 1 874 700 new right granted 796 400 651 200 right forfeited 84 500 206 400 right exercised 394 050 223 250 outstanding right 31 december 2 414 100 2 096 250 significant assumption used measurement fair value share appreciation right share price year end 4322 3251 exercise price 3236 2680 expected volatility 3406 3462 expected option life year 5 5 expected dividend yield 236 308 risk free interest rate 075 314 expected annual forfeiture rate 7 700 2610 share award plan sharebased payment expense related share beneficiary entitled dividend award spread vesting period three year vesting period movement number share award outstanding 31 december follows 2012 2011 number weighted average number weighted average share fair value share fair value outstanding 1 january 268 995 2718 249 910 2608 new share award granted 105 190 3466 115 775 2695 award forfeited 2 000 2695 28 680 2710 award vested paid 108 725 2266 68 010 2280 outstanding 31 december 263 460 2060 268 995 2718 2611 performance share plan movement number performance share outstanding 31 december follows 2012 2011 number weighted average number weighted average share fair value share fair value outstanding 1 january 233 125 2729 236 825 2609 new performance share granted 97 475 3383 77 175 2695 performance share forfeited 19 261 2275 29 030 2411 performance share vested 85 539 2544 51 845 2308 outstanding 31 december 225 800 3121 233 125 2729 u c b n n u l r e p rt 2 0 1 2 97 iv n e h e c n l e f n n c l stat e e n t 2612 option granted 7 november 2002 according transitional provision included ifrs 2 ordinary share 145 200 warrant expired option granted 7 november 2002 yet vested 236 700 warrant issued 2000 confer right 1 january 2005 amortized income statement subscribe one ordinary share following cancellation expiration exercise part warrant 1999 2000 respectively ucb issued 145 200 32 600 warrant still exercised 28 february 2013 236 700 subscription right warrant subscribe one movement number option warrant accounted ifrs 2 described follows 2012 2011 number weighted average number weighted average share fair value share fair value outstanding 1 january 482 089 4051 550 527 4003 option forfeited 400 4168 9 514 4140 option exercised 68 200 3775 0 0 option expired 215 065 4248 58 924 3585 outstanding 31 december 198 424 3933 482 089 4051 27 borrowing carrying amount fair value borrowing follows carrying amount fair value million 2012 2011 2012 2011 noncurrent bank borrowing 174 25 174 25 longterm loan 5 0 5 0 finance lease 14 17 14 17 total noncurrent borrowing 193 42 193 42 current bank overdraft 10 14 10 14 current portion bank borrowing 73 22 73 22 debenture shortterm loan 111 7 111 7 finance lease 3 2 3 2 total current borrowing 197 45 197 45 total borrowing 390 87 390 87 271 borrowing since bank borrowing floating interest rate reset every six month carrying amount bank borrowing equates fair value respect 31 december 2012 group weighted average interest current borrowing carrying amount approximate rate 473 2011 531 prior hedging floating fair value effect discounting considered interest rate payment subject designated cash flow insignificant hedge fixed interest rate payment subject ucb draw 2011 0 million 1 billion designated fair value hedge thereby fixing weighted syndicated revolving facility expires 7 october 2016 average interest rate group 371 2011 449 post hedging fee paid arrangement group access certain committed bond note 28 amended facility agreement noncommitted bilateral credit facility well belgian amortized life instrument commercial paper market respect may 2012 ucb entered 7 year floating rate bullet loan agreement applicable hedge accounting fair value european investment bank eib amount noncurrent borrowing determined based 150 million present value payment associated debt instrument using applicable yield curve ucb credit please refer note 43 maturity analysis group spread various different currency borrowing excluding financial liability u c b n n u l r e p rt 2 0 1 2 98 iv n e h e c n l e f n n c l stat e e n t carrying amount group borrowing denominated following currency million 2012 2011 eur 247 47 usd 0 0 5 0 total interest bearing loan currency 252 47 bank overdraft eur 10 14 debenture short term loan eur 76 7 debenture short term loan usd 19 0 debenture short term loan 16 0 finance lease liability eur 17 19 total borrowing 390 87 272 finance lease liability minimum lease payment million 2012 2011 amount payable finance lease 1 year less 3 2 12 year 10 3 25 year 2 11 5 year 2 3 present value finance lease liability 17 19 less amount due settlement within 12 month 3 2 amount due settlement 12 month 14 17 management considers carrying value group finance lease liability approximate fair value 28 bond carrying amount fair value bond follows carrying amount fair value coupon maturity million rate date 2012 2011 2012 2011 noncurrent convertible bond 450 2015 393 444 450 509 retail bond 575 2014 780 773 793 778 institutional eurobond 575 2016 524 513 551 531 total noncurrent bond 1697 1 730 1794 1 818 281 convertible bond fair value debt component based present value contractually determined stream cash flow discounted rate interest applied september 2009 ucb issued senior unsecured time market instrument comparable credit convertible bond amounting 500 million closing status providing substantially cash flow date transaction 22 october 2009 bond term without conversion option mature 22 october 2015 ie 6year duration residual amount difference total gross convertible bond issued redeemed proceeds bond issuance fair value debt 100 principal amount bear coupon 45 component attributed fair value derivative payable semiannually arrears conversion price component result board decision revoke set 38746 bondholder right convert ucbs right related cash settlement option bond new existing option derivative component reclassified equity based company share company fair value date revocation refer note 254 u c b n n u l r e p rt 2 0 1 2 99 iv n e h e c n l e f n n c l stat e e n t april 2012 ucb purchased 70 million par value interest rate amortized expected life outstanding convertible bond total proceed instrument ie 6 year bond listed 82 million total carrying value amounted 63 million luxembourg stock exchange led loss extinguishment 9 million note 15 fair value debt component convertible 11 million reduction fair value option bond 31 december 2012 amounted 450 million recognized equity 2011 509 million fair value determined 31 december 2012 debt component measured third party financial institution based amortized cost using effective interest rate convertible bond recognized statement financial 7670 per annum accordance ia 39 remaining position calculated follows transaction cost included calculation effective million 2012 2011 balance 1 january 444 432 effective interest expense note 15 31 33 nominal interest accrued yet due 4 4 nominal interest accrual previous period paid current period 4 4 interest paid 20 22 unamortized transaction cost upon initial recognition 0 0 amortization charge period 1 1 repurchase convertible bond 63 0 balance 31 december 393 444 282 retail bond 283 institutional eurobond october 2009 ucb completed public offering december 2009 ucb completed offering 750 million fixed rate bond due 2014 aimed 500 million senior unsecured bond due 2016 aimed retail investor retail bond redeemed institutional investor bond issued 99635 100 principal amount carry coupon 575 redeemed 100 principal amount per annum effective interest rate 575 per bond carry coupon 575 per annum annum bond listed luxembourg effective interest rate 58150 per annum bond stock exchange listed luxembourg stock exchange carrying amount retail bond 31 december 2012 carrying amount institutional eurobond amounted 780 million 2011 773 million group 31 december 2012 amounted 524 million designates derivative financial instrument fair value 2011 513 million group designates derivative financial hedge retail bond increase carrying instrument fair value hedge institutional amount retail bond fully attributable change eurobond increase carrying amount fair value hedged portion retail bond institutional eurobond fully attributable change almost fully offset change fair value fair value hedged portion institutional eurobond corresponding derivative financial instrument almost fully offset change fair value corresponding derivative financial instrument 29 financial liability carrying amount fair value million 2012 2011 2012 2011 noncurrent derivative financial instrument note 36 68 60 68 60 total noncurrent financial liability 68 60 68 60 current derivative financial instrument note 36 19 89 19 89 financial liability 181 27 181 27 total current financial liability 200 116 200 116 total financial liability 268 176 268 176 financial liability include share swap transaction 43 million ucb share otc amounted 176 million note 405 u c b n n u l r e p rt 2 0 1 2 100 iv n e h e c n l e f n n c l stat e e n t 30 deferred tax asset liability ecognized deferred tax asset liability 301 r million 2012 2011 restated intangible asset 216 239 property plant equipment 1 6 inventory 64 58 trade receivables 61 76 employee benefit 58 34 provision 13 20 shortterm liability 249 9 tax loss 536 207 unused tax credit 114 90 total net deferred tax asset liability 382 249 302 unused tax loss amount expiry date unused tax loss deferred tax asset recognized balance sheet detailed million 2012 2011 expiry date 1 year less 0 0 12 year 0 1 23 year 0 4 34 year 0 1 4 year 13 14 without expiration 1 722 2 043 unutilized tax loss 1 735 2 063 emporary difference 303 emporary difference 304 deferred tax deferred tax liability recognized asset recognized deferred tax liability recognized taxable deferred tax asset recognized temporary difference temporary difference arising investment subsidiary carried forward represent income likely realized unrecognized deferred tax liability amount foreseeable future deferred tax asset amounting approximately 8 million 2011 5 million 372 million 2011 262 million respect unutilized tax credit intangible asset recognized view uncertain character recovery 305 deferred tax directly recognized equity million 2012 2011 restated deferred tax recognized oci 5 6 effective portion change fair value cash flow hedge 0 0 deferred tax liability convertible bond 4 0 deferred tax directly recognized equity 9 6 u c b n n u l r e p rt 2 0 1 2 101 iv n e h e c n l e f n n c l stat e e n t 31 employee benefit 2012 ucb early adopted amendment ia 19 consolidated statement financial position independent revised june 2011 consequence retrospective actuary assess main plan annually application ia 19r opening closing statement since 2008 group analysis value risk balance financial position earliest comparative period 2011 sheet profit loss account linked defined benefit restated note 22 plan target risk level term one year consolidated balance sheet profit loss value risk measure employee covered retirement benefit plan defined annually based ucb risk tolerance threshold sponsored group company nature plan varies according legal regulation fiscal requirement ucb main risk linked defined benefit obligation economic condition country employee discount rate inflation longevity majority employed group operates defined contribution risk lay within uk belgium germany u plan defined benefit plan noted longevity considered risk plan belgium benefit either paid lump sum 311 defined contribution plan externalised paid annuity last year ucb implemented major derisking project uk u postemployment benefit plan classified defined contribution plan group pay fixed contribution uk investment decision known buyin separate fund third party financial institution implemented ucb british scheme buyin secured legal constructive obligation pay benefit pensioner dependant deferred member contribution therefore asset liability recognized scheme 17 december 2010 30 june 2012 group balance sheet respect plan apart scheme closed future accrual remaining regular prepayment accrual contribution active member transferred celltech pension life assurance scheme december 2012 pension 312 defined benefit plan board finally secured benefit small number pensioner deferred member left service 17 december 2010 30 june 2012 group operates several defined benefit plan 2011 ucb also carried enhanced transfer value benefit granted include mainly pension benefit jubilee exercise uk celltech pension life assurance premium termination indemnity benefit scheme deferred member offered granted according local market practice regulation enhancement transfer value transferred plan either unfunded funded via outside scheme total approximately gbp 10 million liability pension fund insurance company partially funded 164 member transferred scheme plan asset plan held separately fund u ucb implemented lump sum window exercise control trustee plan unfunded 2012 exercise deferred member notably major defined benefit plan germany offered transfer benefit scheme liability obligation recorded group balance end 2012 exercise resulted approximately sheet funded plan group liable deficit u 21 million liability around 40 deferred fair value plan asset present liability transferring scheme value benefit obligation accordingly liability asset plan overfunded recorded group amount recognized consolidated statement financial position arising group obligation respect defined benefit plan follows million 2012 2011 restated present value defined benefit obligation 781 688 fair value plan asset 528 472 funded status deficit surplus 253 216 effect asset ceiling 7 1 net liability arising defined benefit obligation 260 217 add liability respect cash settled share based payment note 26 30 17 total employee benefit liability 290 234 portion recognized noncurrent liability 290 234 portion recognized noncurrent asset 0 0 u c b n n u l r e p rt 2 0 1 2 102 iv n e h e c n l e f n n c l stat e e n t movement present value defined benefit obligation current year follows million 2012 2011 restated 1 january 688 630 current service cost 21 20 interest expense 30 29 remeasurement gain loss effect change demographic assumption 7 2 effect change financial assumption 93 36 effect experience adjustment 3 5 past service cost gain loss settlement 5 2 effect change foreign exchange rate 7 12 benefit payment plan 20 23 benefit payment employer 8 9 settlement payment 16 9 plan participant contribution 1 3 effect business combination disposal 0 5 0 1 31 december 781 688 movement fair value plan asset current year follows million 2012 2011 restated 1 january 472 443 interest income 21 22 remeasurement gain loss return plan asset excl interest income 23 1 change asset ceiling excl interest income 0 0 effect change foreign exchange rate 6 10 plan participant contribution 1 3 employer contribution 52 37 benefit payment plan 20 22 benefit payment employer 5 5 settlement payment 16 9 expense tax premium paid 6 5 effect business combination disposal 0 3 31 december 528 472 fair value plan asset amount 528 million 2011 216 million expected eliminated 2011 472 million representing 69 2011 70 estimated remaining average service period current defined benefit obligation total deficit 253 million membership amount recognized consolidated income statement consolidated statement comprehensive income respect defined benefit plan follows million 2012 2011 restated total service cost incl gain loss settlement 16 18 net interest cost 7 6 remeasurement long term benefit 1 0 administrative expense tax 6 4 component defined benefit cost recorded income statement 30 28 remeasurements gain loss effect change demographic assumption 7 2 effect change financial assumption 93 36 effect experience adjustment 3 5 return plan asset excl interest income 23 1 change asset ceiling excl interest income 6 0 component defined benefit cost recorded oci 66 42 total component defined benefit cost 96 70 u c b n n u l r e p rt 2 0 1 2 103 iv n e h e c n l e f n n c l stat e e n t total service cost net interest expense remeasurement net defined benefit liability remeasurement long term benfits administrative included statement comprehensive income part expense tax year included employee comprehensive income benefit expense consolidated income statement split recognized expense functional line follows million 2012 2011 restated cost sale 6 6 marketing selling expense 6 5 research development expense 10 10 general administrative expense 7 7 income expense 1 0 total 30 28 actual return plan asset 23 million 2011 1 million actual return reimbursement right 0 million 2011 0 million major category plan asset end reporting period follows million 2012 2011 restated cash cash equivalent 21 27 equity instrument 100 70 europe 71 49 u 7 0 rest world 22 21 debt instrument 115 111 corporate bond 21 19 government bond 43 62 51 30 property 4 3 qualifying insurance policy 192 181 investment fund 96 80 total 528 472 virtually equity debt instrument quoted asset held fund contain direct price active market property classified investment ucb group share property occupied level 3 instrument based definition ifrs 13 fair asset used group though value measurement exclude ucb share included mutual investment fund type investment principal weighted average actuarial assumption used purpose actuarial valuation follows eurozone uk u 2012 2011 2012 2011 2012 2011 2012 2011 discount rate 339 422 428 475 400 425 199 234 inflation 200 200 300 300 na na na na u c b n n u l r e p rt 2 0 1 2 104 iv n e h e c n l e f n n c l stat e e n t significant actuarial assumption determination average duration benefit obligation end defined obligation discount rate inflation reporting period 1638 year 2011 1570 year sensitivity analysis determined based number subdivided duration related reasonably possible change assumption occurring eurozone 1469 year 2011 1350 year end reporting period uk 1848 year 2011 1812 year f discount rate would 25 basis point higher lower defined benefit obligation would decrease u 1380 year 2011 1468 year 30 million increase 31 million ther 1641 year 2011 1224 year assumption held constant group expects make contribution 42 million f inflation rate would increase decrease 25 basis defined benefit plan next financial year point defined benefit obligation would increase 19 million decrease 19 million year alm assetliability matching study assumption held constant performed consequence strategic investment policy analysed term riskandreturn reality one might expect interrelationship profile investment contribution policy integrated assumption especially discount rate expected within study main strategic choice formulated salary increase depends certain extent actuarial technical policy document fund expected inflation rate analysis abstract interdependence assumption sset mix based 25 equity instrument 50 debt instrument 25 investment property group subsidiary fund cost entitlement expected earned yearly basis employee pay fixed interest rate sensitivity caused duration 5 percentage pensionable salary residual contribution defined benefit obligation reduced 30 including back service payment paid entity use debt instrument combination interest group funding requirement based local actuarial rate swap measurement framework framework discount rate aintaining equity buffer give 975 assurance set risk free rate furthermore premium determined asset sufficient within next 12 month current salary base additional liability stemming past service due salary increase backservice liability paid immediately fund apart paying cost entitlement group subsidiary liable pay additional contribution case fund hold sufficient asset case fund take measure restore solvency reduction entitlement plan member 32 provision movement provision disclosed million environment restructuring tax total 1 january 2012 47 35 413 48 543 business combination 5 5 arising year 2 10 3 9 24 unused amount reversed 6 4 27 20 57 transfer one heading another 1 1 effect movement exchange rate 1 1 0 utilized year 6 12 9 27 31 december 2012 37 31 389 32 489 noncurrent portion 17 13 389 19 438 current portion 20 18 13 51 total provision 37 31 389 32 489 u c b n n u l r e p rt 2 0 1 2 105 iv n e h e c n l e f n n c l stat e e n t 321 environmental provision 323 tax provision ucb past retained certain environmental tax provision recorded group considers liability associated acquisition probable tax position taken unlikely sustained schwarz pharma divestiture surface specialty challenged tax authority assessment done latter relates divested site ucb provision individually resulting provision retained full responsibility accordance contractual group best estimate expected exposure event term agreed upon cytec industry inc 2012 tax authority challenge part provision related surface specialty business reversed 324 provision 322 restructuring provision provision relate mainly litigation product liability note 14 2012 restructuring provision utilized mainly provision litigation comprise mainly provision view shape programme announced august 2008 litigation ucb subsidiary might severance cost hand main defendant claim previous employee ucb increase provision includes increase shape provision restructuring support function product liability provision relate risk related severance cost normal course business group might liable selling kind drug assessment per formed respect mentioned risk together group legal adviser expert different domain 33 trade liability oncurrent trade liability 331 n million 2012 2011 gsk sumitomo japan 5 10 gsk japan switzerland 16 18 payable 65 72 noncurrent liability collaboration agreement 64 8 total noncurrent trade liability 150 108 urrent trade liability 332 c million 2012 2011 trade payable 261 285 tax payable income tax 46 36 payroll social security liability 149 153 payable 75 85 deferred income linked collaboration agreement 47 42 deferred income 10 16 royalty payable 46 36 dividend shareholder perpetual subordinated bond 18 18 rebate discount payable 353 340 accrued interest 16 27 accrued expense 274 256 total current trade liability 1295 1 294 vast majority trade liability classified current consequently carrying amount total trade liability assumed reasonable approximation fair value u c b n n u l r e p rt 2 0 1 2 106 iv n e h e c n l e f n n c l stat e e n t 34 note consolidated statement cash flow cash flow statement identifies operating investing effect noncash transaction depreciation financing activity period amortization impairment loss provision markto market etc variance working capital ucb us indirect method operating cash flow net profit loss adjusted item income expense associated investing financing cash flow million note 2012 2011 restated adjustment noncash transaction 175 204 depreciation amortization 9 18 20 230 246 impairment reversal charge 9 12 23 39 equity settled share based payment expense 26 1 6 noncash transaction income statement 19 0 adjustment ia 39 15 67 33 unrealized exchange gain loss 14 56 change provision employee benefit 42 55 change inventory bad debt provision 1 9 adjustment item disclose separately operating cash flow 7 9 tax charge period 16 7 9 adjustment item disclose investing financing cash flow 103 129 gain loss disposal fixed asset 31 0 dividend income expense 0 0 interest income charge 134 129 change working capital inventory movement per consolidated b 79 103 trade receivables asset movement per consolidated b 2 142 trade payable movement per consolidated b 196 124 appears consolidated balance sheet corrected 119 121 noncash items1 74 2 change inventory bad debt provision disclosed separately 1 9 operating cash flow change interest receivable payable disclosed separately 5 5 operating cash flow change dividend receivable disclosed separately 0 0 investing cash flow change dividend payable disclosed separately financing cash flow 23 0 change payable balance disclosed 0 0 cash flow discontinued operation currency translation adjustment 59 5 appears consolidated cash flow statement 15 110 1 noncash item mainly linked transfer one heading another noncash movement linked affiliate revaluation fx currency movement linked entry exit consolidation scope merge entity u c b n n u l r e p rt 2 0 1 2 107 iv n e h e c n l e f n n c l stat e e n t 35 financial instrument category million asset fair value 31 december 2012 derivative loan profit used available asset per balance sheet note receivables loss hedging sale total financial asset asset 21 99 0 0 26 125 excl derivative financial instrument derivative financial asset 36 0 34 6 0 40 trade receivables 23 835 0 0 0 835 including prepaid expense cash cash equivalent 24 318 0 0 0 318 total 1252 34 6 26 1318 million liability fair value financial 31 december 2012 derivative liability profit used amortized liability per balance sheet note loss hedging cost total borrowing 27 0 0 390 390 bond 28 0 0 1697 1697 derivative financial liability 36 79 8 0 87 trade liability 33 0 0 1445 1445 financial liability 29 0 0 181 181 excl derivative financial instrument total 79 8 3713 3800 million asset fair value 31 december 2011 derivative loan profit used available asset per balance sheet note receivables loss hedging sale total financial asset asset excl derivative 21 84 0 0 33 117 financial instrument derivative financial asset 36 0 95 6 0 101 trade receivables including 23 851 0 0 0 851 prepaid expense cash cash equivalent 24 267 0 0 0 267 total 1 202 95 6 33 1 336 million liability fair value financial 31 december 2011 derivative liability profit used amortized liability per balance sheet loss hedging cost total borrowing 27 0 0 87 87 bond 28 0 0 1 730 1 730 derivative financial liability 36 130 19 0 149 trade liability 33 0 0 1 402 1 402 financial liability 29 0 0 27 27 excl derivative financial instrument total 130 19 3 246 3 395 u c b n n u l r e p rt 2 0 1 2 108 iv n e h e c n l e f n n c l stat e e n t 36 derivative financial instrument million asset liability 2012 2011 2012 2011 forward foreign exchange contract cash flow hedge 6 6 7 19 forward foreign exchange contract fair value 27 32 36 99 profit loss interest rate derivative cash flow hedge 0 0 1 0 interest rate derivative fair value profit loss 7 63 14 31 put call option noncontrolling interest 0 0 29 0 total 40 101 87 149 noncurrent note 21 29 8 63 68 60 current note 21 29 32 38 19 89 full fair value hedging derivative classified 12 million deferred tax included equity noncurrent asset liability remaining maturity respect contract gain loss recycled hedged item 12 month current profit loss period hedged asset liability maturity hedged item less forecast transaction affect profit loss 12 month ineffective portion recognized profit loss cash flow hedge entered group arises cash flow hedge amount 0 million assessed highly effective 31 december 2012 2011 0 million net unrealized gain 5 million 2011 net unrealized loss oreign currency derivative 361 f group policy respect use financial group entered several forward foreign exchange derivative contract described note 4 financial contract order hedge portion highly probable risk management future sale royalty income expected occur 2012 fair value foreign currency derivative contract follows million asset liability 2012 2011 2012 2011 usd 24 3 30 72 gbp 3 1 1 31 eur 1 31 10 0 pln 0 1 1 0 mxn 0 0 0 0 jpy 4 0 0 10 chf 0 0 0 0 currency 1 2 1 5 total foreign currency derivative 33 38 43 118 foreign currency derivative maturity analysis noted million 2012 2011 1 year less 13 44 15 year 23 36 beyond 5 year 0 0 total foreign currency derivative net asset net liability 10 80 u c b n n u l r e p rt 2 0 1 2 109 iv n e h e c n l e f n n c l stat e e n t following table show split foreign currency derivative currency denomination currency sold view 31 december 2012 notional amount million usd gbp eur jpy chf currency total forward contract 205 144 178 69 12 121 729 currency swap 1 161 321 362 0 37 16 1 897 option collar 159 0 54 0 0 0 213 total 1 525 465 594 69 49 137 2 839 362 interest rate derivative group us various interest rate derivative contract characteristic aligned fixed rate bond manage exposure interest rate movement outstanding interest rate derivative contract borrowing repricing date amortization follows plus nominal margin value point contract average rate payer contract type million payer receiver receiver period floating interest receipt irs usd 150 369 2212010 2212013 usd libor 3 month irs usd 100 392 2412011 2212013 usd libor 3 month irs usd 100 076 2412011 2212013 usd libor 3 month irs usd 150 076 2412011 2212013 usd libor 3 month irs usd 50 321 2312012 2212014 usd libor 3 month irs usd 50 161 2312012 2212014 usd libor 3 month irs eur 150 359 2312012 2212014 euribor 6 month irs eur 150 309 2312012 2212014 euribor 6 month irs usd 150 330 2212013 2212014 usd libor 3 month irs usd 150 215 2212013 2212014 usd libor 3 month irs usd 250 076 28112011 28112014 usd libor 3 month irs eur 750 025 27112009 27112014 euribor 3 month ccirs usd 1000 usd libor 3 month 023 27112009 27112014 euribor 3 month irs eur 325 054 10122009 10122016 euribor 3 month irs eur 150 086 2182012 2182017 euribor 3 month ccirs usd 100 usd libor 3 month 017 2752011 271i2014 euribor 3 month ccirs usd 130 usd libor 3 month 036 27112012 27112014 euribor 3 month ccirs usd 200 usd libor 3 month 018 2752011 27112013 euribor 3 month ccirs usd 250 usd libor 3 month 032 29112010 27112014 euribor 3 month ccirs usd 205 usd libor 3 month 024 2822011 27112014 euribor 3 month irs eur 250 089 2242014 2242018 euribor 6 month edge net investment 363 h erivative linked 364 foreign entity convertible bond 2006 company entered loan agreement result decision ucb revoke cash partly designated hedge net investment settlement option linked convertible bond 2010 group u operation following internal corporate fair value derivative component linked restructuring net investment hedge relationship convertible bond reclassified equity 56 million terminated december 2007 tax 41 million net tax refer note 226 unrealized cumulative foreign exchange gain 55 million reported separate component equity net investment hedge 2007 unrealized gain remain equity recycled profit loss group longer hold underlying usd asset u c b n n u l r e p rt 2 0 1 2 110 iv n e h e c n l e f n n c l stat e e n t 37 earnings per share change group accounting policy year following table summarises effect early described detail note 22 extent application ia 19 revised 2011 basic change impact result repor ted diluted earnings per share 2011 impact amount repor ted earnings per share 2011 increase decrease profit year attributable owner group million note 22 3 increase decrease basic earnings per share 002 increase decrease diluted earnings per share 002 371 basic earnings per share 2012 2011 restated continuing operation 134 126 discontinued operation 009 008 basic earnings per share 143 134 basic earnings per share calculated dividing profit excluding ordinary share purchased company held attributable shareholder company weighted treasury share average number ordinary share issue year 372 diluted earnings per share 2012 2011 restated continuing operation 133 126 discontinued operation 008 007 diluted earning per share 141 132 diluted earnings per share calculated adjusting would lead reduction interest expense reversal weighted average number ordinary share outstanding mark market adjustment related derivative assume conversion dilutive potential ordinary share financial liability share option calculation done determine number share could potential dilutive effect arise convertible debt acquired fair value determined average annual instrument employee stock option plan market share price company share outstanding instrument converted u c b n n u l r e p rt 2 0 1 2 111 iv n e h e c n l e f n n c l stat e e n t 373 earnings calculation basic diluted earnings per share attributable ordinary equity holder parent based following data basic million 2012 2011 restated profit loss continuing operation attributable shareholder ucb sa 239 224 profit loss discontinued operation 17 14 profit attributable shareholder ucb sa 256 238 diluted million 2012 2011 restated profit loss continuing operation attributable shareholder ucb sa 239 224 adjusted interest expense convertible debt net tax 13 15 profit loss continuing operation used determine diluted eps 252 239 profit loss discontinued operation 17 14 adjusted profit attributable shareholder ucb sa 269 253 374 number share thousand share 2012 2011 restated weighted average number ordinary share basic earnings per share 179 279 178 486 adjusted warrant 33 122 assumed conversion convertible debt 11 098 12 905 weighted average number ordinary share diluted earnings per share 1 90 409 1 91 513 24 april 2008 group issued stock loan note therefore contingently issuable share dilutive represented 30 000 loan stock unit nominal value effect 31 december 2012 31 december 2011 20 1 000 defensive warrant attached taken account calculation diluted defensive warrant confers right holder earnings per share subscribe one share newly issued ucb sa note 40 share related convertible debt dilutive ucb share might result exercise impact 31 december 2012 warrant issued reference market price period prior issue 38 dividend per share gross dividend paid 2012 2011 186 million proposed annual general 181 million 100 per share 180 million 098 per meeting shareholder 25 april 2013 share respectively accordance ia 10 event reporting period dividend respect year ended 31 december 2012 proposed dividend recognized liability 102 per share amounting total dividend yearend u c b n n u l r e p rt 2 0 1 2 112 iv n e h e c n l e f n n c l stat e e n t 39 commitment contingency perating lease commitment 391 future aggregate minimum lease payment noncancellable operating lease follows million 2012 2011 less one year 38 38 one five year 93 99 five year 33 37 total 164 174 group number noncancellable operating lease switzerland construction pilot plant belgium began primarily related company car office space may 2009 expected completed mid2013 pilot plant financed partially government assistance lease cover initial period three five year lease well loan december 2010 ucb initiated project payment increased annually reflect market rental build inhouse biotech manufacturing capacity bulle none lease include contingent rental 2012 switzerland order meet rising future demand 36 million 2011 47 million recognized expense cimzia new manufacturing plant operational income statement respect operating lease 2015 requires investment 250 million ucb entered longterm development agreement 392 capital commitment various pharmaceutical clinical trial operator private equity company collaboration agreement include milestone payment dependent successful 31 december 2012 group committed spend clinical development meeting specified sale target 128 million 2011 127 million mainly respect table set maximum would paid capital expenditure construction biological milestone however unlikely achieved excludes pilot plant braine belgium biological plant bulle variable royalty payment based unit sale million 2012 2011 less one year 39 42 one five year 256 350 five year 567 595 total 862 987 amount riskadjusted discounted philadelphia atlantic city litigation involve timing payment based group current best claim injury resulting alleged failure warn estimate achievement relevant milestone risk associated use metoclopramide 12 week vast majority claim involve alleged injury sustained result use generic 393 guarantee metoclopramide number legal issue court awaiting decision could impact timing outcome resolution case currently guarantee arising normal course business case scheduled trial 2013 early expected result material financial loss predict certainty outcome litigation company belief meritorious defense 394 contingent liability pending claim furthermore group entered various agreement order conduct activity provide potential group continues actively involved litigation contingent liability financial arrangement claim investigation ongoing matter could result walloon region amounting 41 million liability civil criminal penalty loss product exclusivity 2011 41 million manufacturing capacity arrangement cost fine expense associated finding sandoz amounting 4 million elapsed 2012 adverse ucbs interest anticipated material liability arise ucb continues defendant 5 000 reglan contingent liability provided product liability case case largely note 32 2011 material liability consolidated three different jurisdiction san francisco u c b n n u l r e p rt 2 0 1 2 113 iv n e h e c n l e f n n c l stat e e n t 40 related party transaction ntragroup sale 401 efensive warrant 403 service financial year ended 31 december 2012 2011 24 april 2008 general meeting shareholder resolved intraucb group transaction carried based issue stock loan represented 30 000 loan stock unit assessment mutual economic benefit party nominal value 20 1 000 defensive involved applicable condition established warrant attached defensive warrant accordance criterion arm length negotiation defensive warrant confers right holder fair dealing view creating value subscribe one share newly issued ucb sa loan entire ucb group condition governing intraucb subscribed financière de tubize holder group transaction similar condition governing defensive warrant entered agreement thirdparty transaction ucb sa comply term condition relating regard sale intermediary finished product issue exercise defensive warrant criterion accompanied principle increasing mentioned general meeting shareholder party respective production cost arm length also resolved create ad hoc committee decide profit margin regard intraucb group service predefined circumstance implementation rendered criterion accompanied principle defensive measure transfer defensive warrant charging fee sufficient cover party respective defensive warrant may exercised specific incurred cost arm length markup intragroup circumstance existence must assessed transaction carried within ucb group constitute adhoc committee standard transaction biopharmaceutical group transaction include purchase sale intermediary aunch takeover bid third party considered l finished medical product deposit loan ucb group hostile board director affiliate well centralized function activity carried odification control ucb group due ucb group order optimize operation transaction relating ucb share one third economy scale scope party carried either stock market whether concerted fashion inancial transaction 402 f threat takeover bid operation involving related party modification control ucb group ucb sa affiliate defensive warrant agreement holder defensive warrant ucb sa expire 23 april 2013 ucb share resulting exercise financial transaction related party warrant issued reference market price affiliate ucb sa period prior issuance ey management compensation 404 k key management compensation disclosed comprises committee portion year exercised compensation recognized income statement mandate member board director executive million 2012 2011 shortterm employee benefit 11 10 termination benefit 0 0 postemployment benefit 3 3 sharebased payment 5 3 total key management compensation 19 16 shortterm employee benefit include salary including social share explained note 26 termination security contribution bonus earned year car benefit contain compensated amount including benefit leasing allowance applicable sharebased kind deferred compensation compensation includes amortization vesting loan granted company period fair value equity instrument granted subsidiary group director officer comprises share option share award performance group guarantee given respect hereto u c b n n u l r e p rt 2 0 1 2 114 iv n e h e c n l e f n n c l stat e e n t hareholders shareholder structure 405 ucbs main shareholder financière de tubize sa 5306 financière de tubize held janssen family company listed euronext brussels hereafter financière de remainder ucb share held public tubize reference shareholder accordance latest subsequent notification made financière de tubize made transparency notification compliance law 2 may 2007 present ucb holding ucb 1 september 2008 subsequent major shareholding notification compliance law 2 may 2007 publication significant shareholding listed company according article 3 1 13 law 2 may 2007 financière de tubize act concert schwarz vermögensverwaltung gmbh holding listed 1 4 table hereunder share covered agreement including share held financière de tubize represent 4081 share capital ucb ucb controlling major shareholding 31 december 2012 date according notification compliance current voting law 2 may 2007 capital 550 095 156 share 183 365 052 1 financière de tubize sa tubize 66 370 000 3620 5 october 2011 2 ucb sa 801 706 31 december 2012 assimilated securities1 2 500 000 180 26 june 2012 option 2 6 606 638 27 april 2012 3 ucb fipar sa 891 534 31 december 2012 assimilated security 1 800 000 147 27 april 2012 4 schwarz vermögensverwaltung gmbh 2 471 404 135 5 october 2011 tubize linked company concert 4 excluding option 74 834 644 4081 31 december 2012 5 capital group company 20 828 907 1136 5 september 2012 6 vanguard health care fund 5 821 811 317 30 march 2012 1 please see press release 28 june 2012 2 option exercised would represent additional voting right 360 information regarding assimilated securitiesoptions required law tubize declared acting concert schwarz vermögensverwaltung gmbh co kg u c b n n u l r e p rt 2 0 1 2 115 iv n e h e c n l e f n n c l stat e e n t 41 event balance sheet date event balance sheet date 42 ucb company fully consolidated name office holding parent australia ucb australia pty ltd level 1 1155 malvern road 3144 malvern victoria 100 viking trading co ltd austria ucb pharma gesellschaft mbh geis elbergstrasse 1719 1110 wien 100 ucb finance nv belgium ucb fipar sa allée de la recherche 60 1070 brussels be0403198811 100 ucb belgium sa fin ucb sa allée de la recherche 60 1070 brussels be0426831078 100 ucb pharma sa ucb belgium sa allée de la recherche 60 1070 brussels be0402040254 100 ucb pharma sa ucb pharma sa allée de la recherche 60 1070 brussels be0403096168 100 ucb sa sifar sa allée de la recherche 60 1070 brussels be0453612580 100 ucb finance nv brazil ucb farma brasil ltda rue sete de setembro 67 sala 301 20050005 rio de janerio 100 ucb sa meizler ucb alameda araguaia 3833 tamboré barueri 06455000 sao paulo 51 ucb farma brasil ltda bulgaria ucb bulgaria eood 15 lyubata str fl 4 apt 1011 lozenetz sofia 1407 100 ucb sa canada ucb canada inc 2060 winston park drive suite 401 l6h5r7 oakville 100 ucb holding inc china ucb trading shanghai co ltd room 317 439 fu te xi yi road shanghai waigaoqiao 100 ucb sa free trade zone ucb pharma hong kong ltd unit 514 5f south tower world finance center 100 ucb pharma gmbh gateway harbour city hong kong schwarz pharma zuhai company ltd block changsa industrial zone qianshan district 100 ucb pharma gmbh 519070 zhuhai guangdong province czech republic ucb sro thámova 13 186 00 praha 100 ucb sa denmark ucb nordic arne jacobsen alle 15 2300 copenhagen 100 ucb finance nv finland ucb pharma oy finland itsehallintokuja 6 02600 espoo 100 ucb finance nv france ucb pharma sa 420 rue detienne dorves 92700 colombes 100 ucb sa u c b n n u l r e p rt 2 0 1 2 116 iv n e h e c n l e f n n c l stat e e n t name office holding parent germany ucb pharma gmbh alfred nobel strasse 10 40789 monheim rhein 100 ucb gmbh ucb gmbh alfred nobel strasse 10 40789 monheim rhein 100 ucb finance nv ucb bioscience gmbh alfrednobelstrasse 10 40789 monheim rhein 100 ucb pharma gmbh sanol gmbh alfrednobelstrasse 10 40789 monheim rhein 100 ucb pharma gmbh greece ucb ae 63 agiou dimitriou street 17456 alimos athens 100 ucb sa hungary ucb hungary ltd obuda gate building arpád fejedelem ùtja 2628 1023 budapest 100 ucb sa india ucb india private ltd 504 peninsula tower peninsula corporate park 100 ucb sa ganpatrao kadam marg lower parel 400 013 mumbai unimediflex private ltd 504 peninsula tower peninsula corporate park 100 ucb sa ganpatrao kadam marg lower parel 400 013 mumbai ireland ucb pharma ireland ltd united drug house magna drive magna business park 100 ucb sa city west road dublin 24 celltech pharma ireland united drug house magna drive magna business park 100 ucb ltd city west road dublin 24 ucb manufacturing ireland ltd shannon industrial estate shannon county clare 100 ucb pharma gmbh kremers urban kudco ireland ltd shannon industrial estate shannon county clare 100 pharmaceutical inc italy ucb pharma spa via gadames 57 20151 milano 100 viking trading co ltd japan ucb japan co ltd shinjuku grand tower 817 nishishinjuku 1600023 shinjuku tokyo 100 ucb sa luxembourg société financière ucb sa rue eugène ruppert 12 2453 luxembourg 100 ucb sa ucb lux sa rue eugène ruppert 12 2453 luxembourg 100 ucb sa ucb sca rue eugène ruppert 12 2453 luxembourg 100 ucb lux sa mexico ucb de mexico sa de cv homero440 7fl col chapultepec morale 100 ucb sa 11570 mexico df vedim sa de cv homero 440 7fl col chapultepec morale 11570 mexico df 100 sifar sa netherlands ucb finance nv lage mosten 33 4822 nk breda 100 ucb sa ucb pharma bv netherlands lage mosten 33 4822 nk breda 100 ucb finance nv norway ucb pharma grini naeringspark 8b 1361 osteras baerum 100 ucb finance nv poland vedim sp zoo ul kruczkowskiego 8 00380 warszawa 100 sifar sa ucb pharma sp zoo ul kruczkowskiego 8 00380 warszawa 100 ucb sa u c b n n u l r e p rt 2 0 1 2 117 iv n e h e c n l e f n n c l stat e e n t name office holding parent portugal ucb pharma produtos farmaceuticos lda ed amelia piso 0 sala a2 quinta da fonte 100 vedim pharma sa 2770229 paço de arcos vedim pharma prod quimicos e farma lda ed amelia piso 0 sala a2 quinta da fonte ucb pharma produtos 100 2770229 paço de arcos farmaceuticos lda romania ucb pharma romania srl 4044 banu antonache 4th fl district 1 011655 bucharest 100 ucb sa russia ucb pharma llc shturvaluaya 5 bldg 1 125364 moscow 100 ucb sa ucb pharma logistics llc perevedenovky pereulok 13 bldg 21 105082 moscow 100 ucb sa south korea korea ucb co ltd 5th floor grace tower 127 teheranro 135411 seoul 100 ucb sa spain vedim pharma sa paseo de la castellana 141 planta 15 28046 madrid 100 ucb sa ucb pharma sa paseo de la castellana 141 planta 15 28046 madrid 100 vedim pharma sa sweden ucb pharma ab sweden stureplan 4c 4 van 11435 stockholm 100 ucb finance nv switzerland ucb farchim sa ag ltd zi de planchy chemin de croix blanche 10 1630 bulle 100 ucb investissements sa ucb investissements sa zi de planchy chemin de croix blanche 10 1630 bulle 100 ucb finance nv doutors réassurance sa zi de planchy chemin de croix blanche 10 1630 bulle 100 ucb investissements sa ucbpharma ag zi de planchy chemin de croix blanche 10 1630 bulle 100 ucb investissements sa medeva pharma suisse sa chemin de croix blanche 10 1630 bulle 100 ucb investissements sa turkey ucb pharma rüzgarlibahçe cumhuriyet caddesi gerçekler sitesi bblok kat6 100 ucb lux sa kavacik beykoz 34805 istanbul melusin ilac maddeleri pazarlama tl rüzgarlibahçe cumhuriyet caddesi gerçekler 100 ucb pharma gmbh sitesi bblok kat6 kavacik beykoz istanbul u c b n n u l r e p rt 2 0 1 2 118 iv n e h e c n l e f n n c l stat e e n t name office holding parent uk fipar 208 bath road sl1 3we slough berkshire 100 ucb investment ltd ucb fipar ltd sub ucb inc 208 bath road sl1 3we slough berkshire 100 ucb inc fipar uk ltd sub ucb fipar ltd 208 bath road sl1 3we slough berkshire 100 ucb fipar ltd ucb investment ltd 208 bath road sl1 3we slough berkshire 100 ucb lux sa viking trading co ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd vedim ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd ucb watford ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd celltech group ltd 208 bath road sl1 3we slough berkshire 100 ucb lux sa celltech rd ltd 208 bath road sl1 3we slough berkshire 100 celltech group ltd ucb ireland 208 bath road sl1 3we slough berkshire 100 ucb lux sa celltech japan ltd 208 bath road sl1 3we slough berkshire 100 celltech rd ltd celltech ltd 208 bath road sl1 3we slough berkshire 100 medeva ltd chiroscience group ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd chiroscience rd ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd darwin discovery ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd medeva ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd ucb pharma ltd 208 bath road sl1 3we slough berkshire 100 evans healthcare ltd evans healthcare ltd 208 bath road sl1 3we slough berkshire 100 medeva ltd medeva international ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd celltech pharma europe ltd 208 bath road sl1 3we slough berkshire 100 ucb investment ltd international medication system uk ltd 208 bath road sl1 3we slough berkshire 100 ucb pharma gmbh oxford glycosciences 208 bath road sl1 3we slough berkshire 100 ucb investment ltd oxford glycosciences uk ltd 208 bath road sl1 3we slough berkshire 100 oxford glycosciences oxford glycosciences confirmant ltd 208 bath road sl1 3we slough berkshire 100 uk ltd schwarz pharma ltd 208 bath road sl1 3we slough berkshire 100 celltech group ltd u ucb holding inc corporation trust center 1209 orange street 19801 wilmington 100 ucb finance nv delaware fipar u inc corporation trust center 1209 orange street 19801 wilmington 100 fipar uk ltd delaware ucb inc corporation trust center 1209 orange street 19801 wilmington delaware 100 ucb holding inc ucb bioscience inc corporation trust center 1209 orange street 19801 wilmington 100 ucb inc delaware ucb pharco inc 300 delaware avenue 9 th floor 19801 wilmington delaware 100 ucb inc celltech u llc corporation trust center 1209 orange street 19801 wilmington 100 medeva ltd delaware ucb manufacturing inc corporation trust center 1209 orange street 100 ucb inc 19801 wilmington delaware ucb technology inc c corporation system 111 eight avenue ny 10011 new york 100 ucb manufacturing inc upstate pharma llc c corporation system 111 eight avenue ny 10011 new york 100 ucb inc kremers urban pharmaceutical inc 251 e ohio street suite 1100 46204 indianapolis 100 ucb manufacturing inc u c b n n u l r e p rt 2 0 1 2 119 iv n e h e c n l e f n n c l stat e e n t v v responsibili ty statement responsibility statement hereby confirm best knowledge consolidated financial statement 31 december 2012 prepared accordance international financial reporting standard ifrs adopted european union legal requirement applicable belgium give true fair view asset liability financial position profit loss company undertaking included consolidation whole management report includes fair review development performance business position company undertaking included consolidation taken whole together description principal risk uncertainty face signed roch doliveux ceo detlef thielgen cfo behalf board director roch doliveux detlef thielgen chief executive officer chief financial officer 121 vi vi report stat uto ry auditor neil scientist ucb slough statutory auditor report general shareholder meeting consolidated account company ucb sanv year ended 31 december 2012 accordance legal requirement report financial statement order design audit procedure performance mandate statutory auditor report appropriate circumstance includes report consolidated financial statement purpose expressing opinion effectiveness year ended 31 december 2012 defined well group internal control audit also includes evaluating report legal regulatory requirement appropriateness accounting policy used reasonableness accounting estimate made board director well evaluating overall presentation report consolidated financial consolidated financial statement obtained statement company official board director explanation audited consolidated financial statement information necessary performing audit ucb sanv company subsidiary jointly believe audit evidence obtained group prepared accordance international sufficient appropriate provide basis opinion financial reporting standard adopted european union legal regulatory requirement unmodified opinion applicable belgium consolidated financial statement comprise consolidated statement financial position opinion consolidated financial statement set consolidated income statement consolidated statement forth page 52 119 give true fair view comprehensive income consolidated statement group net equity consolidated financial position change equity consolidated statement cash flow 31 december 2012 consolidated financial 31 december 2012 year ended performance consolidated cash flow year related note comprising summary significant accounting ended accordance international financial reporting policy explanatory information total standard adopted european union consolidated statement financial position amount legal regulatory requirement applicable belgium eur 9 360 million consolidated income statement show profit year group share eur 256 million report legal regulatory requirement board director responsibility preparation consolidated financial statement board director responsible preparation content management report board company board director responsible director consolidated financial statement preparation fair presentation consolidated financial statement accordance international financial framework mandate responsibility verify reporting standard adopted european union compliance certain legal regulatory requirement legal regulatory requirement applicable basis provide following additional statement belgium internal control board modify opinion consolidated director determines necessary enable preparation financial statement consolidated financial statement free material management report board director misstatement whether due fraud error consolidated financial statement set forth page 17 51 includes information required law consistent statutory auditor responsibility consolidated financial statement however responsibility express opinion unable comment description principal risk consolidated financial statement based audit uncertainty group facing conducted audit accordance international standard financial situation foreseeable evolution significant auditing standard require comply influence certain fact future development ethical requirement plan perform audit obtain nevertheless confirm matter disclosed reasonable assurance whether consolidated financial present obvious inconsistency information statement free material misstatement became aware performance mandate audit involves performing procedure obtain brussels 26 february 2013 audit evidence amount disclosure consolidated financial statement procedure selected statutory auditor pricewaterhousecoopers reviseurs depend statutory auditor judgment including dentreprises bedrijfsrevisoren assessment risk material misstatement represented consolidated financial statement whether due fraud error making risk assessment statutory auditor considers internal control relevant jean fossion group preparation fair presentation consolidated bedrijfsrevisor 123 vii vii abbreviated statutory financial statement ucb sa 1 introduction accordance belgian company code accordance legislation separate financial decided present abbreviated version statutory statement together management report financial statement ucb sa board director general assembly shareholder well auditor report filed national statutory financial statement ucb sa bank belgium within statutory period prepared accordance belgian generally accepted accounting principle document available website wwwucbcom simple request addressed noted consolidated financial statement presented present true fair view ucb sa financial position performance ucb group corporate communication allée de la recherche 60 statutory auditor issued unqualified audit opinion b1070 brussels belgium certify nonconsolidated financial statement ucb sa year ended 31 december 2012 give true fair view financial position result ucb sa accordance legal regulatory disposition 2 balance sheet million 31 december 2012 31 december 2011 asset formation expense 25 31 intangible asset 0 0 tangible asset 7 7 financial asset 6 993 6 977 fixed asset 7 025 7 015 amount receivable one year 1 801 1 810 amount receivable within one year less 61 56 shortterm investment 147 139 cash bank hand 122 84 deferred charge accrued income 18 26 current asset 2 149 2 115 total asset 9 174 9 130 liability capital 550 550 share premium 1 601 1 601 reserve 3 229 3 079 profit brought forward 132 145 equity 5 512 5 375 provision 57 51 provision deferred tax 57 51 amount payable one year 2 097 3 125 amount payable within one year less 1 418 540 accrued charge deferred income 90 39 current liability 3 605 3 704 total liability 9 174 9 130 125 3 income statement million 31 december 2012 31 december 2011 operating income 46 44 operating charge 87 118 operating result 41 74 financial income 478 502 financial charge 203 218 financial result 275 284 operating result income tax 234 210 exceptional income 94 1 072 exceptional charge 3 99 exceptional result 91 973 profit income tax 325 1 183 income tax 2 19 profit year available appropriation 323 1 202 4 appropriation account million 31 december 2012 31 december 2011 profit period available appropriation 323 1 202 profit brought forward previous year 145 148 profit appropriated 468 1 350 legal reserve 0 0 reserve 150 1 025 appropriation capital reserve 150 1 025 profit carried forward 132 145 result carried forward 132 145 dividend 186 181 profit distributed 181 181 proposed allocation profit approved total gross dividend 102 100 fixed proposed allocation profit approved taking account tax 0765 075 regulation total net dividend withholding tax per share fixed activity ucb sa generated 2012 net profit board director proposes pay gross dividend 323 million income tax taking account 102 holder 182 727 246 ucb share profit brought forward 145 million amount available total dividend distribution 186 million dividend distribution 468 million proposal approved company shareholder meeting 25 april 2013 net dividend 0765 per issued share capital ucb sa represented share payable 7 may 2013 delivery 183 365 052 share without par value per coupon nr 15 attached company bearer share 31 december 2013 capital increase 5 march 2013 52 300 share without par value 690 106 share order honour exercise share option share award granted board director certain category employee u c b n n u l r e p rt 2 0 1 2 126 vii bbr e v e tat u ry f n n c l tat e e n t f u c b 5 summary significant accounting principle board director made following decision inancial asset 53 f accordance article 28 royal decree 30 january 2001 implementing company code shareholding valued accordance proportion held shareholder fund company ntangible asset 51 concerned shareholding included scope consolidation valued cost specific writedown made whenever valuation made research development cost capitalised year show permanent loss value intangible asset purchase cost capitalised cost entirely depreciated year difference actual amount depreciation taken 54 receivables liability year gross amount capitalised treated writeback depreciation exceptional income shown book value receivables straightline depreciation rate 33 13 applied written repayment due entirely cost based threeyear life considering pro partly uncertain doubtful rata temporis depreciation purchase price patent license similar item either accordance prudent assessment economic life intangible ssets commitment 55 asset minimum rate equal asset required handle patent process fixed period expressed foreign depreciation lower five year considering pro currency rata temporis foreign currency transaction accounted exchange rate prevailing date transaction angible asset 52 nonmonetary asset liability intangible tangible asset shareholding denominated foreign currency tangible asset purchased third party translated foreign exchange rate prevailing date included balance sheet purchase price asset transaction monetary asset liability denominated manufactured company valued cost foreign currency translated balance sheet date purchase price cost depreciated straightline rate realised exchange difference foreign currency basis considering pro rata temporis depreciation rate transaction recognised income statement follows nonrealised exchange loss whilst nonrealised exchange administrative building 3 profit included accrued charge deferred income balance sheet industrial building 5 tool 15 rovisions 56 p furniture office machinery 15 vehicle 20 risk born company subject computer equipment office machine 333 provision reviewed year accordance rule prudence good faith sincerity provision recorded prototype equipment 333 normal value u c b n n u l r e p rt 2 0 1 2 127 vii bbr e v e tat u ry f n n c l tat e e n t f u c b viii viii corporate societal responsiblity performance report 1 csr activity 2 materiality stakeholder dialogue 3 global reporting initiative gri indicator 4 global reporting initiative disclosure 5 human resource environmental data 6 scope reporting principle 7 assurance report christer living parkinson disease 1 csr activity 11 background 12 introduction fourth corporate societal responsibility csr 2012 ucb defined presented new strategy report illustrating ucbs strategy societal responsibility executive committee leading also change labeling sustainability report prepared edited effort move corporate social responsibility csr team conformity sustainability reporting corporate societal responsibility csr aim embrace guideline global reporting initiative gri corporation responsibility towards society broadest sense rather limited social aspect kpmg provided limited assurance number selected indicator refer gri table end section new definition corporate societal responsibility elucidated insight combining data united nation development program global footprint network1 2 report countryspecific data health wealth education country ecological footprint published enable bridge challenge pursuit allow create growth diminishing impact environment ucb adopted patientcentric planetcentric vision figure reconciles two dimension deemed critical sustainability human development index combining health education living standard dimension indicator socioeconomic development ii ecological footprint indicator human demand planet csr focus adopted answering following question ucb contribute help community developing country reach higher human development index ucb continue lowering ecological footprint african country undp threshold high human development global hectare person ecological footprint asian country european country latin american caribbean country north american country oceanian country world average biocapacity per person 1961 world average biocapacity per person 2006 high human development within earth limit united nation human development index 1 ecological wealth nation earth biocapacity new framework international cooperation global footprint network 201013 2 human development index data human development report 2009 overcoming barrier human mobility development undp 2009 129 13 patient centricity one strength knowledge epilepsy india hope wheel dedicated ability bring treatment patient living establishment hope wheel entity condition today csr activity predominantly indian ucb affiliate pilot project prime objective directed towards patient developed country however serve patient living epilepsy remote area new csr patientcentric strategy aim reach state rajasthan karnataka underprivileged patient living epilepsy developing country ucb want developing three specific mobile clinic shall enable access education diagnosis dimension education awareness diagnosis treatment building creative solution including treatment build increased value patient telemedicine targeted partnership trained shown drawing dedicated colleague regularly tour 150 village community supported state medical colleague address significant social stigma isolation associated value patient epilepsy villager increase awareness education patient family mobile unit van equipped stateoftheart neurological equipment better health care developing integrated resulting improved telemedicine provide realtime consultation health life work care solution social integration local neurology department university hospital building awareness sustainable access community epilepsy community diagnostic equipment china project hope awareness education diagnosis treatment project hope 55 year tradition global health education humanitarian assistance partnership several organisation pharmaceutical company china 131 project today project hope involved several effort improving health community various province china africa brother charity strong partnership ministry health fracarita belgium nongovernmental organization epilepsy child another important project bring ngo development cooperation brother education access adequate diagnosis treatment charity dedicates improving health condition remote community project hope bringing neurology vulnerable people especially child people department ten university hospital together focus disability mental illness ngo strongly anchored need child living epilepsy family local community 32 country partnership bring professional training support ucb ucb focused people living epilepsy lubumbashi democratic republic congo ndera rwanda family planning pregnancy immunology partner want break negative combination time woman men severe chronic disease poverty mental illness including neurological condition immunological condition often receive epilepsy enabling patient living epilepsy optimal consistent medical advice support family return normal life offering sustained come family planning pregnancy cause support appropriate diagnosis treatment key great distress patient due general lack normal life medical paramedical colleague awareness data complex field pregnancy receive neurology education well supportive material occurring severe disease vice versa severe conducting awareness campaign student school disease occurring pregnancy patient family different primary health center fppi family planning pregnancy immunological centre neuropsychiatrique joseph guislain lubumbashi disease medical education partnership initiative provides care patient living epilepsy city launched ucb globally overall goal fppi mobile team neighboring village kipushi initiative improve outcome parent likasi kitumaini brother charity organise immunological disease child bimonthly visit ensure adequate followup adherence increasing awareness understanding issue relating treatment essential aspect wellbeing patient family planning pregnancy immunology centre neuropsychiatrique de ndera kigali reference timulating research order attempt fill knowledge gap hospital psychiatry also newly equipped 24bed neurology ward hospitalisation patient suffering fppi initiative demonstration patient neurological condition together rwandan league centric leadership vision epilepsy effort underway enhance awareness education well access appropriate diagnosis world health organization treatment partnership ucb contributes within area epilepsy priority within world scientific advanced medical education training health organization who mental health gap action medical paramedical colleague programme mhgap ucb agreed collaborate 4 year project reduce treatment gap two developing country identified 2013 u c b n n u l r e p rt 2 0 1 2 130 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 14 planet centricity inevitably activity impact planet directly indirectly ucb colleague share passion excellence directly major contribution waste production energy patient planet driven initiative reflecting profound water consumption greenhouse gas emission come integration customer insight creativity compliance manufacturing research site indirectly daily activity offering sustainable care patient whole value chain including partner supplier contract living severe condition part everything ucb manufacturing operator transporter also contribute ucb colleague critical stakeholder ecological footprint producing waste emitting greenhouse gas ucb relies extended network external consuming water fuel gas electricity stakeholder family ucb colleague patient advocate school institution local community association public ucb strives continuously improve environmental administration nongovernmental organization ngo ecological footprint actively engaging management medium scientific academic community employee stakeholder seven area engagement 1 ensuring legal regulatory compliance 16 recognition 2 responsibly using natural resource 3 enhancing energy efficiency minimizing carbon footprint 161 ecpi sense sustainability 4 promoting green chemistry ecpi independent leading company dedicated 5 controlling emission sustainability research rating index active integrating intangible valuenontraditional risk factor 6 actively managing waste stream preventing sorting research ie environmental social governance esg recycling since 1997 ecpi provides simple versatile reliable 7 applying greener lifecycle management principle investment tool solution integrate extrafinancial information investment process detail three year thorough reporting please refer website wwwecpigroupcom strengthening ability tool order improve accuracy december 2012 ucb represented two ecpi socially responsible index first ecpi emu ethical next step key performance indicator kpis equity index adjusted capitalizationweighted index defined seven area engagement comprised 150 listed company within euro zone used define local global short long chosen good practice social environmental term objective ethical matter second ecpi euro ethical equity index index selecting 150 top capitalized company 15 csr governance european market eligible investment according ecpi sri screening methodology ecpi index used benchmarking thematic order develop manage policy investment risk management purpose create implementation process csr ucb empowered csr indextracking investment strategy exchange team created csr board csr team traded fund etf primary task managing implementing policy action network engaged ucb colleague different country csr board composed 162 corporate knight functional head senior manager responsible ucb recently ranked global 100 list world setting course design guideline ucbs policy sustainable company corporate knight specialized activity medium financial information product company based csr committee relevant societal toronto canada selection process began 4 000 topic ucb examined selected based ucbs publicly traded company trimmed 350 fundamental business principle core value evaluated using key environmental social governance handled close involvement main stakeholder within performance indicator finally get list 100 vision shared ucb review process continuously sustainable company ucb ranked 76th position refines internal external relevance csr topic assess external impact review process equally embrace systematically lesson learned therefore everlasting change relying feedback selected category patient external stakeholder refine improve value patient planet u c b n n u l r e p rt 2 0 1 2 131 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 2 materiality stakeholder dialogue materiality check performed informally listening concrete initiative engage colleague main contributor telling u significant ucbs strategic decision rise patient standpoint intention formalize ideation campaign materiality check future keeping colleague healthcare expected become personal involved also open external stakeholder forthcoming decade plenty challenge lay ensure ucb initiative bring measurable sustainable ahead although growth healthcare spending must impact patient counterbalanced efficiency saving health although formal report developed yet become individual value decision patient interact concrete example open dialogue main differently healthcare professional payer stakeholder listed considering need embrace change ucb launched first ideageneration campaign june 2012 coupling townhall meeting event newsletter power creative culturaldiverse thinking ucbs field report objective progress result csr talent prompting two simple question project shared colleague occasion concrete action ucb undertake trusted colleague emit comment question ucbs partner provides information solution patient csr project keen engage colleague ii concrete action ucb undertake gain csr initiative favor innovative initiative supported actionable insight patient rise patient sponsored colleague csr team explores way ideation campaign resulted 435 idea posted 291 people involve selection process project well covering 23 country seven language 226 implementation execution program comment building idea total 2 495 vote external world wish learn ucbs casted period three week testimony csr performance action ucb welcome survey engagement commitment trust patient insight interview brings external view ucb partnership performs interaction always opportunity following initial assessment new journey board open constructive informative dialogue member evaluated idea potential strategic impact ucb focus ucb give priority feasibility three pilot project endorsed past year ucb contact several ngo explore define develop way enabling integrated care system underprivileged people living epilepsy create patient liaison role evaluating concept developing country discussion always patient liaison provide support gain actionable conducted within spirit creating launching impactful insight patient sustainable project improved health life work listen customer get comprehensive social integration patient understanding need ucb committed active partner elevate b uild improving patient healthcare professional quality life patient living severe disease relationship close network patient health care professional supplier contractor institution government beyond quality idea generated scientist partner administrator open profound impact exercise came engagement honest dialogue ucb employee carrying connectivity among colleague looking share commitment underprivileged patient build enthusiastic volunteering invaluable insight people part layer organization sometimes hard imagine connection came together focus building solution improve quality patient life u c b n n u l r e p rt 2 0 1 2 132 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 3 global reporting initiative gri indicator 31 labor practice ucb embracing difference cornerstone embrace diversity thought openness different perspective 311 talent nurture sharing experience competency mind set ucb talent respect trust viewpoint ucbs ability create significant difference life different origin different background gender age race people living severe disease depends talent mentor change everchanging world leverage commitment people end 2012 ucb diversity superior performance ucb strives generate employed 9 048 people worldwide composed 70 opportunity active participation influence inspire nationality almost equity man woman creativity innovation respectively 53 47 2012 ucb year creating high performance organization leveraging investment talent made ucb present 37 country total 47 ucb past year attracting additional top scientist colleague located europe 23 north america 18 key leadership talent market middle asia pacific australia 12 rest world management layer ratio external hire versus internal ucb foster diversity talent talent fully expressing promotion 5644 reflective continuous search skill creativity connectivity critical imperative future competency needed company particularly ucb engage dedicated staff execute rigorously science biotechnology sale drug safety medical affair strategy highly connected collaborative innovative importance developing retaining key talent learning way successfully implement engagement company deliver superior sustainable value patient workforce headcount gender distribution 10000 8000 48 48 48 47 6000 4000 52 52 52 53 2000 0 2009 2010 2011 2012 men woman workforce gender region distribution men woman uscanada uk spain italy germany france belgium eu rest world 2036 586 133 131 732 144 1950 610 2726 2012 1899 577 111 139 737 146 1883 649 2365 2011 men woman u c b n n u l r e p rt 2 0 1 2 133 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt workforce gender distribution function workforce organization distribution 5000 4491 4127 4000 4000 2114 3500 3000 3000 2433 2500 2170 1219 2000 2000 2208 1500 1179 1252 1030 872 1000 1000 276 657 1520 500 31 110 593 320 0 0 technical admin sale mgr executive admin marketing rd manufacturing operator support force professional sale men woman 2011 2012 312 diversity shared ucb year ucb become mature biotechnology shared culture accepting diversity open aware company order successful future employee cultural intelligence ability understand colleague engagement work culture vital employee engagement way working cultural consistency commitment remains key element progress 2013 building living value strategy without boundary building brings people together ucbs dedication patient bind u leveraging diversity ucb people across leadership team made 141 colleague world work culture demand active sharing collecting 18 different nationality seen increasing insight patient customer physician payer participation woman compared last year 22 dictate creative sharing knowledge expertise key 2012 v 18 2011 52 leader aged partnership expanding inspired sharing among 35 50 year 48 50 order connect collaborate cocreate future ucbs department continue embrace new sharing platform company putting place new innovative communication approach aimed facilitating sharing collaboration cocreation workforce age pyramid turnover evolution men woman departure recruitment 50 2012 1066 1637 2012 2011 3550 2012 1618 1252 2011 2011 35 2012 2 000 1000 0 1 000 2 000 2011 2 000 1000 0 1 000 2 000 full time part time u c b n n u l r e p rt 2 0 1 2 134 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 313 training education new training development course training skill improvement initiative key whereas several training development course development ucb colleague prepared implemented course detailed every year ucb training community work designing leadership development program training program target personal technical development need training consists online training concept leadership pipeline introduced 2012 module well class room training onthejob refers planned transition preparing emerging leader coaching objective ensuring compliance successful performance future role ensuring achieving improved performance participation sustainable pipeline leader within organization people different responsibility new challenge goal future leader understand act opportunity growth skill behavior required grow 2012 ucb invested 115 million continuous new position guaranteeing adopt competence development colleague 6 500 training expectation transition occurs available ucb colleague 2012 four critical transition identified specific program succeeded organize efficient training program designed average number hour training per colleague individual contributor manager others close 26 total represents 233 754 hour accelerate training hour well distributed men woman respectively 51 49 manager others manager manager navigate ucb strongly believe working within manager manager managing business biopharmaceutical industry requires everyone orchestrate baseline training platform ensuring patient managing business managing enterprise heart landscape gardener elevate ceo everyone leadership program blended people corporate policy training different function order maximize learning development stimulating individual growth resilience one combine currently three corporatewide policy code classroom training elearning coaching action learning conduct security drug safety compliance delivered several month order incorporate rate 950 906 924 respectively proper learning transfer module 31 october 2012 compliance rate expressed percentage people taken three corporate program also supporting ucbs strategy value training active internal ucb employee sense purpose end 2012 updated version code conduct 2012 113 colleague 58 men 42 woman attended one security completed training module leadership transition training introduced ucb drug discovery development training program miniinternship ucb drug discovery development training program offer colleague opportunity benefit better broader knowledge drug discovery development ucb aim program increase organization skill knowledge base training hour per employee 2012 b e important motivator influencer facilitate crossfunctional understanding collaboration 2012 29 training session delivered 388 ucb colleague attending 48 biopharma online training module 29 27 seven different online training module focusing helping 16 11 ucb colleague better understand biopharmaceutics created 2011 2012 end 2012 800 ucb colleague taken technical admin sale mgr executive operator support force professional least one module u c b n n u l r e p rt 2 0 1 2 135 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 314 talent organization review 315 wellbeing work ucb driven performance culture annual cycle major priority ucb create positive environment smart objective setting midyear objective review company individual objective met yearend final appraisal complete ongoing performance people express talent wellbeing feedback throughout year process strives keep professional context encompasses area attention organization aligned common goal measurable safety work health employee psychosocial attainable least 89 8 056 employee stress caused hygiene ergonomics beautification 5050 womenmen ucb population participated workplace environmental management completed cycle 2012 employee rewarded many initiative launched different site affiliate recognised individual contribution sense belgium instance initiative create company success environment working condition offer wellbeing talent organization review also designed identify work launched 2012 concrete effort regard key talent based performance ability grow communication training coaching set key outcome design implementation action nine wellbeing ambassador identified amongst plan develop retain engage also serf colleague contribute equilibrium way identify prepare successor performance wellbeing everyone encouraged business critical position 2012 ucb reviewed 57 management ambassador committed supporting employee population identified 30 top colleague complete confidence talent future newcomer 2012 2011 newcomer region age bracket yearend 2012 men woman u canada 335 rest world 838 2012 uk 79 spain 32 2011 italy 9 germany 74 1000 500 0 500 france 12 belgium 176 35 3550 50 eu 82 departure 2012 2011 departure region age bracket yearend 2012 men woman u canada 196 rest world 475 2012 uk 69 spain 10 2011 italy 16 germany 67 1000 500 0 500 1000 france 15 belgium 112 35 3550 50 eu 106 u c b n n u l r e p rt 2 0 1 2 136 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt convinced programme corresponds perfectly global lost time incident rate ltir 2012 care value ucb socially responsible company calculated 226 incident one day absence per one million hour worked global lost time different conference program organised severity rate ltsr calculated 006 day lost per brussels brainelalleud facility following 1 000 hour worked increase ltir mainly example lecture energy nutrition quality sleep due increased number car accident ucb sophrology attended 130 170 colleague employee involved working time total weight loss program attended 60 person program 41 repor ted lost time incident occur outside melanoma breast cancer prostate cancer screening ucb premise initiated implementation global health safety dashboard 316 health safety including timely accident investigation reporting corrective preventative action well continued focus 2012 workrelated accident slightly increased sharing available hse knowledge competence skill number severity compared 2011 clearly enhanced accident awareness important cause lost time incident slip trip 2012 continued attention also given fall 29 car accident 26 contact stationary program initiated 2011 improving moving object 18 fatal incident occupational hygiene practice research production environment safety performance severity rate safety performance incident rate lost time severity rate ltsr lost time incident rate ltir 011 008 421 006 334 005 233 226 004 18 2008 2009 2010 2011 2012 2008 2009 2010 2011 2012 u c b n n u l r e p rt 2 0 1 2 137 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 317 employee engagement ucb voice ucb voice global employee engagement survey organized second year september 2012 show positive increase staff engagement compared previous year included several question relate directly wellbeing work 2012 favorable 2011 favorable response response evolution employee engagement proud work ucb 73 66 7 overall satisfied ucb place work 79 76 3 would recommend ucb great place work 71 62 9 rarely think looking new job another company 63 56 7 wellbeing work give feeling personal accomplishment 76 79 3 job make good use talent skill ability 77 75 2 able manage work responsibility way allows 68 66 2 maintain healthy balance work home immediate manager treat respect care 84 81 3 feel part team 82 78 3 2012 survey response rate 86 obtained committee significantly reinforced regular lync 78 2011 mean 7 500 colleague call scheduled executive committee member recognized value completing survey open employee encouraged open conversation contribution action take place 2013 answered question colleague feedback colleague helped shape many mind hundred colleague connected improvement development action taking place across dedicated webcalls company 2012 companywide task force established examine example action taken followup survey opportunity implement improvement measure regard global process instill efficiency ligned commitment connect collaborate improve effectiveness several short long term cocreate objective reinforce trust goal established address identified global future interactivity ucb staff executive improvement opportunity u c b n n u l r e p rt 2 0 1 2 138 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 32 society support ac action contre le spondylarthropathies france 321 human right anticorruption ucb support ac financial grant help association develop therapeutic educationrelated code conduct call performance integrity activity core objective association outlining general principle business conduct ethic expected every ucb colleague third party assist people spondylarthropathies better support acting behalf ucb code revised 2012 personal familial socioprofessional disease change content follows encourage research fight new requirement coming u corporate integrity debilitating disease agreement cia added eg topic social represent patient health authority board medium uk antibribery act introduced health facility antitrust section c lear mention corporate societal responsibility running lupus addition ucb integrity line hotline phone following inspirational statement lupus patient run used report compliance concern brussels 20km run around 60 ucb colleague decided put running shoe connect louvain gift entertainment section rewritten foundation aim participate run quite prohibit use giveaway hot day brussels ucb pledged 5 every kilometer code encompasses 10 critical united nation completed colleague resulting 6 000 donation global compact ungc principle human right labor runner enjoyed day especially knowledge environment anticorruption supporting lupus patient objective code conduct 323 animal welfare p rovide guidance spirit direction business practice association assessment accreditation p rovide guidance ucb expects colleague laboratory animal care international aaalac third party acting ucbs behalf 2013 ucb apply aaalac association p rovide set ethical principle help guide u assessment accreditation laboratory animal care decision making process accreditation brainelalleud research site international nonprofit association promotes responsible treatment code conduct found ucbs external laboratory animal voluntary accreditation program website governance section going beyond legal requirement accreditation represents 2012 40 ucb colleague 35 management label quality high professionalism term animal care 40 nonmanagement successfully completed use also help continuously improving scientific excellence training entailing approximately 3 600 hour leading animal experimentation research total code compliance level 95 ucb colleague 2011 last year team performed preparatory work prior 96 2010 97 2009 80 accreditation process help external code also added link contract consultant assessed readiness feasibility external party ensure partner work apply accreditation also invested time spirit written code informing engaging involved colleague 322 involvement local community animal welfare principle 3rs action european federation pharmaceutical industry part commitment patient association efpia 2011 report animal welfare principle understanding severe disease ucb support number 3rs report elucidates effort pharmaceutical program patient family taking account company ensure high standard animal welfare donation exceeding 10 000 spent 2012 detail three principle 1 replace work without 1 million community sponsorship charitable animal possible 2 reduce animal experimentation donation worldwide excluding product donation cannot avoided use less possible 3 refine patientassistance program use animal respect possible animal first anniversary e keppra japan ucb subscribe animal welfare principle applying 3r principle instance investing effort meeting attended 512 health care professional introduced field silico toxicology ie science predicting patient empowerment section anniversary event toxic property computational method reduce also first time japanese epilepsy advocate could number animal used framework etox address audience expert epilepsy advocate project imi ucb participates recent advance mentioned heartwarming chance seen gathering unprecedented amount data share thought epilepsy doctor others used new prediction system etoxsys present audience physician remarked attended add dimension current armamentarium many event never heard patient speaking enable decision process mentioned prof trevor think important momentous focus jones director general abpi association british patient event like pharmaceutical industry progress undoubtedly u c b n n u l r e p rt 2 0 1 2 139 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt lead future reduction animal use safety 33 product responsibility assessment pharmaceutical development animal ucb researcher contractor use ucb core strategy bring highest quality product experiment 985 rodent patient living severe disease addition ucb applies strict rule delivering message public 324 relation public authority health care professional within guideline national international regulatory authority many country ucb business law regulating activity corporation political process law set strict limit contribution 331 review promotional scientific corporation political party candidate prohibit press communication altogether also many country act lobbying promotion sale pharmaceutical product highly presenting company position advocating regulated ucb strong commitment comply company interest government employee agency applicable law regulation industry code regulated requires public disclosure ucb employee must comply law ucb fully respect position trust healthcare professional select best treatment option although ucb reporting significant issue formal patient ucb always promotes product based policy position 2012 ucb actively connected public approved labeling policy maker regulator stakeholder patient provider advocacy organization example ucbs interaction healthcare professional focus ucb established u fully operational public providing exchanging scientific information policy department includes government relation ultimate objective enabling healthcare professional public affair federal state level u select appropriate treatment patient public policy department responsible representing interaction based standard ethic integrity company interest whole host policy issue fair market value healthcare reform implementation include protection expansion reimbursement government managed promotional press scientific communication relating subsidized healthcare along important policy compound product submitted global consideration patent protectionreform taxation local promotional scientific review committee regulation specific corporation based u 2012 total 1 050 communication reviewed belgium ucb participating group rd investor shown graph order improve local business condition support federal government belgian prime 332 drug safety minister particular ucb member local trade association generally make sense general like biopharmaceutical company ucb receives manager member board country thousand adverse event report every year concerning operates around world u ucb member drug product reviewed internally submitted bio biotechnology industry organization president governing regulatory authority safety team u member board european level ucb use various tool identify potential safety signal could also member board efpia european federation related adverse event may may pharmaceutical industry association colleague associated medicine actively participates various taskforces dealing together department safety team draw current sector issue benefitrisk management plan plan describe potential safety issue necessary action timeline required reduce potential risk patient throughout entire lifecycle medicine review communication 2012 ucb provides plan health authority part submission approval market new medicine plan also applied firstinman study regularly reviewed updated new safety data scientific 6 medical knowledge medicine safety profile progress press 15 scientific 52 total 1050 promotional 27 u c b n n u l r e p rt 2 0 1 2 140 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 34 environment energy consumption 2012 new reporting tool selected developed million megajoules rolledout team corporate health safety environment corporate societal responsibility new tool allow precise proactive data 1600 management data reported 1400 validated monthly basis previously 1200 reported semester basis 2012 tested tool 1000 trained user community 50 colleague 800 600 341 energy 400 200 compared last year global energy consumption ucb 2012 line reduction 1 0 2009 2010 2011 2012 electricity fuel consumption respectively increased 3 11 whilst gas consumption decreased 3 electricity fuell oil gas although energy consumption much linked production volume manufacturing site developing energy saving plan plan resulted energy saving almost 355 million mega joule important individual energy saving realized manufacturing plant shannon ireland water consumption elimination thermal oxidation unit million m3 plume suppression resulted energy saving 135 million mega joule past steam added process order suppress visible plume 342 water 15 water consumption m³ 10 compared last year global water consumption 05 ucb 2012 reduced 8 reduction partly linked reduced level activity site monheim germany consumption water almost 0 2009 2010 2011 2012 130 000 m³ lower 2011 343 waste waste management ton waste mostly generated production site compared 2011 see decrease 4 total waste important fact ratio recovered waste waste management also keep improving 2012 91 waste generated ton ucb recovered 2010 2011 ratio respectively 86 89 recovery mainly organized incineration waste energy recuperation 14000 reusing waste secondary liquid fuel third 12000 party recycle solvent packaging material 10000 8000 6000 4000 2000 0 2009 2010 2011 2012 incinerated reused liquid solvent recycled 3rd party packaging recycled 3rd party recovered u c b n n u l r e p rt 2 0 1 2 141 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 4 global reporting initiative disclosure table summarises performance indicator economic environmental social performance ucb 2012 indicator reported line gri guideline 17 fully 6 partially reported legend indicator fully reported compliant gri indicator definition indicator partially reported partially compliant gri indicator definition reported page general 1 strategy analysis 11 statement ceo letter stakeholder p 815 2 organisational profile 21 22 name product service p 47 23 27 structure geographical presence market served p 14 operating financial review p 4451 28 scale letter stakeholder p 815 corporate governance p 1824 29 significant change size structure ownership letter stakeholder business perf review p 4143 corporate governance p 1824 210 award received 2012 csr performane report p 131 3 report parameter 31 34 report profile contact point back cover 35 313 report scope assurance csr performance report p146149 4 governance commitment engagement 41 413 structure governance corporate governance p 1824 csr performance report p 131 414 stakeholder engagement letter stakeholder p 815 417 csr performance report p 132 economic economic performance ec1 ß economic value generated distributed including revenue operating letter stakeholder p 815 cost employee compensation donation community business perf review p 4143 investment retained earnings payment capital provider financial statement p 5257 governmentscore ec3 ß coverage organisation defined benefit plan obligation core financial statement p 82 101105 environmental energy en3 ß direct energy consumption primary energy source core csr performance report p141 145 en4 ß indirect energy consumption primary source core csr performance report p141 145 en5 ß energy saved due conservation efficiency improvement additional en7 initiative reduce indirect energy consumption reduction csr performance report p141 145 achieved additional u c b n n u l r e p rt 2 0 1 2 142 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt water en8 ß total water withdrawal source core csr performance report p 141 145 emission effluent waste en16 ß total direct indirect greenhouse gas emission weight core csr performance report p 145 en19 emission ozonedepleting substance weight core en20 emission volatile organic compound chlorinated non chlorinated weight core en22 ß total weight waste type disposal method core csr performance report p 141 145 en24 weight transported imported exported treated waste deemed csr performance report hazardous term basel convention annex ii iii p 141 145 viii percentage transported waste shipped internationally additional social performance labor practice decent work employment la1 ß total workforce employment type employment contract region csr performance report core p 133134 144 la2 ß total number rate employee turnover age group gender csr performance report region core p 134136 144 occupational health safety la7 rate injury occupational disease lost day absenteeism csr performance report number workrelated fatality region core p 137 144 training education la10 ß average hour training per year per employee employee category core csr performance report p 135 la11 program skill management lifelong learning support continued employability employee assist managing career ending additional la12 ß percentage employee receiving regular performance career development review additional csr performance report p 136 diversity equal opportunity la13 ß composition governance body breakdown employee per csr performance report category according gender age group minority group membership p 133136 144 indicator diversity core social performance human right investment procurement practice hr3 ß total hour employee training policy procedure concerning csr performance report p 139 aspect human right relevant operation including percentage employee trained additional social performance society corruption so3 ß percentage employee trained organization anticorruption csr performance report p 139 policy procedure core public policy so5 ß public policy position participation public policy development csr performance report p 140 lobbying core social performance product responsibility marketing communication pr6 ß program adherence law standard voluntary code related csr performance report p 140 marketing communication including advertising promotion sponsorship core ß h ave reviewed year 2012 kpmg assurance statement detailing work performed well comment conclusion appears page 147149 csr report u c b n n u l r e p rt 2 0 1 2 143 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 5 human resource environmental data human resource data gri indicator definition unit measure 2009 2010 2011 2012 la 1 total workforce workforce 31 december total number 9 324 8 898 8 506 9 048 employee workforce male female employee number woman 4 433 4 167 4 064 4 297 gender 48 48 48 47 number men 4 891 4 583 4 442 4 751 52 52 52 53 workforce europe5 belgium number employee area europe asiapacific eu5 australia north america belgium 2 322 2 320 1 710 1 726 rest world eu 1 944 1 800 1 883 1 950 siapacificaustralia 767 690 649 610 north america 1 215 1 458 1 502 1 670 rest world 2 157 1 829 1 899 2 036 919 801 863 1056 workforce full time employee fte number fte 8 787 8 352 7 992 8 535 fte pte parttime employee pte 94 94 94 94 group number pte 537 546 514 513 6 6 6 6 la 2 recruitment hired number employee 1 648 1 547 1 252 1 637 hired departure left number employee 3 616 1 973 1 618 1 066 left company turnover 39 22 19 12 la 7 absenteeism number working day lost day 39 924 due absenteeism main reported reported reported site excluding u location absenteeism monitored u ltir lost time incident rate number incident 334 233 180 226 resulting lost time one day within 12month period per million hour worked ltsr lost time severity rate number lost day 008 005 004 006 resulting lost time incident within 12month period per thousand hour worked u c b n n u l r e p rt 2 0 1 2 144 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt environmental data gri indicator definition unit measure 2009 2010 2011 2012 en 3 total total gas fuel oil vehicle fuel megajoules 805 668 883 907 366 998 774 500 358 754 414 646 consumption gas gas consumption megajoules 731 752 170 877 599 359 749 110 095 726 110 888 fuel oil fuel oil consumption megajoules 72 712 252 29 331 838 24 354 325 28 016 523 fuel utilitary vehicle fuel consumption megajoules 1 204 461 435 801 1 035 938 287 235 vehicle en 4 electricity electricity consumption kwh 159 292 945 154 489 251 143 534 422 147 525 758 megajoules 573 454 602 556 161 304 516 723 919 531 092 727 en 5 energy saved energy saved due conservation kwh 5 894 000 743 286 9 859 000 efficiency improvement megajoules 21 218 400 2 675 830 35 492 400 en 8 water total water m³ 898 120 1 015 918 936 025 860 923 main water 642 666 651 573 596 755 646 067 ground surface water 255 454 364 345 339 270 214 857 0 0 0 0 cod chemical oxygen demand ton 146 108 76 47 effluent following internal treatment tss discharge residual total ton 40 42 19 21 suspended solid internal treatment en 16 direct indirect electricity ton co2 54 443 52 341 46 450 43 306 co2 emission gas scope 12 fuel 35 160 42 749 34 990 40 703 4 962 1 849 1 706 1 949 en 19 od emission ozone depleting cfc11 equivalent 16 13 18 07 substance ton en 20 chlorinated voc emission chlorinated volatile ton 6 8 11 10 organic compound nonchlorinated emission nonchlorinated ton 119 114 93 122 voc volatile organic compound en 22 waste disposal total waste ton 13 688 11 556 12 339 11 789 incinerated 1 859 1 235 3 098 3 091 reused liquid 3 926 2 923 3 187 2 503 solvent recycled 3rd party 2 145 2 577 2 785 3 525 packaging recycled 3rd party 1 806 1 524 1 359 954 recovered method 789 1 636 544 667 recovered 3163 1 661 1 366 1 049 en 24 hazardous waste hazardous waste product ton 10 415 8 801 9 607 8 730 defined locally applicable regulation nonhazardous solid waste excluding ton 3 273 2 755 2 732 3 059 waste emission effluent u c b n n u l r e p rt 2 0 1 2 145 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 6 scope reporting principle scope people data consolidated ucb company lower heating value applied default emission worldwide globally integrated financial gas reported prior year updated consolidation regardless activity research accordance new method information purpose industrial site sale affiliate headquarters co2 emission value natural gas reported 2011 42 000 ton instead 34 990 ton corporate tool ucb learning consolidating training organised ucb followed ucb employee 4 also accurate method applied exception two site tool place zhuhai calculation co2emissions due electricity consumption china saopaolo brazil population covered site reported specific co2 equivalent tool represents less 3 total population electricity mix consumed 2012 taking account growing part electricity generated renewable however compulsory training code conduct source specific ratio available given pharmacovigilance security tracked site used international energy agency iea ratio consolidated ucb employee default result see co2 equivalence decrease regional split defined following compared last year consumption increased eu5 france germany italy spain united kingdom eu austria bulgaria czech republic denmark reporting principle finland greece hungary ireland luxemburg netherlands poland portugal romania slovakia sweden order ensure uniformity reliability indicator used entity ucb group implemented global asia pacific australia australia china hongkong india reporting initiative g31 sustainability reporting guideline japan south korea covering social factor safety environmental impact north america united state canada company performance selfassessed c reporter according gridefined application level rest world row brazil kazakhstan mexico norway russia switzerland turkey ukraine guideline specify methodology used indicator reporting ucb health safety data occupational accident addressed whole ucb employee population excluding affiliate less 10 employee accuracy planet data consolidated ucb corporate health safety environment hse department corporate societal responsibility manufacturing site research site csr team responsible ensuring data sale affiliate china india italy japan mexico u consolidated basis information provided manufacturing research site sale affiliate headquarters belgium administrative headquarters throughout world scope cover 85 ucbs workforce 10 compared hse coordinator perform initial validation safety last year environmental data prior consolidation element state whether ucbs level corporate hse csr also verify data consistency reporting cover requirement fully partially consolidation validation include data comparison previous year well careful analysis significant observation made data validation discrepancy consolidation social data regarding workforce extracted global 1 atlanta monheim rented facility third hr system used management control database party separate meter installed yet ucb worldwide consequence utility consumption overestimated impact overestimation cannot reliably measured reliability 2 braine diesel utilitary vehicle reported order obtain external review data reliability within fuel consumption stored tank thoroughness reporting procedure asked difficult estimate precisely consumption kpmg perform specific verification certain social hse related utilitary vehicle indicator appearing table page 144145 assurance statement describing work performed well 3 accurate method applied comment conclusion appears page 147149 calculation direct co2emissions natural gas consumption however detailed information ucb continue enhance reliability data heating value reported consumption strenghten reporting process u c b n n u l r e p rt 2 0 1 2 146 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt 7 assurance report u c b n n u l r e p rt 2 0 1 2 147 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt assurance report u c b n n u l r e p rt 2 0 1 2 148 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt assurance report u c b n n u l r e p rt 2 0 1 2 149 viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt financial calendar 2013 25 april annual general meeting 25 april interim report 31 july 2013 halfyear financial result 25 october interim report forwardlooking statement annual report contains forwardlooking statement including without limitation statement containing word belief anticipates expects intends plan seek estimate may continue similar expression forwardlooking statement involve known unknown risk uncertainty factor might cause actual result financial condition performance achievement ucb industry result materially different future result performance achievement expressed implied forwardlooking statement given uncertainty public cautioned place undue reliance forwardlooking statement forward looking statement made date annual report ucb expressly disclaims obligation update forwardlooking statement annual report reflect change expectation regard thereto change event condition circumstance statement based unless statement required pursuant applicable law regulation official report language pursuant belgian law ucb required prepare annual report french dutch ucb also made report available english event difference translation interpretation french version shall prevail availability annual report annual report available website ucb wwwucbcom information website ucb website form part annual report contact investor relation communication corporate societal responsibility antje witte france nivelle isabelle de cambry vp investor relation vp global communication head corporate societal responsibility tel 32 2 559 9414 change support tel 32 2 559 9161 email antjewitteucbcom tel 32 2 559 9178 email csrucbcom email francenivelleucbcom ucb sa design stargraphic allée de la recherche 60 1070 brussels belgium tel 3225599999 fax 3225599900 copyright ucb 2013 wwwucbcom photographyves fonck